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ABSTRACT 
 
The RAS-RAF-MEK-ERK or “ERK” (extracellular signal regulated kinase) 
cascade is a highly conserved signaling module in eukaryotes, that is often 
targeted by oncogenic mutations. Thyroid carcinoma is the most common 
endocrine malignancy and is often associated to oncogenic conversion of 
proteins acting in the ERK cascade. Activation of BRAF (B-type RAF) occurs 
in about 44% of papillary and 25% of undifferentiated thyroid carcinoma. 
Moreover, BRAF mutation is associated with adverse thyroid carcinoma 
clinical features, like extracapsular invasion, metastases and clinical 
recurrence. Genetic alterations targeting components of the ERK cascade other 
than BRAF, such as RAS and RET mutations, are also associated with thyroid 
carcinoma. While well differentiated thyroid cancer is treated by surgery and 
adjuvant radioiodine treatment, there is only modest therapeutic option for 
patients that fail radioiodine ablation. Thus, the ERK pathway might be a 
promising target for molecular therapy of thyroid carcinoma. In this 
dissertation, we have studied, at the biological and molecular level, the effects 
of BRAF/ERK targeting in thyroid carcinoma cell lines. To this aim, we 
applied RNA interference and small molecule inhibitors of BRAF and MEK 
kinases. Some of these compounds are in clinical development. Our data 
demonstrate that BRAF and MEK inhibition is a promising approach to reduce 
proliferation of BRAF mutant thyroid carcinoma cells. However, multiple 
regulatory circuits, that are targeted by BRAF/MEK inhibitors, need to be 
taken into consideration to further increase their efficacy.  
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1. INTRODUCTION 
 
 
1.1 Thyroid gland 
The thyroid gland is formed by two cell populations: follicular and 
parafollicular (C-cells) cells; most of the thyroid follicular cells are derived 
from the endodermal diverticulum, whereas a minority of them derives from 
the ultimobranchial body. The parafollicular cells are neural-crest derived; they 
originate from the ultimobranchial body and are interspersed in small groups 
among the follicles in the intermediate part of the thyroid lobes (Pearse and 
Carvalheira 1967, Reynolds et al. 2001). Follicular cells concentrate inorganic 
iodide from the bloodstream to produce the hormones thyroxine (T4) and its 
bioactive derivative triiodothyronine (T3) from thyroglobulin. The 
parafollicular C-cells secrete calcitonin, which is involved in bone formation. 
Calcitonin secretion is stimulated by elevated calcium concentration in the 
serum (Lin et al. 1991). 
 
 
1.2 Thyroid Carcinoma 
Malignant thyroid tumors comprise a heterogeneous group of neoplasms with 
distinctive clinical and pathological features (Kondo et al. 2006). Table 1 
summarizes the principal clinico-pathological features of thyroid carcinoma. 
More than 90% of thyroid carcinomas are derived from follicular cells while 
the remainder originates from the C-cells or from other cell types. The vast 
majority of follicular cell malignancies are well-differentiated (WDTC) 
carcinomas and include papillary (PTC) and follicular (FTC) carcinomas. 
WDTC is in general characterized by indolent behavior and very good 
therapeutic response (Schlumberger 1998, De Lellis 2006, Durante et al 2006). 
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Undifferentiated, or anaplastic, carcinoma (ATC) is very rare and ranks among 
the most lethal human malignancies, with a median survival from diagnosis of 
less than 1-year (Are et al. 2006, Pasieka 2003). Poorly differentiated thyroid 
carcinoma (PDC) lies, both morphologically and behaviorally, between WDTC 
and ATC, with an average 5-year survival rate of about 50% (Volante et al 
2007, Pulcrano et al 2007). Medullary thyroid carcinoma (MTC), which 
originates from C-cells, comprises approximately 5% of primary thyroid 
carcinoma and has a 5-year survival rate of approximately 80% (Leboulleux et 
al. 2004).  
 
 
Table 1: Clinico-pathological features of thyroid cancer (modified from Kondo et al. 2006) 
Tumor Type Prevalence Age Lymph-node metastasis Distant metastasis 
Survival  
(5 year) 
PTC 80-90% 20-50 <50% 5-7% >90% 
FTC 5-10% 40-60 <5% 20% >90% 
PDC ∼5% 50-60 30-80% 30-80% 50% 
ATC ∼2% 60-80 40% 20-50% 1-17% 
MTC ∼5% 30-60 50% 15% 80% 
 
 
1.2.1 PTC 
PTC is defined as a malignant epithelial tumor that shows evidence of 
follicular cell differentiation and presents characteristic nuclear features 
(Kondo et al. 2006). PTC represents the most common thyroid malignancy 
(Table 1) and also the most common pediatric thyroid malignancy. Numerous 
variants of PTC are recognized (classic, follicular, tall-cell, solid, diffuse 
sclerosing). One of the most common and diagnostically challenging ones is 
the follicular variant (FV-PTC). These tumors may be encapsulated or not and 
are composed almost exclusively of follicles having the characteristic nuclear 
features of PTC. Lymph-node metastases are rare in FV-PTC (De Lellis 2006, 
Kondo et al. 2006). Some PTC variants are recognized as more aggressive with 
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respect to classic PTC (CV-PTC); however, tumor stage or grade may be more 
important to assess prognosis than the histological subtype (Leboulleux et al. 
2005). The solid variant comprises approximately 8% of sporadic PTC and is 
relatively common in children following radiation exposure. This variant is 
associated with a higher frequency of distant metastases and a less favorable 
outcome than CV-PTC (Nikiforov et al. 2001). The diffuse sclerosing variant is 
more common in children than adults and has a higher frequency of pulmonary 
metastases than CV-PTC. Tall-cell (TCV-PTC) and columnar-cell variants are 
also thought to have a worse prognosis than CV-PTC (Asklen and LiVolsi 
2000); importantly, as described below, TCV-PTC has a very high prevalence 
of BRAF mutations. The term papillary ‘‘microcarcinoma’’ is referred to those 
tumors measuring less than 1 cm in diameter. Clinical management of PTC is 
based on total thyroidectomy, followed by adjuvant radioiodine therapy and 
thyroid hormone replacement to suppress TSH (Schlumberger 1998, 
Schlumberger 2007). Recently, guidelines for WDTC treatment have been set-
up by american and european taskforces (Pacini et al. 2006, Cooper et al. 
2006). 
 
 
1.2.2 FTC 
The WHO defines FTC as a malignant epithelial tumor with evidence of 
follicular cell differentiation but lacking the diagnostic nuclear features of PTC 
(Sobrinho-Simoes et al. 2004). FTC comprises less than 10% of thyroid 
malignancies and it occurs in the 5th decade of life (Table 1). FTC is rare in 
children. In general, FTC is encapsulated and composed of follicles or 
follicular cells arranged in follicular, solid or trabecular patterns. FTC is 
classified, according to the level of invasion, in: FTC with limited vascular 
invasion (minimally invasive FTC) and FTC with evidence of widespread 
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vascular invasion (widely invasive FTC). Tumors of the last category are 
associated with significant morbidity and mortality (De Lellis 2006).  
 
 
1.2.3 ATC 
ATC is the most aggressive thyroid tumor, and ranks among the most lethal 
human malignancies, with a median survival from diagnosis of ∼4-12 months 
(McIver et al.  2001, Are et al. 2006, Pasieka 2003). Despite accounting for 
only 2-5% of all thyroid tumors, ATC is responsible for more than half of the 
deaths attributed to thyroid cancer (Table 1). Clinically, these tumors usually 
present during the 6th to 7th decade of life as a rapidly enlarging neck mass that 
extends locally, compressing the adjacent structures and tends to disseminate 
both to regional nodes and to distant sites, including lung, pleura, bone and 
brain. Worse prognosis associated with large tumor mass, distant metastases, 
and acute obstructive symptoms (Pierie et al. 2002, McIver et al.  2001). 
Current treatment of ATC has often only palliative purposes, particularly relief 
of airway compression, having little impact on patient’s survival (De 
Crevoisier et al. 2004). 
 
 
1.2.4 MTC 
MTC derives from the neuroendocrine C-cells of the thyroid. Sporadic disease 
accounts for 80% of cases; the remainder 20% of patients inherit MTC in the 
context of autosomal dominant multiple endocrine neoplasia type 2 syndromes 
(MEN2A, MEN2B and FMTC). Sporadic MTC usually presents with palpable 
thyroid nodules in the 3rd-6th decades of life (Table 1). Total thyroidectomy is 
recommended for MTC patients. Clinical recurrence in the neck or 
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mediastinum is a common problem for MTC patients (Leboulleux et al. 2004, 
Cote and Gagel 2004). 
 
 
1.3 Dominant oncogenes involved in thyroid carcinoma 
A significant increase in our understanding of thyroid tumorigenesis at the 
molecular level has been obtained in the past three decades. Recent review 
articles (see for instance Kondo et al. 2006) summarize this knowledge. 
Briefly, WDTC is typically associated to the oncogenic conversion of proto-
oncogenes coding for proteins acting in growth factor signal transduction 
cascade (the ERK and the PI3K cascades). A subgroup of FTC is characterized 
by the PAX8-PPARγ rearrangement. Finally, undifferentiated or poorly-
differentiated thyroid carcinoma (ATC and PDC), but not WDTC, features 
loss-of-function of the p53 tumor suppressor. Table 2 summarizes these genetic 
alterations. In this dissertation, we will refer in particular to signal transduction 
casades (mainly the ERK one) with a view of using this information to 
hypotesize possible novel therapeutic strategies. 
 
 
Table 2: Genetic alterations in thyroid cancer (modified from Kondo et al. 2006) 
Genetic alteration PTC FTC ATC sporadic  MTC 
RET rearrangement 13-43%    
     
RET mutation    30-50% 
     
NTRK1 rearrangement 5-13%    
     
BRAF mutation 44%  25%  
     
RAS mutation 0-21% 40-53% 20-60%  
     
PPARγ rearrangement  25-63%   
     
P53 mutation   67-88%  
     
PIK3CA amplification or mutation 1-14% 13-29% 15-39% 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1.3.1 MAPK pathway 
The mitogen-activated protein kinase (MAPK) pathways are evolutionarily 
conserved kinase modules that play fundamental roles in several cell functions. 
Aberrant regulation of MAPK cascades contributes to cancer and other human 
diseases. MAPK cascades function downstream of cell surface receptors and 
other cytoplasmic signaling proteins (Sebolt-Leopold and Herrera 2004, 
Roberts and Der 2007). Mammalian cells possess four well characterized 
MAPK modules. They share a common architecture with three protein kinases 
that act sequentially: a MAPK kinase kinase (MAPKKK), a MAPK kinase 
(MAPKK) and a MAPK. The terminal kinases (MAPK) are the ERK1/2, the c-
Jun amino-terminal kinases (JNK), p38 kinases (p38) and ERK5 (Roberts and 
Der 2007). The ERK pathway is activated by growth factor-stimulated cell 
surface receptors, whereas the JNK, p38 and ERK5 pathways are activated by 
stress and growth factors. In this dissertation we will refer in particular to the 
ERK pathway (Figure 1).  
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Fig 1: Schematic representation of the ERK signaling module.  
 
When growth factors bind to their cognate receptors, conformational changes 
are induced in the receptor, leading to receptor dimerization, kinase activation, 
autophosphorylation and activation of proteins, such as the RAS small GTPase, 
at the inner surface of the cell membrane. The activated RAS, in turn, activates 
RAF family (CRAF, BRAF, ARAF) serine/threonine kinases. RAFs activate 
MEK1/2 dual-specificity kinases through phosphorylation on Ser217/Ser221 in 
their activation loop. Finally, MEK1/2 activate the ERK (p44 and p42 ERKs) 
subgroup of MAPKs by dual-phosphorylation on Thr202/Tyr204 within the 
Thr-Glu-Tyr motif in the activation loop (Sebolt-Leopold and Herrera 2004, 
Roberts and Der 2007). ERK integrates responses to extracellular signals by 
regulating gene expression, cytoskeletal rearrangements, and metabolism, as 
well as cell proliferation, differentiation, and apoptosis (MacCorkle and Tan 
2005, Torii et al. 2004). MEK and ERK activation is transient and is followed 
by the initiation of negative feedback mechanisms that terminate the signal 
(Amit et al. 2007). These include up-regulated expression of dual-specificity 
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phosphatases (DUSPs, also referred to as MAPK phosphatases -MKP), which 
are able to dephosphorylate ERKs, thereby controlling intensity and duration of 
ERKs stimulation (Jeffrey et al. 2007). A schematic representation of the 
growth factor signaling to ERK is provided in Figure 2. 
 
 
 
 
 
 
 
Fig. 2: Schematic representation of growth factor receptors signaling to ERK. Tyrosine-
phosphorylated receptors recruit intracellular docking proteins/adapters such as Shc and Grb2 
which in turn bring SOS, a RAS exchange factor (GEF), in close proximity to RAS. GTP 
loading on RAS fires the cascade. Phosphorylated p44 and p42 ERKs translocate to the 
nucleus, where they phosphorylate and regulate various transcription factors. 
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Importantly, oncogenic conversion of proteins in the ERK cascade is very 
frequently observed in human cancer. Prominent examples include mutations 
in growth factor receptors (like EGFR in lung cancer and RET in thyroid 
cancer), RAS mutations (in pancreatic, lung colon and thyroid carcinoma), and 
BRAF mutations in melanomas and thyroid carcinoma (Mercer and Pritchard 
2003, Rodriguez-Viciana et al. 2005). Hereafter, oncogene mutations occurring 
in thyroid cancer are described, with a particular view to those intercepting the 
ERK cascade. A summary of the major genetic alterations found in thyroid 
cancer is reported in Table 2. 
 
1.3.1.1 RET  
The RET (REarranged during Transfection) proto-oncogene codes for a single-
pass transmembrane receptor tyrosine kinase (Manie’ et al. 2001). RET protein 
contains three functional domains: an extracellular ligand-binding domain, a 
hydrophobic transmembrane domain and an intracellular tyrosine kinase (TK) 
domain (Figure 3). The ligands of the RET receptor are growth factors 
belonging to the glial cell-line derived neutrophic factor (GDNF) family 
(Manie’ et al. 2001). Binding of the ligand causes receptor dimerization, 
autophosphorylation, and activation of the signaling cascade (Manie’ et al. 
2001). RET is normally expressed in neural crest and urogenital precursor 
cells. In the thyroid gland, RET is normally expressed in parafollicular C-cells 
but not in follicular cells. In a fraction (about 20%) of PTC, RET is 
oncogenically activated by chromosomal aberrations, resulting in the in-frame 
fusion of the 3’-portion of the RET gene (encoding the intracellular domain) to 
the 5’-portion of several unrelated gene partners, forming the chimeric 
RET/PTC oncogenes (Fusco et al. 1987, Grieco et al. 1990) (Figure 3). 
Virtually all breakpoints in RET occur within intron 11, leaving intact the 
intracellular and the TK domain of the receptor (Figure 3). Several RET/PTC 
variants have been reported, differring for the RET fusion partner (Santoro et 
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al. 2004). The RET partners share some common features: i) they are expressed 
in thyroid follicular cells, and therefore provide an active promoter for the 
expression of rearranged RET TK domain; ii) they contain protein-protein 
dimerization motifs and therefore mediate ligand-independent dimerization and 
activation of the truncated RET protein (Tong et al. 1997). The two most 
common RET/PTC variants are RET/PTC1 and RET/PTC3.  RET/PTC1 is the 
RET fusion with the H4/CCDC6 gene (Grieco et al. 1990) while RET/PTC3 is 
the NCOA4-RET fusion (Santoro et al. 1994, Bongarzone et al. 1994). 
RET/PTC oncogenes transform thyroid cells in culture (Santoro et al. 1993) 
and initiate thyroid carcinomas in transgenic mice (Jhiang et al. 1996, Santoro 
et al. 1996, Powell et al. 1998). Several pieces of evidence indicate that 
RET/PTC transforming effects require signaling along the ERK pathway 
(Castellone et al. 2003, Knauf et al. 2003, Melillo et al. 2005). However, the 
wild-type receptor and truncated RET/PTC forms are also known to activate a 
number of other pathways, particularly the phosphatidylinositol-3 
kinase(PI3K)/AKT pathway (Segouffin-Cariou et al 2000, Miyagi et al. 2004, 
Jung et al. 2005, De Falco et al. 2005, Freche et al. 2005).  
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Fig. 3: Schematic representation of RET/PTC rearrangements 
 
 
The prevalence of RET/PTC rearrangements is high in PTC from patients with 
a history of radiation exposure and pediatric PTC (Nikiforov et al. 1997, 
Bongarzone et al. 1996, Fenton et al. 2000, Soares et al. 1998). Overall, 
RET/PTC-positive PTC typically presents lymph node metastases, classic 
histology (CV-PTC), and a favorable prognosis (Adeniran et al. 2006).  
Besides PTC also MTC is associated to oncogenic conversion of RET. 
Germ-line point mutations in RET are responsible for familial MEN2-
associated MTC and similar mutations, at the somatic level, are found in a 
fraction (30-50%) of sporadic MTC cases (Manie’ et al. 2001, Cote and Gagel 
2003, Santoro and Carlomagno 2006).  
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1.3.1.2 RAS 
RAS genes are the most common targets for somatic gain-of-function 
mutations in human cancer (Schubbert et al. 2007, Ramjaun and Downward 
2007). Three different RAS are present in mammalian genome: HRAS, KRAS 
and NRAS. The three RAS genes encode four highly homologous 21 kD (p21) 
proteins: HRAS, NRAS, KRAS4A and KRAS4B (the 2 KRAS proteins result 
from alternative splicing at the C-terminus). The N-terminal portion of the 
RAS proteins comprises a highly conserved GTPase domain; the C-terminal 
hypervariable region contains residues that specify post-translational protein 
modifications (Schubbert et al. 2007). RAS proteins are bound to the inner 
leaflet of the cell membrane where they exhibit guanosine triphosphatase 
activity (GTPase). When RAS is in the inactive form it binds guanosine 
diphosphate (GDP), in the active form, instead, it is bound to GTP (Schubbert 
et al. 2007) (Figure 2). Guanine-nucleotide exchange factors (GEF), like SOS, 
are involved in the RAS activation step, while GTPase-activating proteins 
(GAP) are involved in the inactivation of RAS. In normal cells, RAS conveys 
intracellularly signals originating from tyrosine kinase membrane receptors to 
the ERK and many additional signaling cascades, including the PI3K-AKT 
pathway (Schubbert et al. 2007, Ramjaun and Downward 2007). RAL and 
RAC smallGTPases are additional RAS effectors; RAL, in turn, triggers the 
activity of phospholipase D while RAC regulates cytoskeleton dynamics. 
However, among the various RAS effectors, the BRAF-MEK-ERK cascade 
plays a prominent role in cell proliferation. 
Activating RAS mutations occur in approximately 30% of human 
cancers. Specific RAS genes are mutated in different malignancies: KRAS 
mutations are prevalent in pancreatic, colorectal, endometrial, biliary tract, 
lung and cervical cancers; KRAS and NRAS mutations are found in myeloid 
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malignancies; and NRAS and HRAS mutations predominate in melanoma and 
bladder cancer, respectively (Schubbert et al. 2007). These mutations introduce 
amino-acid substitutions at positions 12, 13 and 61, and constitutively activate 
RAS function by impairing the intrinsic GTPase activity.  
Mutations of all three RAS oncogenes have been identified in tumors 
originating from follicular thyroid cells. Up to 50% of FTC harbour RAS 
mutations (Kondo et al. 2006). RAS mutations are also found in benign 
adenomas and thyroid nodules, suggesting they may be early events in thyroid 
tumorigenesis. The NRAS mutation in codon 61 is the most frequent RAS 
mutation in FTC and it is more frequent in malignant than in benign thyroid 
tumors (Basolo et al. 2000, Garcia-Rostan et al. 2003). PDC and ATC (up to 
60% of the cases) are often RAS mutation positive. RAS mutations in PTC are 
restricted to FV-PTC (Zhu et al. 2003, Di Christofaro et al. 2006). Overall, 
these clinico-pathological correlations suggest that RAS mutation may mark a 
subset of thyroid tumors that is more likely to undergo de-differentiation and 
tumor progression. The phenotype of NRAS(Q61) transgenic mice generated 
by our group is consistent with this view (Vitagliano et al. 2006). Mitsutake et 
al. (2005), Saavedra et al. (2000) and Knauf et al. (2006) demonstrated that the 
expression of oncogenic RAS, as well as BRAF (see below), alleles bypassed 
G2/M and mitotic spindle checkpoints and induced signs of genomic instability 
in thyrocytes, an observation that may explain the high oncogenic activity of 
these oncoproteins. 
 
 
1.3.1.3 BRAF 
BRAF (B-type RAF) belongs to the RAF family of serine/threonine kinases. 
There are three RAF kinases in mammals: ARAF, BRAF, and CRAF (or RAF-
1) (Marais and Marshall 1996). The RAF proteins display a common 
architecture, with two N-terminal regulatory domains (CR1 and CR2) and one 
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kinase C-terminal domain (CR3) (Figure 4). The three RAF members show 
differences in tissue distribution and activation modalities. Importantly, several 
residues must be phosphorylated in ARAF and CRAF for full activation, while 
some of them are constitutively phsophorylated or replaced with 
phosphomimetic residues in BRAF. This makes BRAF activation more rapid 
and efficient than that of CRAF or ARAF (Figure 4). Accordingly, BRAF has 
a strong basal kinase activity and is the most potent activator of MEK in many 
cell types; this may account for the high prevalence of mutations in BRAF, 
rather than other RAF family members, in human tumors (Marais et al. 1997, 
Garnett and Marais 2004, Emuss et al. 2005, Dhomen and Marais 2007). In 
fact, whereas BRAF can be activated by single amino acid substitutions, CRAF 
and ARAF require at least two mutations for oncogenic conversion (Dhomen 
and Marais 2007). 
 
 
 
Fig. 4: Schematic representation of the RAF proteins. The three conserved regions: CR1 
(yellow), CR2 (orange) and CR3 (red) are highlighted. The amino acids indicated below the 
individual isoforms refer to known regulatory phosphorylation sites. CR1 contains the RAS-
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binding domain and CR3 contains the catalytic domain (the activation segment is highlighted 
in pink).  
 
BRAF mutations were recently discovered to be a prime cause of aberrant 
activation of the ERK pathway in human cancer, particularly in melanoma, 
where approximately 70% of cases carry BRAF mutations (Dhomen and 
Marais 2007). Also ovarian, colon and thyroid (see below) carcinoma often 
harbours BRAF mutations. 
The most common BRAF mutation (>90%), is a thymine to adenine 
transversion at nucleotide 1799 (T1799A) leading to a glutamic acid for valine 
substitution at position 600 (V600E). Other more rare mutations have been 
described (www.sanger.ac.uk/genetics/CGP/cosmic/). Importantly, most (but 
not all, see below) mutations have a gain-of-function effect. X-ray structural 
analysis has clarified that activating BRAF mutations invariably map in the 
activation loop of the kinase or the glycine-rich P loop (ATP-binding site). The 
inactive conformation of the BRAF kinase is maintained secondary to 
interactions between these two loops; therefore, the substitution of key residues 
within these domains disrupts the inactive conformation, switching the BRAF 
kinase into a catalytically competent conformation able to constitutively 
phosphorylate MEK (Wan et al. 2004). BRAFV600E kinase function is 
activated approximately 500-fold with respect to wild type protein. Moreover, 
it induces constitutive ERK signaling through hyperactivation of the MEK–
ERK pathway, thereby stimulating proliferation, survival and transformation.  
About 70 other oncogenic mutations in BRAF have been identified 
(www.sanger.ac.uk/genetics/CGP/cosmic/). Surprisingly, the activity of some 
BRAF mutants is actually impaired rather than potentiated. However, these 
impaired activity mutants can still activate MEK through CRAF (Figure 5). 
Indeed, BRAF can activate CRAF through a direct BRAF/CRAF protein-
protein interaction, followed by allosteric activation and trans-phosphorylation 
of CRAF by BRAF (Garnett et al. 2005, Dhomen and Marais 2007). 
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Fig. 5: Direct and indirect (via CRAF) BRAF signaling to MEK according to the potency of 
BRAF mutations (modified from Dhomen and Marais 2007). 
 
 
BRAF mutation in thyroid carcinoma was initially reported about 5-years ago 
by three research groups and then confirmed by many other studies (Kimura et 
al. 2003, Soares et al. 2003, Cohen et al. 2003). The V600E accounts for the 
great majority of BRAF alterations in thyroid cancer (Figure 6); however, 
more rare mutations have also been described. In some cases, these rare 
changes are missense mutations, in others, they are small insertions/deletions. 
Virtually always, these mutations target residues close to the V600 amino acid 
in the activation loop of the kinase (Trovisco et al. 2004, Carta et al. 2006, 
Castro et al. 2006, Moretti et al. 2006, Hou et al. 2007, Koh et al. 2007, Lupi et 
al. 2007). The K601E mutation is prevalent in FV-PTC, a PTC variant that is, 
overall, rarely BRAF mutation positive (see also below) (Trovisco et al. 2004, 
Trovisco et al. 2005). Also the VKSR600-603del+T599I (Lupi et al. 2007) and 
the G474R (Castro et al. 2006) mutations have been so far found only in FV-
PTC cases (Hou et al. 2007). Finally, another mechanism of BRAF activation 
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has been identified, involving an inversion of chromosome 7q that leads to the 
in-frame fusion between BRAF and the AKAP9 gene (Ciampi et al. 2005). The 
AKAP9-BRAF protein contains the BRAF kinase domain but it lacks the 
regulatory N-terminal region. This rearrangement is rare and found in PTC 
associated with radiation exposure (Fusco et al. 2005). 
 
 
 
Fig. 6: BRAF mutations described in thryoid cancer 
 
 
BRAF is the most common genetic event in PTC, occurring in approximately 
44% of cases (Ciampi and Nikiforov 2005, Groussin and Fagin 2006, Xing 
2007) (Table 2). FTC and benign thyroid tumors are invariably negative for 
BRAF mutations. Instead, BRAF mutations are found in ATC (about 25% of 
the cases) and PDC (Table 2). In ATC, BRAF mutations are typically present 
in those cases with morphological areas of PTC differentiation, and therefore 
probably derived from pre-existing PTC (Nikiforova et al. 2003). This suggests 
that BRAF mutation may play a role in promoting progression from 
differentiated to undifferentiated carcinomas. Consistently, a transgenic mouse 
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model demonstrated that thyroid targeting of BRAF initiates the formation of 
PTC than tends to progress to PDC (Knauf et al. 2005). These tumors 
frequently show invasion of blood vessels, thyroid capsule, and skeletal muscle 
(Knauf et al. 2005). 
Interestingly, BRAF mutations and RET/PTC rearrangements are 
mutually exclusive, pointing to a key role played by te RET-BRAF-ERK 
cascade in PTC formation (Kimura et al. 2003). Several features differentiate 
PTC harbouring RET/PTC from those positive for BRAF mutation. Differently 
from RET/PTC, pediatric PTC (both sporadic and radiation-induced) have a 
low prevalence of BRAF mutations (Lima et al. 2004, Kumagai et al. 2004, 
Nikiforova et al. 2004). In general, BRAF mutation is associated with 
aggressive clinico-pathological characteristics. BRAF mutation occurs most 
commonly in TCV-PTC (∼77%) than CV-PTC (∼ 60%) and FV-PTC (∼ 12%) 
(Xing 2007, Adeniran et al. 2006). Moreover, BRAF mutation correlates with 
advanced tumor stage, extrathyroid extension, advanced age, relapses and 
reduced disease-free survival (Xing 2007). In a large study conducted on 500 
independent PTC samples, Lupi and colleagues found that BRAF mutation 
correlates with caspule infiltration (Lupi et al. 2007). Rodolico and colleagues 
(2007) recently demonstrated that metastatic PTC lesions in lymph nodes 
harboring BRAF mutation are larger in size than those harboring wild-type 
alleles. Systemic treatment of PTC is principally based on radioiodine therapy. 
However, thyroid cancer may lose radioiodine avidity, this being associated 
with increased morbidity and mortality (Schlumberger 1998, Schlumberger et 
al. 2007). BRAF mutation is typically associated to the loss of radioiodine 
avidity in PTC cells (Xing 2007).  
It is still unclear why BRAF mutation is associated with increased 
aggressiveness and recurrence of PTC when compared with other genetic 
alterations that also intercept the ERK pathway. Plausible explanations may be 
the capability of BRAF oncogenes, similarly to RAS, of inducing genetic 
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instability (Mitsutake et al. 2005, Knauf et al. 2006), coupled with the 
preferential regulation exerted by BRAF of genes involved either in tumor 
invasion (like metalloproteases) or thyroid cell differentiation (like the NIS, 
sodium-iodine symporter) (Melillo et al. 2005, Mesa et al. 2006, Riesco-
Eizaguirre et al. 2006, Xing 2007).  
 
 
 
1.3.2 PI3K/AKT 
Phosphatidylinositol 3-kinase (PI3K) is a heterodimer formed by p85 
regulatory and p110 catalytic (PIK3CA) subunits. Ligand-mediated activation 
of tyrosine kinase receptors recruits p85-p110 complex on cell membrane 
where the p85 regulatory subunit can be phosphorylated; conformational 
changes relieve the inhibitory effect exerted by p85 on p110 activity (Vivanco 
and Sawyers 2002). Growth factor receptors can also activate PI3K indirectly 
through RAS, which can bind and activate the p110 subunit. Once activated, 
PIK3CA generates phosphatidylinositol-3-phosphate (PIP3), which functions 
as a second messenger to activate downstream effectors including the 
AKT/PKB protein kinase (Vivanco and Sawyers 2002). Termination of 
PI3K/AKT activity occurs through the lipid phosphatase activity of PTEN 
(Cantley and Neel 1999). 
The PI3K/AKT pathway is involved in many cellular processes as cell 
survival, cell cycle progression, cell motility and invasion (Brazil et al. 2004). 
Genetic or epigenetic alterations causing gain-of-function of PI3K and AKT or 
loss-of-function of PTEN are associated to a wide spectrum of human cancers 
(Hay 2005). Reduced expression of PTEN is common in  different types of 
thyroid tumors, particularly in more aggressive subtypes (Halachmi et al. 1998, 
Bruni et al. 2000, Frisk et al. 2002). FTC is characterized by increased 
expression of AKT1 and AKT2 (Ringel et al. 2001). Importantly, point 
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mutations and gene amplifications of PIK3CA have been found in a significant 
fraction of ATC and less frequently in WDTC (Garcia Rostan et al. 2005, 
Wang et al. 2007, Santarpia et al. 2007, Hou et al. 2007) (Table 2). 
 
 
 
1.4 Molecularly targeted cancer therapy 
“Targeted therapy” refers to measures that interfere with specific proteins 
involved in disease. This type of concept has been successfully applied to 
oncogenic protein kinases. The human genome contains 518 protein kinase 
genes (known as “kinome”). Recent highthroughput genomic sequencing 
efforts have demonstrated that the kinome is the favourite target of “driver” 
oncogenic mutations in human cancer (Bardelli et al. 2003, Sjöblom et al. 
2006, Greenman et al. 2007). Importantly, protein kinases are “druggable” 
molecules and this has prompted scientists to search for new drugs able to 
intercept kinase function for cancer therapy (Sebolt-Leopold and English 2006, 
Baselga 2006, Sawyers 2007).  
Kinase-directed small-molecule drugs and monoclonal antibodies are 
already used in the clinical setting. Most small-molecule compounds obstruct 
kinase activity by binding to the ATP pocket within the catalytic domain (ATP 
mimetics). These compounds were initially identified by random screening of 
libraries of natural products or synthetic compounds. Although the ATP 
binding pocket is highly conserved among the different kinases, there are 
significant differences in its primary sequence or tridimensional fold to warrant 
specificity of its targeting. Other compounds target regions outside the ATP-
binding site of the enzyme (allosteric inhibitors); by binding to domains highly 
divergent among the various kinases, these compounds are believed to be more 
selective than the ATP mimetics (Sebolt-Leopold and English 2006, Baselga 
2006).  
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The clinical efficacy of small molecule inhibitors of ABL, KIT and 
EGFR in different tumor types is witness to the power of this approach. To 
date, at least 10 different protein kinase inhibitors have received approval by 
the FDA (Food and Drug Administration). These include: the ABL and KIT 
inhibitor imatinib for the treatment of CML and GIST, the EGFR inhibitors 
erlotinib and gefitinib for NSCLC, and the multikinase inhibitors sunitinib and 
sorafenib (BAY 43-9006) for metastatic renal cancer (Baselga 2006). 
The presence of activating mutations of a kinase may anticipate tumor 
responsiveness to its targeting in a given cancer patient. This is well illustrated 
by the case of EGFR inhibitors and NSCLC. Most tumors responsive to EGFR 
inhibitors had gain-of-function mutations in EGFR or an increased EGFR gene 
copy number. This could be explained by the fact that mutant EGFR variants 
were more efficently inhibited than wild type protein by the EGFR targeting 
agents (gefitinib and erlotinib) but also by the observation that only EGFR-
mutant NSCLC cells were addicted to EGFR signaling (Niculescu-Duvaz et al. 
2007). In this context, the protein kinases of the ERK cascade appear to be 
excellent molecular targets for the treatment of thyroid cancer. 
 
 
1.4.1 ERK pathway inhibitors 
Two protein kinases in the ERK pathway have received attention as potential 
targets for pharmacological intervention: RAF and MEK. No ERK inhibitor, 
instead, is as yet available (Sebolt-Leopold and Herrera 2004, Kohno and 
Pouyssegur 2006, Roberts and Der 2007). RAS is a promising non-kinase 
target in the cascade. However, inhibitors directed at intercepting post-
translational RAS protein modifications did not exerted sufficient specificity to 
prove that their clinical activity was indeed due to RAS inhibition (Roberts and 
Der 2007). Moreover, the RAS level of inhibition may prove not useful when 
the oncogenic mutation maps downstream, e.g. at the level of BRAF. 
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Several small-molecule RAF inhibitors have been developed (Table 3). 
One of them, sorafenib (BAY 43-9006), has been extensively studied in 
clinical trials and has been approved by the regulatory authorities for the 
treatment of metastatic renal cell carcinoma (RCC) (Wilhelm et al. 2006). 
BAY 43-9006 is a multitarget compound that inhibits besides RAF a range of 
other kinases, including many tyrosine kinases. Probably, BAY 43-9006 anti-
angiogenic properties account for its clinical activity in RCC. In melanoma, 
instead, a tumor with high prevalence of BRAF mutations, BAY 43-9006 did 
not show significant clinical activity (Eisen et al. 2006). Other small molecule 
compounds are being developed against RAF kinases (Table 3).  
 
Table 3. RAF/MEK inhibitors in clinical development (modified from Sebolt-Leopold and 
Herrera 2004, Roberts and Der 2007) 
Agent Company Target Clinical development 
BAY 43-9006 
(sorafenib) 
Bayer RAF, VEGFR, KIT, 
PDGFR, RET 
Approved for advanced RCC 
RAF265 
(CHIR-265) 
Novartis ARAF, BRAF, 
CRAF 
Phase I 
PLX4032 Roche/Plexxi
kon 
BRAF(V600E) Phase I 
CI-1040 
(PD184352) 
Pfizer MEK1/2 Clinical trials terminated 
PD0325901 Pfizer MEK1/2 Phase II: breast, colorectal ca., 
NSCLC, melanoma 
AZD6244 
(ARRY-142886) 
AstraZeneca/
Array 
MEK1/2 Phase II: NSCLC, malanoma, 
pancreatic ca. 
 
 
Potent MEK inhibitors have been developed. These are selective, non ATP-
competitive kinase inhibitors that bind to a pocket that is adjacent to, but 
distinct from the ATP-binding site. Binding of the inhibitor is thought to 
stabilize the inactive conformation of the kinase potently inhibiting its function 
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(Sebolt-Leopold and Herrera 2004, Kohno and Pouyssegur 2006, Roberts and 
Der 2007, Messersmith et al. 2006). The development of pharmacological 
inhibitors of MEK was launched with the discovery of PD98059; this 
compound became a tool to explore the role of the ERK pathway but, because 
of its pharmaceutical limitations, it was not clinically developed. U0126 was 
subsequently reported as a dual MEK (MEK1/2) inhibitor more potent than 
PD98059 (half maximal inhibitory concentration -IC50: 13 µM). U0126 has 
also been widely used as a reagent for in vitro studies (Davies et al. 2000).  
These initial anti-MEK compounds were followed by novel and more 
potent molecules that are being explored for clinical activity (Table 3 and 
Figure 7). The first MEK inhibitor reported to inhibit tumor growth in vivo 
was CI-1040 (PD184352). Its IC50 for MEK is 300nM and at doses as high as 
10 µM it did not inhibit other kinases (Davies et al. 2000). Although there was 
encouraging evidence of anti-tumour activity in the Phase I, similar results 
were not observed in Phase II (Rinehart et al. 2004, Lorusso et al. 2005, Wang 
et al. 2007). PD0325901, which is structurally highly similar to CI-1040, has 
been subsequently developed as a significantly more potent MEK inhibitor. 
PD0325901 has an IC50 of 1 nM against activated MEK1 and MEK2. This 
compound is also significantly more potent than CI-1040 in vivo. Anticancer 
activity of PD0325901 has been demonstrated for a broad spectrum of human 
tumor xenografts. Phase II trials with this agent are now in progress (Sebolt-
Leopold and Herrera 2004, Massersmith et al. 2006, Brown et al. 2007). 
Finally, the benzimidazole AZD-6244 has also been reported to be a highly 
potent MEK inhibitor, with an IC50 of 12 nM against purified MEK (Yeh et al. 
2007) and has recently entered clinical trials.  
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Fig. 7: Chemical structures of MEK inhibitors. 
 
The X-ray structure of MEK1 in combination with a related molecule, 
PD318088, proved that the mode of binding of compounds of the “PD” series 
is non competitive with respect to ATP but rather involves an allosteric pocket 
mapping close to the ATP-binding one (Ohren et al. 2004). 
 
 
1.4.2 Novel molecular therapy strategies for undifferentiated thyroid 
carcinoma 
In recent years, an extensive program for the identification of potential 
therapeutic targets suitable to pharmacological intervention in ATC has been 
launched in our laboratory. Some of these studies are attached to this 
dissertation and lead to the identification of one serine/threonine kinase PLK1 
(Polo-like kinase 1) (attached manuscripts #2 and 4) and one G-coupled 
transmembrane receptor (CXCR4) (attached manuscript #3) as overexpressed 
in ATC samples and cell lines and required for proliferation of ATC cells in 
culture. The results of these studies are briefly summarized below. 
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 We have identified a gene expression signature associated with the high 
proliferative and aneuploid ATC phenotype (attached manuscript #2). Such 
expression profile featured the up-regulation of PLK1 that belongs to the Polo 
family of serine/threonine kinases. PLK1 plays a pivotal role in several G2 and 
M-phase related events, i.e., centrosome maturation, bipolar spindle formation, 
CDC2 (CDK1)-cyclin B activation, and anaphase-promoting 
complex/cyclosome (APC/C) activation. We could show that chemical and 
genetic (RNAi) blokade of PLK1 resulted in a potent cytotoxic effect in 
cultured ATC cells (attached manuscript #4). 
 CXCR4 is the receptor for the SDF-1/CXCL12 chemokine and we 
could show that ATC cell lines and ATC tumor samples overexpress CXCR4, 
both at the level of mRNA and protein. Treatment of ATC cells with SDF-1 
induced proliferation and increased ERK phosphorylation. Importantly, these 
effects were blocked by the specific CXCR4 antagonist AMD3100 and by 
CXCR4 RNAi. Accordingly, AMD3100 effectively reduced ATC xenograft 
tumor growth in nude mice (attached manuscript #3). 
 The rest of this dissertation is based on the attached manuscripts #1 and 
5, in which we have explored in detail the effects of BRAF-MEK blockade in 
thyroid carcinoma cells.  
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2 AIMS OF THE STUDY 
The aim of this work was to evaluate the in vitro effects of ERK pathway 
blockade in cultured ATC cell lines. In particular: 
• We analysed by cell growth and flow cytometry assays the activity of 
some classes of ERK pathway inhibitors, including the ATP-
competitive BRAF inhibitor BAY-439006 and the non-ATP-
competitive MEK inhibitor PD0325901. 
• We analysed biochemically the capability of these compounds to hit 
their intended targets in thyroid carcinoma cells.  
• We explored regulatory circuits elicited in thyroid carcinoma cells by 
these compounds and the possibility that such mechanisms may 
dampen the efficacy of the approach. 
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3. MATERIALS AND METHODS  
The experimental procedures used in this study are described in detail in the 
attached publications. Only, a brief description is provided here. 
 
 
3.1 Compounds 
The chemical name of BAY 43-9006 (sorafenib) is: N- (3-trifluoromethyl-4-
chlorophenyl)-N‘-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea. BAY 
43-9006 was provided by Bayer HealthCare Pharmaceuticals (West Haven, 
CT, USA). For in vitro experiments, BAY 43-9006 was dissolved in dimethyl 
sulfoxide (DMSO). For in vivo experiments, it was dissolved in Cremophor 
EL/ethanol (50:50; Sigma Cremophor EL, 95% ethyl alcohol) at 4-fold (4X) 
the highest dose, foil-wrapped, and stored at room temperature (attached 
manuscript #1). The chemical name of PD0325901 is N-((R)-2,3-dihydroxy-
propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. 
PD0325901 was provided by Pfizer Inc, (New York, NY USA). PD0325901 
was dissolved in DMSO at a concentration of 10 mM and stored at –80°C 
(attached manuscript #5). U0126, LY294004 and Wortmannin were purchased 
from Cell Signaling (Beverly, MA, USA). Orthovanadate was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). 
 
 
3.2 Cell cultures  
The thyroid cell lines used in this study are described in Table 4. Cancer cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) (GIBCO, Paisley, PA), 2 mM L-glutamine 
and 100 units/ml penicillin-streptomycin (GIBCO). The P5 primary culture of 
normal human thyroid follicular cells was kindly donated by Francesco Curcio 
(Università di Udine). The rat-derived differentiated thyroid follicular cell lines 
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PCCl3 (hereafter named PC) and FRTL5 were grown in Coon’s modified Ham 
F12 medium supplemented with 5% calf serum and a mixture of six hormones 
(6H), including thyrotropin (10mU/ml), hydrocortisone (10nM), insulin 
(10µg/ml), apo-transferrin (5µg/ml), somatostatin (10ng/ml), and glycyl-
histidyl-lysine (10ng/ml) (Sigma-Aldrich, St. Louis, MO, USA) (Fusco et al. 
1987).  
 
 
 Table 4: Cell lines used in this dissertation. 
Name Species 
Primary/ 
Continous 
Tumor type 
BRAF V600E 
status  
FRO Human C ATC Homozygous 
ARO Human C ATC Heterozygous 
KAT4 Human C ATC Heterozygous 
FB1 Human C ATC Heterozygous 
SW1736 Human C ATC Heterozygous 
8505C Human C ATC Homozygous 
BHT101 Human C ATC Heterozygous 
NPA Human C PDC Homozygous 
BHP14.9 Human C PTC Heterozygous 
BCPAP Human C PTC Heterozygous 
P5 Human P Normal negative 
PCCL3 Rat C Normal negative 
FRTL5 Rat C Normal negative 
 
 
 
3.3 Cell proliferation assays 
5x104 cells were plated in 35-mm dishes in low serum (¼ of normal serum 
concentration). The day after plating, the compounds or vehicle were added. 
The media was changed every 2 days and cells were counted in triplicate every 
day for four days (attached manuscripts #1 and 5) 
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3.4 FACS analysis 
For cytofluorimetric analysis, cells were plated at 5x105 cells in 100-mm dishes 
in low serum. The following day, cells were incubated with fresh medium with 
or without the compound. Cells were collected every 12 hours after treatment 
and fixed in cold 70% ethanol in phosphate-buffered saline. Propidium iodide 
(25 µg/ml) was added in the dark, and samples were analyzed with a 
FACSscan flow cytometer (Becton Dickinson, San Jose, CA) interfaced with a 
Hewlett Packard computer (Palo Alto, CA). 
 
 
3.5 RNA silencing (attached manuscript#1) 
The small inhibitor duplex RNAs (siRNA) targeting human BRAF were 
chemically synthesized by PROLIGO (Boulder, CO). Sense strands for siRNA 
targeting were: BRAF:  5’-AGAAUUGGAUCUGGAUCAUTT-3’; and Lamin 
A/C: 5’-CUGGACUUCCAGAAGAACATT-3’. As control, we used a non-
specific siRNA duplex containing the same nucleotides but in irregular 
sequence (scrambled). For siRNA transfection, cells were grown under 
standard conditions. The day before transfection, 1x105 cells were plated in 35-
mm dishes in DMEM supplemented with 10% FBS without antibiotics. 
Transfection was performed using 360 pmol of siRNA and 18 µl of 
oligofectamine reagent (Invitrogen, Groningen, The Netherlands), following 
the manufacturer’s instruction. Cells were kept in 2.5% serum and counted 48 
and 72 hours after transfection.  
 
 
 36 
3.6 Protein studies 
Immunoblotting experiments were performed according to standard 
procedures. Briefly, cells were harvested in lysis buffer (50 mM Hepes, pH 7.5, 
150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 
10 mM NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 10 µg of 
aprotinin/ml, 10 µg of leupeptin/ml) and clarified by centrifugation at 10,000 g. 
For protein extraction, samples of mouse xenografts were snap-frozen and 
immediately homogenized in lysis buffer by using the Mixer Mill MM300 
(Qiagen, Crawley, West Sussex, UK) (attached manuscript #1). Protein 
concentration was estimated with a modified Bradford assay (Bio-Rad, 
Munich, Germany). Antigens were revealed by an enhanced 
chemiluminescence detection kit (ECL, Amersham Pharmacia Biotech, Little 
Chalfort, UK). Signal intensity was evaluated and quantified with the 
Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech) interfaced 
with the ImageQuant software. 
 
 
3.7 Antibodies 
The antibodies used in this work are described in detail in the original articles 
(attached manuscripts #1 and 5).  
 
 
3.8 BRAF kinase assay (attached manuscript #1) 
Cells were cultured for 12 hours in serum-deprived medium. Thereafter, cells 
were treated with the indicated compounds for one hour; BRAF kinase was 
immunoprecipitated with the anti-BRAF antibody and resuspended in a kinase 
buffer containing 25 mM sodium pyrophosphate, 10 µCi 32P ATP and 1 µg of 
recombinant GST-MEK (Upstate Biotechnology Inc., Lake Placid, NY). After 
30 min incubation at 4°C, reactions were stopped by adding 2X Laemmli 
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buffer. Proteins were then subjected to 12% SDS gel electrophoresis. The 
radioactive signal was analyzed using a Phosphorimager (Molecular 
Dynamics). 
 
 
 
3.9 Reverse transcription and quantitative PCR (attached manuscript 
#5) 
Total RNA was isolated with the RNeasy Kit (Qiagen, Crawley, West Sussex, 
UK). One µg of total RNA from each sample was reverse-transcribed with the 
QuantiTect® Reverse Transcription (Qiagen) according to manufacturer’s 
instructions. The effects of PD0325901 on the level expression of ERK 
phosphatases DUSP-5 and MKP-3 were measured by quantitative RT-PCR 
assay, using the Human ProbeLibrayTM system (Exiqon, Denmark). PCR 
reactions were performed in triplicate and fold changes were calculated with 
the formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the 
amplification fluorescent thresholds of the mRNA of interest and the mRNA of 
RNA polymerase 2 used as an internal reference. Primers sequences for 
targeted genes were:  
MKP3 forward 5’-CGACTGGAACGAGAATACGG-3’,  
MKP3 reverse 5’-TTGGAACTTACTGAAGCCACCT-3’;  
DUSP5 forward 5’-ACAAATGGATCCCTGTGGAA-3’,  
DUSP5 reverse 5’-CCTTTTCCCTGACACAGTCAA-3’;  
As control for normalization RNA polymerase 2 mRNA was amplified: 
forward 5’-TGCGTGACATTAAGGAGAAG-3’,  
reverse 5’-GCTCGTAGCTCTTCTCCA-3’.  
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3.10 Tumorigenicity in nude mice (attached manuscript #1) 
Animals were housed in barrier facilities at the Dipartimento di Biologia e 
Patologia Cellulare e Molecolare (University of Naples “Federico II”, Naples, 
Italy). The cells (1 x 106ARO) were inoculated subcutaneously into the right 
flank of 4-week-old male BALB/c nu/nu mice (Jackson Laboratory, Bar 
Harbor, ME). When tumors reached approximately 100 mm3, the animals were 
treated with the compound or vehicle by oral gavages for five consecutive 
days/week for three weeks. Tumor diameters were measured with calipers. 
Tumor volumes (V) were calculated by the rotational ellipsoid formula: V = A x 
B2/2 (A = axial diameter; B = rotational diameter). Another group of animals 
(surrogate) was treated with vehicle or 60 mg/kg of BAY 43-9006 (5 animals 
per group) for 5 days starting when the tumors reached approximately 300 
mm3. Tumors were excised three hours after the last dose and snap-frozen in 
liquid nitrogen and used for protein extraction.  All animal manipulations were 
conducted in accordance with Italian regulations for experimentation on 
animals. 
 
 
3.11 Statistical Analysis 
Two-tailed unpaired Student’s t test (normal distributions and equal variances) 
was used for statistical analysis. Differences were significant when P < 0.05. 
Statistical analysis was performed using the Graph Pad InStat software 
program (version 3.06.3, San Diego, CA, USA). 
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4 RESULTS  
 
 
4.1 Effects of genetic BRAF knock-down in BRAF mutant thyroid 
carcinoma cells (attached manuscript #1). 
We first studied the effect of BRAF expression knockdown by RNA 
interference (siRNA). We used two ATC cell lines: FRO that expresses only 
the mutated BRAFV600E allele and ARO carrying the same mutation at the 
heterozygous level (Table 4). We used siRNA against BRAF and, as control, a 
scrambled siRNA sequence or siRNA against the housekeeping lamin A/C 
mRNA. Results are described in the attached manuscript #1. Briefly, 
transfection with BRAF siRNA, but not with the control siRNA, reduced 
BRAF, but not CRAF, protein levels in ARO cells (Figure 8A).  
 
 
Fig. 8: Knockdown of BRAF by siRNA blocks ERK signaling pathway and growth of ARO 
cells (modified from attached manuscript #1, Fig.1). 
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BRAF silencing also resulted in a reduction of p44/42 ERK (MAPK) (∼5 fold) 
and MEK1/2 (∼3 fold) phosphorylation levels 48 hours after transfection 
(Figure 8A).  Importantly, transient silencing of BRAF significantly inhibited 
the growth of ARO cells, whereas the negative control siRNA had virtually no 
effect (Figure 8B). Similar results were obtained in FRO cells (attached 
manuscript #1, Fig 1). Thus, BRAF mutant ARO and FRO cells depend on 
continous BRAF expression to sustain ERK pathway stimulation and in vitro 
growth. 
 
 
4.2 Biochemical effects of BAY 43-9006 in BRAF mutant thyroid 
carcinoma cells (attached manuscript #1). 
We evaluated the effect of chemical BRAF inhibition in BRAF mutant thyroid 
carcinoma cells. To this aim, we used BAY 43-9006 (sorafenib) on the ATC 
cell lines ARO, KAT4 and FB1, carrying the BRAFV600E mutation at the 
heterozygous level, and 8505C, FRO and NPA, which carry only the mutated 
allele (Table 4). Cells were treated with different concentrations of BAY 43-
9006 or vehicle (NT) and the phosphorylation of MEK1/2, p44/p42 ERK 
(MAPK) and p90RSK (a p44/p42 MAPK substrate) was monitored by 
immunoblot with phospho-specific antibodies. Antibodies recognizing the non-
phosphorylated proteins were used for normalization. Experiments in 
representative cell lines are reported in Figure 9. Treatment with BAY 43-
9006 reduced the phosphorylation of MEK1/2, p44/p42 MAPK and p90RSK 
with a half maximal inhibitory concentration (IC50) of 1 µM in ARO, KAT4 
and NPA cells and of 500 nM in FB1, 8505C and FRO cells.  
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Fig. 9: In vivo inhibition of ERK cascade in BRAF mutant thyroid carcinoma cells by BAY 43-
9006 (modified from attached manuscript #1, Fig. 2). 
 
 
BAY 43-9006 is a multitarget agent. To verify whether the reduced 
phosphorylation of the ERK cascade was indeed mediated by BRAF inhibition, 
we performed an in vitro BRAF kinase assay. ARO and FRO cells were treated 
with different concentrations of compound or vehicle (NT); BRAF was 
immunoprecipitated and its kinase activity measured by the phophorylation of 
recombinant GST-MEK protein. Figure 10 shows that BAY 43-9006 readily 
inhibited BRAF enzymatic activity at the concentration of 1 µM. 
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Fig. 10: In vitro inhibition of BRAF V600E kinase activity by BAY 43-9006 (modified from 
manuscript # 1, Fig. 3). 
 
4.3 Biological effects of BAY 43-9006 in BRAF mutant thyroid 
carcinoma cells (attached manuscript #1). 
We evaluated the effects exerted by BAY 43-9006 on ATC cell viability. To 
this aim, ATC cells were treated with different concentrations of BAY 43-9006 
or vehicle and counted at different time points. Figure 11 shows that the 
treatment readily reduced the growth of ATC cells but not of normal thyroid P5 
cells. The average IC50 for the ATC cell lines tested was ∼1 µM. At 5 µM BAY 
43-9006, complete growth arrest was achieved (P < 0.0001). 
 
 
 
Fig. 11: BAY 43-9006 causes growth inhibition of BRAF mutant thyroid carcinoma cells 
(modified from manuscript # 1, Fig 4)  
 
Finally, 1x106 ARO cells were injected subcutaneously in nude mice. When 
tumors reached ∼100 mm3, animals (7 for each group) were randomized and 
treated per os 5 days/week with BAY 43-9006 (30 mg/kg or 60 mg/kg) or with 
vehicle. Tumor growth was monitored with calipers. After 22 days of 
treatment, mice treated with BAY 43-9006 at either 30 mg/kg or 60 mg/kg had 
significantly smaller tumors than control mice (P<0.0001) (Figure 12A). A 
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group of mice (n=5) bearing tumors of approximately 300 mm3 were treated 
daily with 60 mg/kg of BAY 43-9006 or with vehicle for 5 days. Three hours 
after administration of the final dose, tumors were excised and used for protein 
extraction and immunoblot analysis. As shown in Figure 12B, tumor-growth 
inhibition was associated with a remarkable reduction of p44/42 MAPK, 
MEK1/2 and, at a lower extent, RSK in vivo phosphorylation levels. These 
findings suggest that, in the applied experimental conditions, BAY 43-9006  is 
able to hit the ERK pathway in tumor cells. 
 
 
 
 
Fig. 12: (A) Anti-tumorigenic effects of BAY 43-9006 in ARO cell tumor xenografts. (B) 
Inhibition of ERK signaling cascade in ARO xenografts (modified from manuscript # I, Fig 5). 
 
However,  it is well-established that BAY 43-9006 is a multitarget agent and 
therefore it is feasible that its in vivo effects are also associated with inhibition 
of kinases other than BRAF (primarily VEGFR, thereby blocking tumor 
angiogenesis). Accordingly, prominent necrotic features were observed in 
treated xenografts suggesting that anti-angiogenic effects played a role in 
tumor shrinkage induced by BAY 43-9006 (Figure 13). 
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Fig. 13: ARO tumors (∼300 mm3)-bearing animals were treated with vehicle or 60 mg/kg of 
BAY 43-9006 for 5 days. Tumors were excised and examined by conventional hematoxylin 
and eosin, and immunostaining with anti-Ki67/MIB-1. Apoptotic cell death rate was assessed 
by in situ labeling of DNA strand breaks (modified from manuscript # 1, Fig 5). 
 
Overall, these experiments demonstrated that BAY 43-9006 exerts anti-tumor 
effects in an experimental model of ATC. Phase II clinical assessment of the 
compound is in progress in patients with metastatic or unresectable aggressive 
thyroid carcinomas (www.cancer.gov/clinicaltrials/). In melanomas, the 
clinical results with this compound used as a single agent have been 
disappointing (Eisen et al. 2006). The patients in the study were not stratified 
based on the presence of BRAF mutation: however, given the high prevalence 
of BRAF mutations in melanoma (> 70%) it is unlikely that the study was 
unsuccessful because of the lack of the genetic target in the enrolled patients. 
More likely, either the compound is in vivo not potent enough at intercepting 
BRAF or targeting BRAF alone in tumors as aggressive as advanced 
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melanomas is not sufficient. In any case, given its multitargeting activity, BAY 
43-9006 does not appear to be a suitable agent to clarify whether BRAF 
targeting in vivo holds promise for the treatment of aggressive thyroid cancers. 
Other new BRAF-targeting compounds became available and we obtained 
promising preliminary results with those compounds of the PLX series (Table 
4) (data not shown). Hereafter, in this dissertation, we report our findings 
relative to MEK targeting.  
 
 
4.3 PD0325901 inhibits the proliferation of BRAF mutant thyroid 
carcinoma cells (attached manuscript #5) 
Blocking MEK, the kinase immediately downstream BRAF in the ERK 
cascade (Figure 1), may be a suitable therapeutic alternative to  direct BRAF 
targeting. Very potent and selective (non ATP-competitive) allosteric MEK 
kinase inhibitors are available. At least, given the high selectivity of these 
compounds, the approach should prove useful to define whether ERK pathway 
blockade holds promise for cancer treatment. Solit and colleagues have shown 
that cancer cells bearing an activating BRAF mutation are more sensitive to 
MEK kinase inhibitors than cells bearing different mutations (even in the same 
pathway, e.g. at the level of RAS) (Solit et al. 2006). Therefore, we selected 
again for the experiments thyroid carcinoma cell lines derived from aggressive 
tumor variants (ATC or PDC) and positive for oncogenic BRAF alleles. We 
used PD0325901 for these experiments. PD0325901 is a dual MEK inhibitor 
(equally potent on MEK1 and MEK2); its in vitro IC50 is of 1 nM (Brown et al. 
2007). The structurally related PD184352 compound did not inhibit kinases 
other than MEK up to 10 µM concentration (Davies et al. 2000). 
We initially tested the effects of PD0325901 on the proliferation rate of 
ARO, BHT101, FRO and SW1736 ATC cell lines carrying homozygous or 
heterozygous BRAF V600E alleles (Table 4). Normal PC and FRTL5 
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thyrocytes served as control. Cells were treated with different concentrations of 
PD0325901 or vehicle (NT) and counted every day for four days. The average 
results of three independent determinations are reported in Figure 14 and 
calculation of half maximal efficacy concentration (EC50) is reported in Figure 
15.  
 
 
Fig. 14: PD0325901 treatment caused growth inhibition of BRAF mutant thyroid carcinoma 
cells but had no significant effect on normal thyrocytes (from attached manuscript #5). 
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Treatment with PD0325901 caused a dose-dependent growth inhibition of all 
carcinoma cell lines with a half maximal efficacy concentration (EC50) ranging 
from 0.4 to 5 nM (P < 0.0001). Doses of 10 nM or higher had to be used to 
suppress ATC cell proliferation by 90%. Importantly, 50% growth inhibition 
was observed in normal thyrocytes only at concentrations ≥ 50 nM 
 
 
 
 
Fig. 15: EC50 for PD0325901-mediated growth inhibitory effects. 
 
Flow cytometry was applied to establish the nature of PD325901 effects on 
thyroid cell growth. ARO and SW1736 cells underwent a marked G1 arrest 
upon PD0325901 (10 nM) treatment, starting at 24 hours and lasting up to 96 
hours (Figure 16 and Figure 2A of the attached manuscript #5). No significant 
subG1 fraction was detectable, indicating that the treatment did not kill thyroid 
carcinoma cells. Importantly, PD0325901 (10 nM) did not modify cell cycle 
profile of normal control cells.  
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Fig. 16: FACS scan of cell cycle upon treatment with PD0325901 (modified from attached 
manuscript #5, see also Fig. 2A of the attached manuscript #5). 
 
Progression through the G1/S phase of cell cycle is positively controlled by the 
activity of cyclin-dependent kinases (CDKs) in association with cyclins; in 
particular, CDK4/6 in association with D-type cyclins, and CDK2 in 
association with E-type cyclins phosphorylate the retinoblastoma protein (Rb). 
Phosphorylated Rb in turn releases E2-promoter-binding factor (E2F)-related 
proteins and enhances transcription of genes participating in cell cycle 
progression (Sherr 1996). Cell cycle, by contrast, is negatively regulated by the 
inhibitory activity of members of the CIP/KIP family of cyclin-dependent 
kinase inhibitor proteins. Thus, to study the mechanism of cell cycle arrest 
upon MEK inhibition, ARO and SW1736 were treated with PD0325901 and 
the levels of cell cycle regulator proteins were determined by immunoblot. 
Figure 17 (and Fig. 2 of the attached manuscript #5) shows that upon treatment 
with PD0325901 a significant increase in the protein levels of both p21Cip1 
and p27Kip1 was observed in ATC cells at 12 up to 48 hours of treatment. 
Moreover, PD0325901 treatment induced a remarkable reduction of 
phosphorylation of the serine 795 (a CDK2 phosphorylation site) of pRb 
protein. Treatment with U0126, used as control, gave similar results (Fig. 2B in 
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the attached manuscript #5). We did not detect significan changes in cyclin D1 
and cyclin E protein levels (not shown). 
 
 
 
Fig. 17: Expression levels of cell cycle regulatory proteins upon treatment with PD0325901 
were determined by immunoblot. Anti tubulin was used for normalization. (modified from 
attached manuscript #5, see also Fig. 2B of the attached manuscript). 
 
 
4.4 PD0325901 inhibits the ERK pathway in BRAF mutant thyroid 
carcinoma cells (attached manuscript #5) 
We examined the phosphorylation levels of downstream effectors of MEK, p44 
and p42 ERKs, and RSK, a kinase that is phosphorylated by ERK. This was 
performed in the same ATC cell lines (ARO, BHT101, FRO, SW1736) used 
for the proliferation assays as well as in additional cell lines (Table 4). These 
included: FB1 (an ATC cell line which carries a heterozygous BRAF V600E 
mutation), NPA (a poorly-differentiated PTC cell line which carries only the 
BRAF V600E allele) and BCPAP (a PTC cell line, which carries a 
heterozygous BRAF V600E mutation). After 12 hours in low serum (2.5%), 
cells were treated for 2 hours with different concentrations of PD0325901 or 
vehicle (NT) and examined by immunoblot. Treatment with PD0325901 
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strongly reduced the phosphorylation of ERK at the activatory sites 
Thr202/Tyr204 and of RSK with an IC50 of about 1 nM for NPA, FRO, 
BHT101, FB1,  BCPAP and between 1 and 10 nM for ARO and SW1736 cells 
(Figure 18). Importantly, the compound also efficiently inhibited MAPK 
pathway phosphorylations in PC cells, demonstrating that its reduced growth 
inhibitory activity in normal thyrocytes was not due to defective effects on the 
target kinase but rather to the fact that normal cells are not addicted to MEK 
signaling.  
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Fig. 18: Inhibition of the ERK signaling cascade in thyroid carcinoma cell lines by PD0325901 
(modified form attached manuscript # 5). 
 
4.5 Transient nature of ERK inhibition in thyroid carcinoma cells 
(attached manuscript #5) 
We measured time-course of ERK phosphorylation upon PD0325901 treatment 
in ARO cells. Phosphor-imager quantitation of three independent experiments 
(1 and 10 nM PD0325901) at various time points is reported in Figure  19A,  
and a representative immunoblot (10 nM PD0325901), performed at early 
times, is reported in Figure 19B.  
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Fig. 19: Time-course of inhibition of the ERK signaling cascade in ARO cells by PD0325901 
or U0126 (modified form attached manuscript # 5). 
ERK inhibition was very rapid and detected as soon as after 15 min of 
treatment. It was almost complete, at both 1 and 10 nM PD0325901, after 1 
hour of treatment. Then, ERK phosphorylation started to resume after 3 hours 
and returned to levels almost equivalent to untreated cells after 6 hours. RSK 
phosphorylation paralleled ERK activity. These transitory effects were also 
detected in the other BRAF mutant thyroid carcinoma cells, although they were 
more evident in ARO cells. Figure 20 shows kinetics of ERK and RSK 
phosphorylation upon PD0325901 or U0126 treatment in ARO and SW1736 
cells. Although more slowly than in ARO, also in SW1736 cells, ERK pathway 
resumed after a transient inhibition. The transient nature of ERK inhibition was 
not unique to PD0325901, because it was seen also with U0126 (Figures 19 
and 20). Compound decay did not account for the transient nature of the 
effects, because PD0325901 replenishment one-hour before protein harvest did 
not prevent ERK phosphorylation recovery (not shown).  
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Fig. 20: Time-course of inhibition of the ERK signaling cascade (ERK in panel A and RSK in 
panel B) in ARO and SW1736 cells by PD0325901 or U0126. 
 
4.6 Regulatory circuits elicited by MEK inhibition in thyroid 
carcinoma cells (attached manuscript #5) 
In the search for the mechanism of ERK pathway restoration after MEK 
inhibition, we initially asked whether resumed ERK phosphorylation remained 
MEK-dependent. Thus, we treated ARO cells with increased doses of 
PD0325901 and measured ERK phosphorylation at different time points. 
Figure 21 shows that at 6 hours, when in cells treated with 1 nM PD0325901 
ERK phosphorylation had returned to levels comparable to untreated cells, 10 
nM of compound maintained ERK phosphorylation at levels of about 50% 
those of untreated cells; 50 nM compound blunted almost completely ERK 
phosphorylation.  
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Fig. 21: Time-course of ERK phosphorylation inhibition by increasing PD0325901 doses 
(modified from attached manuscript #5). 
 
ERK phosphorylation at Thr202/Tyr204 may resume either secondary to 
reduced response of MEK kinases to PD0325901 (which would increase the 
“on” rate), or to reduced levels of ERK-specific phosphatases (which would 
decrease the “off” rate).  
We initially verified whether PD0325901 or U0126 treatment modified 
MEK phosphorylation levels at the activatory sites Ser217/Ser221 in the 
activation loop. Noteworthy, phosphorylation at these sites enhances by 7,000-
fold the MEK kinase activity and it is also expected to reduce MEK inhibitor 
binding. Figure 22 shows that, as soon as after 1 hour of PD0325901 
treatment, MEK phosphorylation increased and remained elevated thereafter 
for at least 12 hours.  
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Fig. 22: PD0325901 or U0126 treatment rapidly increases stoichiometry of activatory MEK 
phosphorylations (modified from attached manuscript #5). 
 
RAF proteins are the only kinases known to phosphorylate Ser217/Ser221 of 
MEK. Importantly, it is known that active ERKs phosphorylate CRAF on 
various Ser/Pro sequences (Ser29, Ser289, Ser296, Ser301, and Ser642), this 
resulting in the inhibition of CRAF catalytic activity, membrane localization 
and association to BRAF (Dougherty et al. 2005, Rushworth et al. 2006). Thus, 
PD0325901 treatment could result in the potentiation of CRAF secondary to 
the blockade of ERK-mediated inhibitory phosphorylations. Since CRAF, in 
turn, is involved in oncogenic BRAF-triggered phosphorylation of MEK 
(Garnett et al. 2005), it is possible that this mechanism has an effect on MEK 
phosphorylation even in BRAF mutant cells. Finally, it is important to note that 
also BRAF is directly phosphorylated and inhibited by ERK (Brummer et al. 
2003), and therefore also BRAF de-phosphorylation upon PD0325901 may 
contribute to MEK hyper-phosphorylation (Figure 23).  
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Fig. 23: Possible negative feedback on RAF kinases abrogated by MEK targeting agents 
 
We used the available antibodies specific for CRAF phosphorylated at 
Ser289/296/301 to test this possibility. Figure 24 shows that indeed the 
phosphorylation state of CRAF at these inhibitory sites was decreased starting 
at 1-6 hours after PD0325901 treatment; again these effects were also seen 
with the control MEK inhibitor. Accordingly, our preliminary data indicate that 
both CRAF and BRAF kinase activities are potentiated upon PD0325901 
treatment (not shown). 
 
 
 
Fig. 24: Inhibitory CRAF phsophorylations are blunted by MEK targeting agents (modified 
from attached manuscript #5). 
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Dual-specificity phosphatases (DUSPs, also referred to as MAPK phosphatases 
-MKP), are able to dephosphorylate ERKs, and control intensity and duration 
of ERKs stimulation (Jeffrey et al. 2007). Importantly, DUSP/MKP are 
transcriptional targets of the ERK pathway, this representing a negative 
feedback circuit that terminates ERK signal (Jeffrey et al. 2007). Indeed, ERK 
activation in cells is in general transient; novel RNA transcription is required to 
switch-off the signal and de novo transcription of DUSP/MKP has been 
demonstrated to play a key role in signal termination (Camps et al. 2000, 
Keyse 2000). MKP3 (Muda et al. 1996) and DUSP5 (Mandl et al. 2005) have 
shown specificity for ERKs. In mammalian cells, DUSP5 expression is 
inducible by heat shock and growth factors (Ishibashi et al. 1994). The 
regulation of MKP3 expression is not clearly understood. Although MKP3 
expression seems to be constitutive in some cell types (Groom et al. 1996), in 
others MKP3 expression is induced after exposure to growth factors (Reffas 
and Schlegel 2000). In thyroid PC cells, both DUSP5 and MKP3 expression is 
markedly induced by conditional activation of RET/PTC or BRAF V600E. 
Thus, changes in expression levels of DUSP/MKPs may modify the “off” rate 
of ERK phosphorylation and contribute to the transient nature of ERK de-
phosphorylation upon treatment with pathway inhibitors (Figure 25). 
Accordingly, Ouyang et al (2006) showed that BRAF inhibition caused 
reduced levels of MKP3 and DUSP5 ERK phosphatases in thyroid carcinoma 
cells.  
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Fig. 25: Possible negative feedback based on the expression of DUSP phosphatases that may 
be abrogated by MEK targeting agents 
 
To verify this possibility, we initially treated ARO cells with orthovanadate, a 
potent DUSP/MKP inhibitor. This treatment increased the phosphorylation 
levels of ERK, suggesting that, at the steady state, ERK phosphorylation is 
under phosphatases control in ARO cells (Fig. 5C of the attached manuscript 
#5). Then, we measured expression levels of DUSP5 and MKP3 in ARO and 
SW1736 cells treated with PD0325901, by quantitative RT-PCR. PD0325901 
treatment, evoked a rapid and sustained decrease of mRNA abundance of both 
phosphatases starting 30 minutes upon treatment and lasting up to 12 hours 
(Figure 26). 
 
 
 59 
 
 
 
Figure 26: Quantitative RT-PCR measurement of MKP3 and DUSP5 mRNA levels in ARO 
cells treated with 10nM PD0325901 for the indicated times (modified from Fig 5D of the 
attached manuscript #5). 
 
 
 
4.7 Cross-talk between ERK and PI3K/AKT pathways  
Our data indicate that multiple levels of regulation, both at ERK upstream and 
downstream level, are evoked by MEK targeting agents, this blunting in turn, 
the efficacy of chemical ERK inhibition. We considered the possibility that 
similar regulatory circuits may also affect pathways other than the ERK one 
and focused our attention on the PI3K/AKT cascade. To this aim, we treated 
ARO and SW1736 cells with PD0325901 and U0126 at different time points 
and measured AKT phosphorylation levels by using a phosphospecific 
antibody recognizing Ser473-phosphorylated AKT. Intriguingly, AKT 
phosphorylation levels readily increased upon treatment of ATC cells with 
MEK inhibitory agents (Figure 26). This occurred with different kinetics in the 
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two cell lines; moreover, the effect was transient and quite rapidly it 
disappeared. 
 
 
 
 
Fig. 27: Phosphorylation of AKT on serine 473 in cells treated with PD0325901 or U0126 at 
the indicated time points. 
 
 
In principle, AKT activation could counteract cytostatic effects of MEK 
targeting. In turn, simultaneous inhibition of MEK and AKT could increase the 
efficacy of the approach. To verify this possibility, we treated ARO cells with 
1 nM PD0325901 (a dose able to only partially inhibit the cellular growth) in 
the presence or not of two different PI3K inhibitors (LY294002 and 
Wortmannin). The cells were counted every day for 4 days. Figure 28 shows 
 61 
that PD0325901 cooperated with both LY294002 or Wortmannin, in the 
induction of ARO cells growth arrest.  
 
 
 
Fig 28: Additive effects of PD0325901 and LY294002 or Wortmannin in ARO cell growth 
inhibition. 
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5 DISCUSSION 
Thyroid cancer has in general an indolent course and patients with WDTC are 
efficiently treated by surgery and adjuvant radioiodine treatment (Cooper et al. 
2006, Pacini et al. 2006, Schlumberger 1998, Schlumberger et al. 2007). 
However, advanced WDTC (PTC and FTC) and ATC typically exhibit 
radioiodine resistance and poor prognosis. For these particular patients novel 
treatment strategies are urgently needed.  
Clinical trials with different agents are in progress for aggressive 
thyroid cancers (www.thyroidtrials.org; www.cancer.gov/clinicaltrials) (Table 
5). These agents include compounds targeting the 26S proteasome, inhibitors 
of molecular chaperones, inhibitors of histone deacetylases and of DNA 
methylases, angiogenesis inhibitors. 
 
Table 5: Examples of ongoing clinical trials in thyroid cancer patients (informations retrieved 
from the American Thyroid Association and the National Institutes of Health web sites) 
Trial number Phase Agent Molecular target 
NCT00104871 Phase II Bortezomib (Velcade) 26S proteasome  
NCT00098852 Pilot Rosiglitazone PPARγ  
NCT00118248 Phase II 17-AAG HSP90 
NCT00098813 Phase II Depsipeptide HDAC  
NCT00085293 Phase II Decitabine DNA methylation  
NCT00389441 Phase II AG-013736 (axitinib) VEGFR  
 
Our studies at the preclinical level suggest that additional proteins that are 
highly up-regulated in ATC samples, like the chemokine receptor CXCR4 
(attached manuscript #3) and the cell cycle-regulated kinase PLK1 (attached 
manuscript #4), deserve attention as promising targets for therapeutic 
intervention in ATC.  
 Protein kinases have emerged as prime targets for the development of 
novel molecularly targeted therapies for cancer patients. This concept has 
being applied also to thyroid cancer. For instance, different agents inhibiting 
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the RET kinase, involved in MTC and PTC formation, are being studied in 
thyroid cancer patients (Carlomagno et al. 2002, Carlomagno et al. 2006, 
Santoro and Carlomagno 2006). The BRAF/MEK/ERK pathway is a promising 
molecular therapeutic target for PTC and ATC. BRAF mutations are highly 
prevalent in these tumor types and, in PTC, they correlate with adverse clinical 
features.  
 Here, we studied at the molecular level the effects of BRAF and MEK 
targeting in BRAF mutant thyroid carcinoma cells. Our findings show the 
efficacy of this approach to arrest thyroid carcinoma cell proliferation. 
However, they also anticipate possible shortcomings of this strategy. In 
summary, our findings have shown that: 
• BRAF mutant thyroid carcinoma cell lines are addicted to continous 
BRAF expression; 
• BAY 43-9006 (sorafenib) at µM concentration has cytostatic effects in 
vitro in BRAF mutant thyroid cell lines;  
• BAY 43-9006 (sorafenib) has therapeutic efficacy in a xenograft model 
of ATC;  
• MEK targeting by PD0325901 at nM concentration has cytostatic 
effects in vitro in BRAF mutant thyroid cell lines.  
BAY 43-9006 (sorafenib) is a multitarget compound, able to inhibit many other 
kinases besides RAF, including KIT, PDGFR, RET and VEGFR (Wilhelm et 
al. 2006, Sebolt-Leopold and Herrera, 2004). Therefore, it remains unclear 
whether its clinical activity is mediated by inhibition of RAF, other kinases, or 
both. The compound has been approved for treatment of RCC (Baselga 2006). 
The disappointing clinical results obtained in melanoma can be explained by 
the aggressive phenotype of this tumor or by the fact that the compound in 
patients is not potent enough at targeting BRAF. Our data, obtained with MEK 
kinase inhibitors (see below), suggest that regulatory circuits elicited by ERK 
pathway targeting may hamper the efficacy of the inhibitors and therefore 
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require rational combinations rather than single agents. Other BRAF chemical 
inhibitors are available and some of them, like PLX4032, are in clinical 
development (Wang et al. 2007). We tested in ATC cell lines PLX4032 and the 
related compound PLX4720 and found that they potently inhibit cell 
proliferation (data not shown). 
  MEK1 and MEK2 appear to be the most critical downstream mediators 
of BRAF V600E signaling (Garnett and Marais 2004). Potent and selective 
non-ATP competitive inhibitors of MEK kinases are in clinical development 
(Sebolt-Leopold and Herrera 2004, Sebolt-Leopold and English 2006, 
Schubbert et al. 2007). Previous studies have shown that MEK blockade with 
U0126 inhibited proliferation of ARO and NPA thyroid carcinoma cells 
(Braga-Basaria et al. 2004) and partially restored thyroid differentiated 
phenotype (Liu et al. 2007). Recently, Ball et al (2007) and Liu et al (2007) 
have studied the effects of AZD6244 and CI-1040 on thyroid carcinoma cells. 
MEK inhibition had potent cytostatic effects in thyroid carcinoma cells 
harbouring the BRAF or the HRAS (Ball et al. 2007, Liu et al. 2007) mutation 
but not in wild type BRAF cells. The two compounds inhibited the growth of 
xenograft tumors in nude mice and CI-1040 restored the expression of some 
thyroid cell differentiation markers.  
  In this work, we studied the effect of PD0325901 in ATC cell lines 
harbouring the V600E BRAF mutation. The compound resulted extremely 
potent at intercepting ERK signaling and causing cell growth inhibition. 
Importantly, PD0325901 had effects in normal thyrocytes only at doses 5-10-
fold higher than cancer cells, indicating the opportunity of a therapeutic 
window. Probably, normal cells as well as cancer cells bearing mutations at 
levels other than the BRAF one, may use redundant cell growth signaling 
pathway and therefore be less dependent on MEK activity. This is an important 
observation because MEK targeting may potentially be an extremely toxic 
approach. Erk1null mice have a twofold reduction in the number of mature 
 65 
thymocytes. The involvement of the MAPK pathway in immune signalling has 
therefore raised important concerns about the possibility that the tretament is 
immunosuppressive. Mek1null mice undergo embryonic lethality for impaired 
placental development, raising further concerns about the potential deleterious 
clinical consequences of MEK inhibition (Sebolt-Leopold and Herrera, 2004). 
However, initial results of Phase I and II studies with CI-1040, ARRY-142886 
and PD0325901 have demonstrated that the tretament is overall well-tollerated 
with rash, diarrhea, nausea, astenia, and anemia among the most frequent side 
effects (Wang et al. 2007). 
  Besides toxicity, other possible shortcomings may limit the efficacy of 
kinase inhibitors in cancer teatment. Molecular resistance formation has been 
described as a serious concern, causing disease relapse after a initial response. 
Numerous mechanisms may cause resistance to protein kinase inhibitors. 
Among them, the expansion of clonal cells carrying mutations of the target 
kinase appears to be an important mechanism. In the paradigmatic example of 
imatinib for the treatment of CML, resistance causing mutations occur and 
either prevent the ABL adopting the inactive conformation to which the 
compounds binds, or alter the compound contact point (Sawyers 2007). It is 
still unknown whether BRAF or MEK kinases may be subjected to similar 
mutations. 
  Besides direct mutation in the target kinase, regulatory signaling 
circuits may be elicited by the treatment and dampen its efficacy. These 
circuits may either activate parallel pathways to complement the targeted one 
or may resume, at different levels, the targeted cascade. Signal transduction 
pathways are indeed controlled by a network of regulatory circuits. Although 
the major effect of these circuits is probably to prevent excessive signaling, 
their abrogation by molecularly targeted agents, may cause a compensatory 
stimulation of the pathway (Amit et al. 2007). As an example, treatment with 
inhibitors of mTOR, a kinase acting downstream AKT and PI3K, by removing 
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negative feedbacks that act upstream or at the level of AKT, exerted only 
transient biological effects. Importantly, this could be circumvented by 
combining PI3K and mTOR inhibitors (Sun et al. 2005, O’Reilly et al. 2006, 
Fan et al. 2006).  
  Our data show that treatment with MEK targeting agents is able to tune 
many of these controls and kinetics analysis suggests that these events 
contribute to rapidly attenuate ERK inhibition and perhaps biological effects of 
PD0325901 and U0126 treatment. We found, indeed, that these circuits affect 
both the ERK and the PI3K/AKT signaling cascades (Figure 29).  
 
 
 
 
Fig. 29: Schematic representation of regulatory loops that are elicited when MEK is targeted in 
BRAF mutation positive thyroid cancer cells. 
 
As far as the ERK cascade is concerned: 
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• at the transcriptional level, the downregulated expression of MKP3 and 
DUSP5, likely reduced the turn-over rate of ERK phosphorylation 
thereby blunting ERK inhibition upon MEK blockade; 
• at the post-translational level, treatment with MEK targeting agents 
attenuated ERK-dependent inhibitory phosphorylations of RAF kinases, 
this, in turn, likely accounting for the rapid attenuation of MEK 
inhibition in cells treated with PD0325901.  
We cannot exclude that additional regulatory mechanisms result in MEK 
overactivation, thus hampering the efficacy of MEK inhibitory agents. For 
instance, in some but not all reports, ERK-mediated phosphorylation of MEK1 
on Thr292 was found to attenuate MEK activity, anticipating that ERK 
inhibition could potentiate it (Eblen et al. 2004, Brunet et al  1994; Gardner et 
al 1994). Furthermore, changes in the expression levels of MEK phosphatases, 
such as PP2A, may occur and affect cell response to MEK inhibition. 
 As far as the PI3K/AKT cascade, we noted a rapid phosphorylation of 
AKT secondary to MEK inhibition. The mechanism of this unexpected result is 
still unclear. We cannot exclude that AKT is directly modified (for instance 
secondary to mTOR modulation by MEK inhibitors) or that, alternatively, it is 
stimulated by upstream signals. The deletion of ERK-mediated inhibitory 
feedbacks may not only affect the RAF level of the cascade but also other 
upstream components, like RAS or even the growth factor receptors or their 
direct signaling mediators. ERK-mediated phosphorylations may inhibit 
receptor-coupled signaling intermediates such as the SOS exchange factor or 
the GAB1 docking protein. Thus, ERK inbibition secondary to MEK blockade 
may promote the function of these signalling molecules, thereby resulting, not 
only in ERK pathway, but also PI3K pathway resume. Whatever the 
mechanism our findings suggest that the AKT activation secondary to MEK 
targeting is PI3K-dependent and therefore suggest combination of MEK and 
PI3K inhibitors as a potential strategy to overcome the phenomenon. This 
 68 
information needs to be intepreted cautiously, however, since the PI3K 
inhibitors we used are known to be not specific and off-target effects cannot be 
ruled out. Similarly, the rapid resume of the ERK cascade may be theoretically 
prevented by combining MEK with BRAF inhibitors. Although non-specific 
also Hsp90 inhibitors like 17-AAG, known to be able to promote the 
proteasome-mediated degradation of BRAF V600E, may also be exploited.  
 69 
6 CONCLUSIONS 
Here we provide evidence that BRAF and MEK targeting may be suitable 
approaches to arrest proliferation of thyroyd cancer cells positive for the BRAF 
mutation. We also show that there is opportunity for a therapeutic window be 
achieved with MEK kinase inhibitors. Although MEK inhibitory agents exerted 
significant growth inhibitory properties in thyroid carcinoma cells, they also 
elicited compensatory mechanisms that attenuate the duration of their effects 
and caused the activation of parallel signaling cascades. As with conventional 
chemotherapeutic agents, which are often most effective when administered as 
combination therapies, rationally developed combinations of molecularly 
targeted agents at multiple levels of the ERK cascade or at both ERK and PI3K 
cascades may prove to be more effective targeting strategies than single-agent 
therapies.  
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Abstract Purpose: Oncogenic conversion of BRAF occurs inf44% of papillary thyroid carcinomas and
24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is associated
with anunfavorable clinicopathologic outcome. Our aimwas to exploit BRAFas a potential thera-
peutic target for thyroid carcinoma.
Experimental Design:Weused RNA interference to evaluate the effect of BRAF knockdown in
the human anaplastic thyroid carcinoma cell lines FRO and ARO carrying the BRAF V600E
(V600EBRAF) mutation.We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-
chlorophenyl)-N’-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea], a multikinase inhibitor
able to inhibit RAF family kinases in a panel of sixV600EBRAF-positive thyroid carcinoma cell lines
and in nudemice bearing ARO cell xenografts. Statistical tests were two sided.
Results: Knockdown of BRAF by small inhibitory duplex RNA, but not control small inhibitory
duplex RNA, inhibited the mitogen-activated protein kinase signaling cascade and the growth of
AROandFROcells (P < 0.0001).These effectsweremimickedby thyroid carcinoma cell treatment
with BAY 43-9006 (IC50 = 0.5-1 Amol/L; P < 0.0001), whereas the compound had negligible
effects in normal thyrocytes. ARO cell tumor xenografts were significantly (P < 0.0001) smaller in
nude mice treated with BAY 43-9006 than in control mice. This inhibition was associated with
suppression of phospho ^mitogen-activated protein kinase levels.
Conclusions: BRAF provides signals crucial for proliferation of thyroid carcinoma cells
spontaneously harboring the V600EBRAF mutation and, therefore, BRAF suppression might have
therapeutic potential inV600EBRAF-positive thyroid cancer.
Thyroid tumors are the most frequent neoplasms of the
endocrine system (1). Well-differentiated thyroid carcinomas
account for >90% of all thyroid cancers and include papillary
and follicular carcinomas. Papillary thyroid carcinoma is the
most prevalent subtype. Although papillary thyroid carcinoma
is usually curable with surgery and adjuvant radioiodine treat-
ment, some patients may show an aggressive disease and lose
radioiodine concentration ability. Papillary thyroid carcinoma
subtypes, like the tall-cell variant, more frequently have an
aggressive behavior (2). Undifferentiated (anaplastic) thyroid
carcinoma accounts for f2% to 5% of all thyroid cancers (3).
Despite its rarity, more than half of the deaths attributed
to thyroid cancer result from anaplastic thyroid carcinoma
(3–5). More than 25% of anaplastic thyroid carcinoma patients
have coincidentally detected well-differentiated carcinoma,
suggesting that, at least in some cases, anaplastic thyroid
carcinoma derives from a preexisting well-differentiated
carcinoma (3–5). Rapid growth and dissemination characterize
the clinical course of anaplastic thyroid carcinoma. Virtually,
all anaplastic thyroid carcinoma patients die from their disease
in 2 to 7 months; death is attributable to upper airway
obstruction and suffocation in half of the patients (3–5).
Anaplastic thyroid carcinomas do not concentrate radioiodine
and do not respond to conventional chemotherapy (3–5).
BRAF belongs to the RAF family of serine/threonine kinases.
RAF proteins are components of the RAF-MEK [mitogen
activated protein (MAP)/extracellular signal-regulated kinase
(ERK) kinase]-ERK pathway, a highly conserved signaling
module in eukaryotes. They are activated through binding to
RAS in its GTP-bound state. Once activated, RAF kinases
phosphorylate MEK, which in turn phosphorylates and
activates ERK (6). Activation of BRAF has emerged as the most
prevalent oncogenic mutation in thyroid carcinoma (7–14).
Overall, this genetic alteration is found in f44% of papillary
thyroid carcinoma and 24% of anaplastic thyroid carcinoma
(reviewed in ref. 15). In the case of anaplastic thyroid
carcinoma, BRAF mutations are restricted to those cases that
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arose in association with papillary thyroid carcinoma (12, 14).
A transversion from thymine to adenine (T1799A), leading to
a Glu for Val substitution at residue 600 (V600E), accounts
for >90% of BRAF mutations in thyroid carcinomas. Other
more rare mutations have been described (reviewed in ref. 15).
The V600E mutation enhances BRAF activity by disrupting the
autoinhibited state of the kinase (16). Another interesting
mechanism for BRAF activation has been described in
radiation-induced papillary thyroid carcinoma, where a para-
centric inversion of chromosome 7q resulted in the in-frame
fusion between the AKAP9 gene and BRAF (17).
Consistent with a pivotal role in thyroid cancer initiation,
V600EBRAF has been found in microcarcinomas (15), and it was
shown to induce transformed features in thyroid follicular cells
in culture (18, 19) and thyroid carcinoma formation in
transgenic mice (20). Many evidences suggest that V600EBRAF
plays a role in thyroid cancer progression as well: (a) Adoptive
expression of V600EBRAF induces genomic instability in cultured
thyrocytes (19); (b) thyroid tumors in V600EBRAF-transgenics
undergo dedifferentiation and metastasis formation (20); and
(c) papillary thyroid carcinoma with the V600EBRAF mutation
often presents with extrathyroidal invasion, lymph node
metastasis, and advanced tumor stage (14). Importantly, the
V600EBRAF mutation was frequently associated to loss of I-131
avidity and papillary thyroid carcinoma recurrence (14).
In this framework, BRAF could be an appealing therapeutic
target for thyroid carcinomas, especially for aggressive papillary
thyroid carcinoma subtypes and anaplastic thyroid carcinoma.
Here, we show that suppression of BRAF expression exerts
cytostatic activity in V600EBRAF-positive thyroid carcinoma
cell lines. Moreover, we show that BAY 43-9006 [N-(3-
trifluoromethyl-4-chlorophenyl)-N ’-(4-(2-methylcarbamoyl
pyridin-4-yl)oxyphenyl)urea], a multikinase ATP-competitive
inhibitor able to obstruct RAF kinases (21–24), reduces tumor
growth in an anaplastic thyroid carcinoma xenograft model.
Materials andMethods
Compounds. BAY 43-9006 was provided by Bayer HealthCare
Pharmaceuticals (West Haven, CT). For in vitro experiments, BAY 43-
9006 was dissolved in DMSO. For in vivo experiments, BAY 43-9006
was dissolved in Cremophor EL/ethyl alcohol (50:50; Sigma Cremo-
phor EL, 95% ethyl alcohol; Sigma Chemical Co., St. Louis, MO) at
4-fold (4) the highest dose, foil-wrapped, and stored at room
temperature. A fresh supply of the 4 stock solution was prepared
every 3 days. Final dosing solutions were prepared on the day of use by
dilution of the stock solution to 1 with water.
Cell cultures. We used six cancer cell lines in this study: (a) the
anaplastic thyroid carcinoma cell lines ARO (25), FB1 (26), KAT4 (27),
and FRO (28); (b) the 8505C cell line (29), established from an
anaplastic thyroid carcinoma containing areas of papillary thyroid
carcinoma; (c) the NPA cell line (28) established from a poorly
differentiated thyroid carcinoma. The ARO (11), KAT4 (12), and FB1
(12) cells harbor a heterozygous BRAF V600E mutation, whereas 8505C
(12), NPA, and FRO (13) express only the mutated BRAF allele. Cells
were grown in DMEM supplemented with 10% fetal bovine serum (Life
Technologies, Paisley, PA), 2 mmol/L L-glutamine, and 100 units/mL
penicillin-streptomycin (Life Technologies). The P5 primary culture of
normal human thyroid follicular cells was kindly donated by Francesco
Curcio (Dipartimento Di Patologia e Medicina Sperimentale e Clinica,
Udine, Italy) and was grown as described elsewhere (30). For cell
proliferation assays, 5  104 cells were plated in 35 mm dishes in 2.5%
serum. The day after plating, BAY 43-9006 or vehicle was added. Cells
were counted in triplicate every day. For flow cytometry analysis,
5  105 cells were plated in 100 mm dishes in 2.5% serum, and the
next day they were treated with different concentrations of BAY 43-9006
or vehicle. After harvesting, cells were fixed in cold 70% ethyl alcohol in
PBS. Propidium iodide (25 Ag/mL) was added in the dark and samples
were analyzed with a FACSscan flow cytometer (Becton Dickinson, San
Jose, CA) interfaced with a Hewlett-Packard computer (Palo Alto, CA).
RNA silencing. The small inhibitor duplex RNAs targeting human
BRAF we used in this study (31) were chemically synthesized by
PROLIGO (Boulder, CO). Sense strands for small inhibitory duplex
RNA (siRNA) targeting were as follows: BRAF, 5V-AGAAUUGGAUCUG-
GAUCAUTT-3V; lamin A/C, 5V-CUGGACUUCCAGAAGAACATT-3V. As a
control, we used a nonspecific siRNA duplex containing the same
nucleotides but in irregular sequence (scrambled). For siRNA transfec-
tion, cells were grown under standard conditions. The day before
transfection, 1  105 cells were plated in 35 mm dishes in DMEM
supplemented with 10% fetal bovine serum and without antibiotics.
Transfection was done using 360 pmol siRNA and 18 AL Oligofect-
AMINE reagent (Invitrogen, Groningen, the Netherlands) following the
instructions of the manufacturer. Cells were kept in 2.5 serum and
counted 48 and 72 hours after transfection.
Protein studies. Immunoblotting experiments were done according
to standard procedures. Briefly, cells were harvested in lysis buffer
[50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1%
Triton X-100, 1 mmol/L EGTA, 1.5 mmol/L MgCl2, 10 mmol/L NaF,
10 mmol/L sodium PPi, 1 mmol/L Na3VO4, 10 Ag aprotinin/mL, and 10
Ag leupeptin/mL] and clarified by centrifugation at 10,000  g . For
protein extraction, samples of mouse xenografts were snap frozen and
immediately homogenized in lysis buffer by using the Mixer Mill
MM300 (Qiagen, Crawley, West Sussex, United Kingdom). Protein
concentration was estimated with a modified Bradford assay (Bio-Rad,
Munich, Germany). Antigens were revealed by an enhanced chemilu-
minescence detection kit (ECL, Amersham Pharmacia Biotech, Little
Chalfont, United Kingdom). Signal intensity was evaluated with the
Phosphorimager (Typhoon 8600, Amersham Pharmacia Biotech)
interfaced with the ImageQuant software. Anti-phospho-p44/42
MAP kinase (MAPK), specific for MAPK (ERK1/2) phosphorylated at
Thr202/Tyr204, anti-p44/42 MAPK, anti-phospho-p90RSK (90 kDa
ribosomal S6 kinase), specific for p90RSK phosphorylated at Thr359/
Ser363, anti-p90RSK, anti-phospho-MEK1/2 (MAPK1 and MAPK2),
specific for MEK1 and MEK2 phosphorylated at Ser217/Ser221, and
anti-MEK1/2 were purchased from Cell Signaling (Beverly, MA). Anti-
BRAF antibody was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Monoclonal anti-a-tubulin was from Sigma Chemical.
Secondary antibodies coupled to horseradish peroxidase were from
Santa Cruz Biotechnology. For the BRAF kinase assay, cells were cultured
for 12 hours in serum-deprived medium. Thereafter, cells were treated
with BAY 43-9006 for 1 hour; BRAF kinase was immunoprecipitated
with the anti-BRAF antibody and resuspended in a kinase buffer
containing 25 mmol/L sodium PPi, 10 ACi [32P]ATP, and 1 Ag
recombinant glutathione S-transferase–MEK (Upstate Biotechnology,
Inc., Lake Placid, NY). After 30-minute incubation at 4jC, reactions were
stopped by adding 2 Laemmli buffer. Proteins were then subjected
to 12% SDS gel electrophoresis. The radioactive signal was analyzed
using a Phosphorimager (Molecular Dynamics, Piscataway, NJ).
Tumorigenicity in nude mice. Animals were housed in barrier
facilities at the Dipartimento di Biologia e Patologia Cellulare e
Molecolare (University of Naples ‘‘Federico II,’’ Naples, Italy). They
were exposed to a 12-hour light-dark cycle and received food and water
ad libitum . All manipulations were conducted in accordance with Italian
regulations for experimentation on animals. No mouse showed signs
of wasting or other signs of toxicity. ARO cells (1  106/mouse) were
inoculated s.c. into the right flank of 4-week-old male BALB/c nu/nu
mice (The Jackson Laboratory, Bar Harbor, ME). Tumors (f100 mm3)
were treated with BAY 43-9006 (30 or 60 mg/kg) or vehicle alone
by oral gavage for 5 consecutive days per week for 3 weeks. Tumor
diameters were measured with calipers. Tumor volumes (V) were
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calculated by the formula: V = A  B2 / 2 (A = axial diameter; B =
rotational diameter). Another group of animals (surrogate) was treated
with vehicle or 60 mg/kg of BAY 43-9006 (five animals per group) for
5 days starting when the tumors reached f300 mm3. Tumors were
excised 3 hours after the last dose and divided in two parts. Half of the
tissue was snap-frozen in liquid nitrogen and used for protein
extraction. The other half of the tissue was fixed overnight in neutral
buffered formalin and processed by routine methods. Paraffin-
embedded blocks were sliced into 5 Am sections and stained by H&E
for histologic examination or processed for immunohistochemistry.
Briefly, sections were deparaffinized, alcohol-rehydrated, subjected to
heat-induced antigen retrieval, and incubated overnight with anti-Ki67/
MIB-1 (1:50, 3,3V-diaminobenzidine, DAKO, Carpinteria, CA) or anti-
CD31 antibodies [platelet/endothelial cell adhesion molecule 1 (M-20)
goat polyclonal; Santa Cruz Biotechnology; ref. 32]. Finally, the slides
were incubated with biotinylated anti-IgG and with premixed avidin-
biotin complex (Vectostain ABC kits, Vector Laboratories, Burlingame,
CA). The immune reaction was revealed with 0.06 mmol/L diamino-
benzidine (DAKO) and 2 mmol/L hydrogen peroxide. As a negative
control, tissue slides were incubated with preimmune serum. Apoptotic
cell death rate was assessed in tissue slides by in situ labeling of DNA
strand breaks as previously described (33). Briefly, dewaxed tissue
sections were digested with Proteinase K (Boehringher Mannheim,
Mannheim, Germany) and processed with the in situ cell death
detection kit (Roche Diagnostics, Mannheim, Germany) used according
to the instructions of the manufacturer.
Statistical analysis. Two-tailed unpaired Student’s t test (normal
distributions and equal variances) were used for statistical analysis.
Differences were significant when P < 0.05. Statistical analysis was done
using the Graph Pad InStat software program (version 3.06.3, San
Diego, CA).
Results
Selective knockdown of BRAF by siRNA blocks the
MAPK cascade and growth of anaplastic thyroid carcinoma cell
lines. We used RNA interference (RNAi) to specifically knock
down BRAF expression in two anaplastic thyroid carcinoma cell
lines: FRO that express only the mutated V600EBRAF allele and
ARO carrying the same mutation at the heterozygous level. We
used siRNAs against BRAF and, as control, a scrambled siRNA
sequence or siRNA against the housekeeping lamin A/C mRNA.
Transfection with BRAF siRNA, but not with the control
siRNAs, diminished BRAF, but not c-RAF, protein levels in
FRO and ARO cells (Fig. 1A and C). BRAF protein knockdown
was significant 48 hours after transfection (Fig. 1A and C), but
only very modest after 24 hours (not shown). As a positive
control of transfection, lamin A/C siRNA caused a strong
inhibition of lamin protein levels (Fig. 1A and C). MEK1/2
kinases, once phosphorylated by RAF kinases at serine 217 and
221, phosphorylate threonine 202 and tyrosine 204 in the
activation segment of p44 and p42 MAPK (ERK1 and 2; ref. 34).
Thus, we analyzed MEK1/2 and MAPK phosphorylation upon
BRAF knockdown in anaplastic thyroid carcinoma cells.
Consistent with a key role of BRAF in MAPK cascade, BRAF
silencing in FRO and ARO cells resulted in a reduction of p44/
42 MAPK (f5-fold) and MEK1/2 (f3-fold) phosphorylation
levels 48 hours after transfection (Fig. 1A and C).
We asked whether BRAF expression was required for the
growth of BRAF mutation–positive anaplastic thyroid carcino-
ma cells. Cell counts were obtained in triplicate after FRO and
ARO cell transfection with BRAF or scrambled siRNA. The
transient silencing of BRAF significantly inhibited the growth of
FRO and ARO cells (in 2.5% serum), whereas the negative
control siRNA had virtually no effect (Fig. 1B and D). After
48 hours, FRO cells treated with scrambled RNAi numbered
77.3  103 and those treated with BRAF RNAi numbered
23.3  103 (P < 0.0001). After 48 hours, ARO cells treated with
scrambled RNAi numbered 48  103 and those treated with
BRAF RNAi numbered 18  103 (P < 0.0001). Thus, continued
BRAF expression is essential for MAPK stimulation and growth
of FRO and ARO cells.
Inhibition of oncogenic BRAF signaling in thyroid carcinoma
cell lines by BAY 43-9006. Of the small-molecule RAF kinase
inhibitors in clinical development, BAY 43-9006 is the furthest
along (35). BAY 43-9006 is a multikinase inhibitor able to
target not only RAF kinases but also receptor tyrosine kinases,
including vascular endothelial growth factor receptor-2 (KDR)
and platelet-derived growth factor receptor B. Thus, its
anticancer activity is currently thought to be the result of
the dual inhibition of RAF signaling and KDR-mediated and
Fig. 1. Knockdown of BRAF by siRNA blocks signaling and growth of FRO and
AROcells. Cells were grownunder standard conditions.The day before transfection,
1105 cells were plated in 35 mm dishes in DMEMsupplemented with10% serum
andwithout antibiotics.Transfection (day 0) was done in triplicate using 360 pmol
of the indicated siRNA. Mock-transfected cells (NT) served as a control. Cells
were kept in 2.5% serum; protein lysates were harvested after 48 hours and
analyzed by immunoblot with the indicated antibodies: FRO cells are shown in (A)
and ARO cells are shown in (C).Transfected cells were counted 24 and 48 hours
after transfection. Points, mean of triplicate determinations; bars, 95% confidence
intervals (B andD). Statistical significancewas determined by the two-tailed
unpaired Student’s t test.
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platelet-derived growth factor receptor B–mediated tumor
angiogenesis (23, 35).
Because BRAF expression was found to be essential for
thyroid carcinoma cell growth, chemical BRAF blockade by
BAY 43-9006 could exert cytostatic effects; thus, BAY 43-9006
could be exploited as a therapeutic tool for BRAF mutation–
positive thyroid carcinoma models. To investigate this possi-
bility, we studied the effects of BAY 43-9006 on the anaplastic
thyroid carcinoma cell lines ARO, KAT4, and FB1, which carry
the V600EBRAF mutation at the heterozygous level, and 8505C,
FRO, and NPA, which carry only the mutated allele. After 12
hours of cultivation in low serum (2.5%), cells were treated for
6 hours with different concentrations of BAY 43-9006 or
vehicle (NT) and the activity of MEK1/2, p44/p42 MAPK, and
p90RSK (a p44/p42 MAPK substrate) was monitored by
immunoblot with phosphospecific antibodies. Antibodies that
recognize the same proteins also when nonphosphorylated
were used for normalization. Immunoblots were examined
with the Phosphorimager. Representative experiments are
reported in Fig. 2. Consistent with the expression of an
oncogenic BRAF, the MAPK cascade was constitutively active
(even in low serum) in all the thyroid carcinomas tested.
Treatment with BAY 43-9006 reduced the phosphorylation of
MEK1/2, p44/p42 MAPK, and p90RSK with a IC50 of 1 Amol/L
for ARO, KAT4, and NPA cells and of 500 nmol/L for FB1,
8505C, and FRO cells. After treatment with 5 Amol/L BAY
43-9006, only residual phosphorylation levels of MEK1/2,
p44/p42 MAPK, and p90RSK were detected in the carcinoma
cell lines (Fig. 2).
To verify whether MAPK kinase knockdown was mediated
by an inhibition of BRAF activity, we used an immunocom-
plex in vitro BRAF phosphorylation assay. Based on the
presence of the V600E mutation, BRAF activity was high in
NPA, KAT4, ARO, FRO (Fig. 3A), and FB1 and 8505C (not
shown) cells, but not in normal P5 thyrocytes. We treated ARO
and FRO cells with different concentrations of the compound
or vehicle (NT) and examined them with the in vitro BRAF
kinase assay. Figure 3B shows that BAY 43-9006 readily
inhibited intrinsic BRAF enzymatic activity at the concentration
of 1 Amol/L.
Fig. 3. V600EBRAF kinase blockade by BAY 43-9006. A, the indicated cell lines
were cultured for12 hours in serum-deprivedmedium andharvested; a BRAF kinase
assay was done (see below). B, cells were treated for1hour with different doses of
BAY 43-9006 and then harvested. Cell lysates (500 Ag) were immunoprecipitated
with an anti-BRAF-specific antibody and subjected to a kinase assay with
recombinant glutathione S-transferase ^ MEK (GST-MEK ; 1 Ag) as substrate. After
30 minutes of incubation at 4jC, reactions were stopped and proteins were
subjected to12% SDS gel electrophoresis.The radioactive signal was evaluated
with the Phosphorimager. Representative of at least three different experiments.
Fig. 2. In vivo inhibition of MAPK cascade in thyroid
carcinoma cells by BAY 43-9006.The indicated
thyroid carcinoma cell lines carrying homozygous or
heterozygous mutations of BRAF were kept in 2.5%
serum and treated with increasing concentrations of
BAY 43-9006. Six hours later, cells were lysed and
50 Ag of total cell lysates were analyzed byWestern
blotting with the indicated phosphospecific antibodies.
Total amounts of MEK, MAPK, and RSK are shown for
normalization.The results were quantified by the
Phosphorimager. Representative of at least three
different experiments.
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Finally, ARO, KAT4, FRO, and NPA cells were treated (in
2.5% serum) with different concentrations of BAY 43-9006 or
vehicle and counted at different time points. The average results
of three independent determinations are reported in Fig. 4. BAY
43-9006 treatment readily reduced the proliferation rate of
thyroid carcinoma but not of normal thyroid P5 cells. The IC50
for the four carcinoma cell lines was f1 Amol/L; at 5 Amol/L,
BAY 43-9006 virtually arrested thyroid carcinoma cell growth
(P < 0.0001; Fig. 4). Examination of the ARO cell cycle profile
after BAY 43-9006 treatment (in 2.5% serum) by flow cytometry
showed a marked G1 arrest upon treatment with 2.5 Amol/L BAY
43-9006. There were a few cells in the sub-G1 fraction, which
indicates that BAY 43-9006 treatment results mainly in a
cytostatic effect in these cells (not shown).
Inhibition of ARO-induced tumor formation in nude mice by
BAY 43-9006. ARO cells were selected based on their high
tumorigenic potential. Nude mice were injected with 1  106
ARO cells and afterf10 days, when tumors had reachedf100
mm3, animals (seven for each group) were randomized and
treated orally 5 d/wk with BAY 43-9006 (30 or 60 mg/kg) or
with vehicle. Tumor growth was monitored with calipers.
The experiment was done twice and a representative experiment
is shown in Fig. 5A. After 22 days of treatment, mice treated
with BAY 43-9006 at either 30 or 60 mg/kg had significantly
smaller tumors than control mice (P < 0.0001). No significant
improvement of the therapeutic effect was noted at 60 mg/kg
with respect to 30 mg/kg, indicating that maximal therapeutic
efficacy was already achieved at 30 mg/kg.
For mechanism of action studies, a group of mice (n = 5)
bearing tumors off300 mm3 were treated daily with 60 mg/kg
of BAY 43-9006 or with vehicle for 5 days. Three hours after
the final dose, tumors were excised. Half the tissue was used for
protein extraction and immunoblot analysis, and the other half
was used for histologic examination. There were large areas of
necrosis in tumors from treated animals at the H&E staining
(Fig. 5B). Moreover, Ki67/MIB-1 immunolocalization was
reduced and terminal deoxynucleotidyl transferase–mediated
nick end labeling reactivity increased in treated tumors
(Fig. 5B). These in vivo cell death effects were in contrast with
the lack of apoptotic effects of the drug (see above) as well as of
Fig. 4. BAY 43-9006 causes growth
inhibition of V600EBRAF-positive thyroid
carcinoma cells.The indicated cells
(5 104) were plated in triplicate in
35 mm dishes. One day later, different
concentrations of BAY 43-9006 or vehicle
(0) were added (in 2.5% serum). Cells were
counted at different time points. Day 0
was the treatment starting day. Points, mean
value for the three dishes; bars, 95%
confidence intervals. Statistical significance
was determined by the two-tailed unpaired
Student’s t test.
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BRAF RNAi (data not shown) in cultured cells. However, by
directly targeting vascular endothelial growth factor receptors
in tumor endothelium (23) and by targeting RAF-regulated
vascular endothelial growth factor receptor secretion (36), BAY
43-9006 might prevent the development of tumor neovascula-
rization and therefore cause tumor cell death. Accordingly,
blood vessel counting by immunoperoxidase staining with anti-
CD31 revealed that BAY 43-9006 treatment reduced the number
of vessels (from 20 F 4 to 10 F 3 per microscopic field),
demonstrating that BAY 43-9006 exerted antiangiogenic effects
in ARO cell xenografts. To ensure that BRAF kinase inhibition
in vivo participated to the therapeutic effect as well, proteins
were extracted from ARO tumors treated with BAY 43-9006.
As shown in Fig. 5C, tumor growth inhibition was associated
with a remarkable reduction of p44/42 MAPK, MEK1/2, and,
at a lower extent, RSK in vivo phosphorylation levels.
Discussion
There is an urgent need for therapies that can slow down the
progression of anaplastic thyroid carcinoma. On the other
hand, although papillary thyroid carcinomas in general have an
excellent prognosis, there is no effective treatment for tumors
that have lost radioiodine uptake. Based on the experimental
and clinicopathologic evidences indicating that BRAF is
involved in papillary thyroid carcinoma initiation and progres-
sion to anaplastic thyroid carcinoma, BRAF has emerged as a
promising therapeutic target for thyroid carcinomas (15).
By siRNA-mediated BRAF knockdown, here we could show
that V600EBRAF-expressing thyroid carcinoma cells depend on
continuous BRAF activity for intracellular signaling and cell
proliferation; these finding suggest that indeed BRAF can be
exploited to develop novel therapies for thyroid carcinomas
carrying BRAF mutations.
At a preclinical level, recent insights have shown that
chemically modified siRNAs can silence endogenous genes after
i.v. injection in mice and, therefore, be exploited for treatment
of disease (37). Moreover, injection of lentiviral vectors that
produce RNAi-mediated silencing of specific genes proved
efficacious in animal models of disease (38). Nevertheless,
in clinical setting, molecular targeting of specific protein
kinases, like ABL and KIT, with small-molecule inhibitors has
already proved efficacious (39). Various BRAF inhibitors have
been reported and, among them, the orally available by-aryl
Fig. 5. Antitumorigenic effects of BAY
43-9006 in ARO cell xenografts.A, ARO cells (1106
per mouse) were inoculated s.c. into the right dorsal
portion of BALB/c nude mice.When tumors
(f100 mm3) appeared, animals were randomly
assigned to three groups (sevenmice per group) to
receive BAY 43-9006 (30 or 60 mg/kg) or vehicle by
oral gavage.Treatment was administered for 5
consecutive days per week for 3 weeks (day1is
the treatment-starting day).Tumor diameters were
measured with calipers and tumor volumes were
calculated.This experiment was done twice. Results
are from one representative experiment. Points, tumor
volume; bars, 95% confidence intervals. P values for
the comparisons (at the different time points) between
compound and vehicle are reported. Statistical
significancewas determined by the two-tailed
unpaired Student’s t test. B, animals (n = 5) bearing
ARO tumors (f300 mm3) were treated with vehicle or
60 mg/kg of BAY 43-9006 for 5 days.Tumors were
excised and examined by conventional H&E and
immunostaining with anti-Ki67/MIB-1. Apoptotic cell
death rate was assessed by in situ labeling of DNA
strand breaks. Representative micrographs are shown.
C, proteins (100 Ag) extracted from a representative
tumor (day 5) from untreated or treated animals
were immunoblotted with the indicated antibodies.
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urea BAY 43-9006 has reached the clinical testing stage (35).
BAY 43-9006 inhibits RAF kinases and the tyrosine kinases
vascular endothelial growth factor receptor receptors 2/3, Flt-3,
platelet-derived growth factor receptor B, FGFR1, and KIT (23).
It inhibits the V600E BRAF mutant albeit with a slightly
lesser potency than the wild-type kinase (23). BAY 43-9006 is
undergoing advanced clinical trials (35). It is being tested in
a phase II study of patients with locally advanced, metastatic,
or recurrent thyroid cancer (www.cancer.gov/clinicaltrials).
Thus far, phase III is achieving promising results on renal cell
carcinoma, where probably BAY 43-9006 is effective for its
activity on angiogenic kinases (35). Here, we show that BAY 43-
9006 targets signal transduction along the MAPK cascade and
tumor cell proliferation in V600EBRAF-positive thyroid carcino-
ma cell lines. Although in vitro, the compound mainly exerted
cytostatic effects, it also caused tumor cell death in nude mice
xenografts very likely for the concomitant angiogenesis inhibi-
tion. Tumor cells are often selected to bypass the effects of
antineoplastic agents and the simultaneous assault on both
neoplastic and endothelial cells may circumvent the develop-
ment of resistance. This might be an advantage of drugs like BAY
43-9006 that are able to pinpoint more than one target
simultaneously (40). However, BAY 43-9006 treatment did
not cause a complete regression of ARO cell tumors. Similar
observations have been reported upon mutant BRAF targeting in
melanomas (41).
In conclusion, these findings provide the proof-of-concept
that BRAF is a therapeutic target in thyroid cancer analogous to
ABL and KIT in other tumors. Thus, BAY 43-9006, and perhaps
other small molecules with a similar specificity profile, holds
promise for molecular therapy of thyroid cancer. In a clinical
setting, it will be mandatory to know the BRAF mutational
status of treated patients and to show that the compound has
sufficient activity to inhibit the BRAF kinase at the concentra-
tion achieved in patient tissues. Based on the preclinical data,
one possibility could be to combine the drug with other
synergistic therapeutics that may facilitate tumor regression.
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Abstract
Here, we show that the anaplastic thyroid carcinoma (ATC)
features the up-regulation of a set of genes involved in the
control of cell cycle progression and chromosome segregation.
This phenotype differentiates ATC from normal tissue and
from well-differentiated papillary thyroid carcinoma. Trans-
criptional promoters of the ATC up-regulated genes are
characterized by a modular organization featuring binding
sites for E2F and NF-Y transcription factors and cell cycle–
dependent element (CDE)/cell cycle gene homology region
(CHR) cis-regulatory elements. Two protein kinases involved in
cell cycle regulation, namely, Polo-like kinase 1 (PLK1) and T
cell tyrosine kinase (TTK), are part of the gene set that is
up-regulated in ATC. Adoptive overexpression of p53, p21
(CIP1/WAF1), and E2F4 down-regulated transcription from the
PLK1 and TTK promoters in ATC cells, suggesting that these
genes might be under the negative control of tumor suppres-
sors of the p53 and pRB families. ATC, but not normal thyroid,
cells depended on PLK1 for survival. RNAi-mediated PLK1
knockdown caused cell cycle arrest associated with 4N DNA
content and massive mitotic cell death. Thus, thyroid cell
anaplastic transformation is accompanied by the overexpres-
sion of a cell proliferation/genetic instability-related gene
cluster that includes PLK1 kinase, which is a potential mole-
cular target for ATC treatment. [Cancer Res 2007;67(21):10148–58]
Introduction
Anaplastic thyroid carcinoma (ATC) is a highly malignant tumor
that accounts for 2% to 5% of all thyroid cancers and is usually
seen in the sixth to seventh decades of life. ATC ranks among the
most lethal solid tumors, with a median survival of 4 to 12 months
after diagnosis (1–3). ATC shares genetic alterations with well-
differentiated papillary (PTC) and follicular thyroid carcinomas,
namely, point mutations in RAS and BRAF (1–4) and point
mutations or gene amplification of PIK3CA (5, 6), suggesting that it
may derive from a preexisting differentiated lesion. Whereas well-
differentiated thyroid carcinomas are rarely (<10%) p53-mutated,
more than 70% of ATC are associated with p53 mutations (2, 4).
Besides direct gene mutation, several other mechanisms can
obstruct p53 function in thyroid cancer, including the up-
regulation of negative p53 regulators like HMGA1 (high-mobility
group A1) and DNp73, or proteins fostering p53 protein
degradation, like HDM2 (7, 8).
ATC has a high proliferation rate and marked aneuploidy (9).
Gene expression profiles correlating with mitotic rate and chro-
mosomal instability in cancer cells have been recently defined. A
gene expression signature represented by 168 cell cycle–regulated
genes has been identified in in vitro transformed normal human
fibroblasts and termed ‘‘the proliferation cluster’’ (10). Increased
expression of many of these genes, in particular of a core set of
44 of them (‘‘44-gene proliferation cluster’’), is a surrogate measure
of tumor cell proliferation and is often associated with poor
outcome (11). Moreover, the up-regulation of a set of 70 genes,
known as the chromosomal instability 70 (‘‘CIN70’’) cluster,
partially overlapping with the proliferation signature, predicted
aneuploidy in several cancers (12).
Genes coding for two protein kinases, Polo-like kinase 1 (PLK1)
and T cell tyrosine kinase (TTK), are included in these signatures
(10–12). TTK (also called PYT or hMps1, human monopolar spindle
1 kinase) is a dual-specificity kinase involved in mitotic checkpoint
control; it has been implicated in the apoptosis of p53-negative
cells after DNA damage (13). PLK1 belongs to the Polo family of
serine/threonine kinases. It is important for many cell cycle–
related events, i.e., CDC2 activation, chromosome segregation,
centrosome maturation, bipolar spindle formation, activation of
the anaphase-promoting complex (APC), and cytokinesis and is
overexpressed in many tumors (14). Adoptive overexpression of
PLK1 induces NIH 3T3 cell transformation, whereas PLK1
inhibition leads to mitotic arrest and cell death (14).
Here, we show that ATC is characterized by a gene expression
profile that overlaps the proliferation and CIN70 signatures, and
that PLK1, which is part of these signatures, is essential for survival
of ATC cells.
Materials and Methods
Tissue samples. Frozen thyroid tissue samples from 10 patients affected
by PTC, 5 patients with ATC, and 4 normal thyroids (N) were used for the
microarray screening (Supplementary Table S1). Independent tissue
samples (19 normal thyroids, 39 PTC, and 22 ATC) were used for validation
assays. All samples were retrieved from the files of the Pathology
Department of the University of Pisa (Italy). The study was approved by
the Institutional Ethics Committee. The samples were classified according
to the diagnostic criteria required for the identification of PTC and ATC
(15). The number of neoplastic cells in five areas of 0.2 mm2 was calculated
with a Nikon laser microdissector.
cDNA microarray screening and data analysis. The 12,000 sequence-
verified human cDNA set was from the National Genome Institute
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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(NIH, Bethesda, MD). The cDNA clones were printed as described elsewhere
(16, 17). Sample preparation and microarray hybridizations procedures are
reported in detail elsewhere (17). Briefly, total RNA was labeled by direct
incorporation of Cy5-dUTP or Cy3-dUTP (Amersham Pharmacia Biotech)
in a reverse transcription reaction using anchored oligodeoxythymidylate
primer (Genosys) and Superscript II reverse transcriptase (Life Technologies
Inc.). Cy3-dUTP–tagged cDNAs were mixed with Cy5-dUTP–tagged
common reference and subsequently cohybridized to the microarrays.
The reference was composed of a pool of RNA from thyroid cell lines and
was used throughout all hybridizations to ensure normalized measures for
each gene in each individual sample. Hybridized slides were scanned using
an Agilent microarray scanner (Agilent Technologies), and images were
processed using a collection of IPLab (Scanalytics, Inc.) extensions
developed at the Cancer Genetics Branch, National Human Genome
Research Institute. The fluorescence intensities of scanned images were
quantified, normalized, and corrected to yield the transcript abundance of
a gene as an intensity ratio with respect to that of the signal of the
references. Genes were ranked according to the weighted gene analysis.
Genes with high weight (w) values create greater separation between groups
and denser compaction within the groups, i.e., they have a high power to
discriminate between normal thyroid, PTC, and ATC. To test the statistical
significance of the discriminative weights, sample labels were randomly
permutated as previously described (17). This was repeated 1,000 times
to generate a w distribution that would be expected under the assumption
of random gene expression, i.e., no difference between the groups. Genes
that were deemed to significantly (P < 0.001) discriminate between the
three categories were listed. The entire data set has been deposited in
the National Center for Biotechnology Information’s Gene Expression
Omnibus (GEO)6 and is accessible through GEO series accession number
GSE9115.
RNA extraction and quantitative reverse transcription-PCR. Total
RNA was isolated with the RNeasy Kit (Qiagen). About 1 Ag of RNA from
each sample was reverse-transcribed with the QuantiTect Reverse
Transcription (Qiagen). To design a quantitative (Q) reverse transcription-
PCR (RT-PCR) assay, we used the Human ProbeLibray system (Exiqon).
Primers pairs and PCR conditions are available upon request. PCR reactions
were done in triplicate, and fold changes were calculated with the formula:
2(sample 1 DCt  sample 2 DCt), where DCt is the difference between the
amplification fluorescent thresholds of the mRNA of interest and the mRNA
of RNA polymerase 2 used as an internal reference.
Cell cultures. The P5-3N primary culture of normal human thyroid
follicular cells was grown as previously described (18). Normal human
thyroid cells (S11N and S63N) were grown in RPMI (Invitrogen) containing
20% fetal bovine serum. The human ATC cell lines FB1 (19), BHT101 (20),
CAL62 (20), KAT-4 (21), ARO (22), FRO (22), HTH7 (23), HTH83 (23),
SW1736 (23, 24), C643 (23), and the poorly differentiated thyroid carcinoma
NPA (22) were grown in DMEM (Invitrogen) containing 10% fetal bovine
serum. The Fischer rat-derived differentiated thyroid follicular cell line PC
Cl 3 (hereafter ‘‘PC’’) was grown in Coon’s modified Ham F12 medium
supplemented with 5% calf serum and a mixture of six hormones (6H).
Protein studies. Immunoblotting was carried out according to standard
procedures. Anti-PLK1 monoclonal antibody was from Zymed Laboratories;
anti-TTK polyclonal antibody was from Santa Cruz Biotechnology;
monoclonal anti–a-tubulin was from Sigma-Aldrich; anti-cleaved (Asp175)
caspase-3 p17 and p12 fragments polyclonal (5A1) was from Cell Signaling
Technology, Inc.; anti-poly(ADP-ribose) polymerase (anti-PARP) monoclonal
antibody, which detects full-length PARP and the large fragment (89 kDa)
produced by caspase cleavage, was from BD Biosciences. Secondary anti-
mouse and anti-rabbit antibodies coupled to horseradish peroxidase were
from Santa Cruz Biotechnology.
Reporter gene assay. PCR fragments of the human TTK and PLK1
promoters spanning, respectively, from 524 to +72 and from 148 to +63
relative to the transcription start were cloned into the pGL3 Basic vector
(Promega Corporation), carrying the Firefly luciferase reporter gene.
Primer sequences are available upon request. Cells were transfected using
the LipofectAMINE reagent according to manufacturer’s instructions,
with 500 ng of the reporter plasmid DNA, together with (when required)
p53 wild-type, p21(CIP/WAF1) (25), or E2F4 (kindly donated by M. Crescenzi,
Istituto Superiore di Sanita’, Rome) expression vectors. A plasmid express-
ing the enzyme Renilla luciferase (pRL-null) was used as an internal
control. In all cases, the total amount of transfected plasmid DNA
was normalized by adding empty vector DNA. Forty-eight hours after
transfection, Firefly and Renilla luciferase activities were assayed using
the Dual-Luciferase Reporter System (Promega Corporation), and the
Lumat LB9507 luminometer (EG Berthold). Each experiment was done in
triplicate.
RNA silencing. Small inhibitor duplex RNAs targeting PLK1 and the
scrambled control [nonspecific small interfering RNA (siRNA) duplex
containing the same nucleotides but in irregular sequence] are described
elsewhere (26). Cells were grown under standard conditions. The day before
transfection, 5  104 cells were plated in 35-mm dishes in DMEM
supplemented with 10% fetal bovine serum and without antibiotics.
Transfection was done using OligofectAMINE reagent (Invitrogen) with
100 nmol/L (250 nmol/L for PC cells) siRNA. Cells were harvested and
counted 24 and 48 h after transfection.
Immunofluorescence. Fixed and permeabilized cells were incubated
with anti–a-tubulin antibody (Sigma) for 45 min at 37jC. Washed coverslips
were incubated with rhodamine-conjugated secondary antibody (Jackson
ImmunoResearch) for 30 min at 37jC. After 15 min propidium iodide (1 Ag/
mL) counterstaining and coverslips mounting, stained cells were observed
with a Zeiss LSM 510 META confocal microscope. The ‘‘In situ Cell Death
Detection Kit, TMR red’’ (Roche) was used to detect terminal nucleotidyl
transferase–mediated nick end labeling (TUNEL)–positive cells. At least 300
cells were counted in triplicate experiments.
Fluorescence-activated cell sorter scan analysis. Cells were harvested
and fixed in 70% ethanol for 4 h. After washing with PBS, cells were treated
with RNase A (100 units/mL) and stained with propidium iodide (25 Ag/mL;
Sigma) for 30 min. Samples were analyzed with a CyAn ADP flow cytometer
interfaced with the Summit V4.2 software (DakoCytomation). Data were
analyzed with the Modfit software (Verity Software House).
Statistical analysis. The two-tailed unpaired Student’s t test (normal
distributions and equal variances) was used for statistical analysis. All
P values were two sided, and differences were significant when P < 0.05.
All statistical analyses were carried out using the GraphPad InStat software
program (version 3.06.3).
Results
Proliferation- and chromosomal instability-associated
genes are up-regulated in ATC. We used cDNA microarrays to
characterize the gene expression profile of ATC compared with
PTC and normal thyroid tissue samples (Supplementary Table S1).
Genes were ranked according to weight values (16, 17), with the
highest value indicating the most discriminative power (P < 0.001)
between the different tissue groups. A set of 914 genes distin-
guished ATC from normal tissue: 371 of them were up-regulated,
and 543 were down-regulated in ATC (Supplementary Table S2).
Most of these genes were typical of ATC, and only 114 of them
discriminated normal thyroid from both PTC and ATC (Supple-
mentary Tables S2 and S3).
ATC featured the up-regulation of a set of 54 genes involved in the
control of cell cycle progression and chromosome segrega-
tion; 7 and 13 of them were part of the 44-gene proliferation
cluster (10, 11) and the CIN70 cluster (12), respectively, and 9
of both clusters (Table 1). These genes were not significantly
up-regulated in PTC (Supplementary Table S3). Additional genes
of the two clusters tended toward up-regulation in ATC, but the
data were not statistically significant (Supplementary Table S4).
Thus, ATC overexpressed genes that coded for cyclins (CCNB2,6 http://www.ncbi.nlm.nih.gov/geo
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Table 1. Proliferation- and chromosomal instability-related genes up-regulated in ATC
Gene Gene description (gene ontology biological process) Unigene
number
Weight N
versus ATC
Include
Prolifer
ZWINT ZW10 interactor (cell cyle) Hs.42650 31.36
KNSL6 KIF2C kinesin family member 2C (mitosis) Hs.69360 29.69
CENPA{ Centromere protein A (17 kDa; mitosis) Hs.1594 27.61
NEK2{ NIMA (never in mitosis gene a)-related
kinase 2 (cell cycle)
Hs.153704 21.77
CEP55 Centrosomal protein (55 kDa; cell cycle) Hs.14559 19.15
CDC20{ Cell division cycle 20 homologue (cell cycle) Hs.82906 17.71
CENPF Centromere protein F (350/400 kDa, mitosin; mitosis) Hs.77204 15.24
PARP1 Poly(ADP-ribose) polymerase family 1 (adenosine
diphosphate ribosyltransferase; base excision repair)
Hs.177766 14.60
SSRP1 Structure-specific recognition protein 1
(DNA replication)
Hs.523680 14.39
CCNB2{ Cyclin B2 (cell cycle) Hs.194698 14.01
PBK PDZ binding kinase (mitosis) Hs.104741 13.98
TTK{ TTK protein kinase (mitotic spindle checkpoint) Hs.169840 13.52
EXOSC9 Exosome component 9 (rRNA processing) Hs.91728 13.18
CDCA8{ Cell division cycle–associated 8 (cell cycle) Hs.48855 12.93
CCNA2 Cyclin A2 (cell cycle) Hs.58974 12.14
TOP2A{ Topoisomerase (DNA) IIa (DNA topological change) Hs.156346 11.87
PLK1{ Polo-like kinase 1 (mitosis) Hs.329989 11,23
GMPS Guanine monophosphate synthetase
(purine synthesis)
Hs.518345 11.17
PPM1G Protein phosphatase 1G (cell cycle) Hs.17883 10.81
CENPE Centromere protein E (mitotic metaphase) Hs.75573 10.79
PRC1{ Protein regulator of cytokinesis 1 (mitotic
spindle elongation)
Hs.366401 10.71
NOL5A Nucleolar protein 5 (rRNA processing) Hs.376064 10.22
TPX2 Microtubule-associated, homologue (mitosis) Hs.244580 9.92
NUSAP1 Nucleolar and spindle-associated protein 1 (mitosis) Hs.615092 9.82
ZWILCH Kinetochore-associated, homologue
(kinetochore component)
Hs.21331 9.47
NCAPH Non-SMC condensin I complex, subunit H (mitosis) Hs.308045 9.39
HMMR Hyaluronan-mediated motility receptor
(cell motility)
Hs.72550 9.31
PAICS Phosphoribosylaminoimidazole carboxylase
(purine synthesis)
Hs.331420 9.30
RCC1 RCC1 regulator of chromosome condensation
1 (cell cycle)
Hs.469723 8.93
CTPS CTP synthase (nucleotide metabolism) Hs.473087 8.58
TYMS Thymidylate synthetase (nucleotide metabolism) Hs.592338 7.96
CKS1 CDC28 protein kinase regulatory subunit 1B (cell cycle) Hs.374378 7.93
FOXM1 Forkhead box M1 (regulation of transcription) Hs.239 7.91
HNRPF Heterogeneous nuclear ribonucleoprotein
F (RNA processing)
Hs.808 7.53
HPRT1 Hypoxanthine phosphoribosyltransferase
1 (purine synthesis)
Hs.412707 7.08
SMC4 Structural maintenance of chromosomes
4 (cell cycle)
Hs.58992 6.83
CCNE2 Cyclin E2 (cell cycle) Hs.567387 6.79
GMNN Geminin, DNA replication inhibitor (cell cycle) Hs.234896 6.66
UBE2S Ubiquitin-conjugating enzyme E2S (ubiquitin cycle) Hs.396393 6.56
CDC2 Cell division cycle 2 (mitosis) Hs.334562 6.55
GINS2 GINS complex subunit 2 (DNA replication) Hs.433180 6.30
PLK4 Polo-like kinase 4 (cell cycle) Hs.172052 6.28
DNMT1 DNA (cytosine-5-)-methyltransferase 1
(DNA methylation)
Hs.202672 5.54
(Continued on the following page)
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Table 1. Proliferation- and chromosomal instability-related genes up-regulated in ATC (Cont’d)
Gene Included in p53 inhibited DNA elements (binding sites)
Proliferation
cluster*
44-gene
proliferation cluster
c
CIN70
b
E2F NF-Y CDE CHR
ZWINT Yes Yes Yesx,k Yes* Yes* Yes*
KNSL6 Yes Yesx
CENPA{ Yes Yesx,k Yes* Yes* Yes*
NEK2{ Yes Yes Yesk,**
CEP55 Yes
CDC20{ Yes Yes Yes Yesx,k,** Yes* Yes*
CENPF Yes Yes Yesx,k Yes* Yes*,
cc
Yes* Yes*,
cc
PARP1 Yes
SSRP1 Yes
CCNB2{ Yes Yes Yesx,** Yes* Yes*,
cc
Yes*,
cc
PBK Yes Yes Yesk
TTK{ Yes Yes Yesx Yes
cc
Yes*,
cc
Yes*,
cc
EXOSC9 Yes Yes
CDCA8{ Yes Yes* Yes*,
cc
Yes Yes*,
cc
CCNA2 Yes Yes Yesx,k Yes* Yes*
TOP2A{ Yes Yes Yes Yesx,k,** Yes*,
cc
Yes*,
cc
PLK1{ Yes Yes Yesx,** Yes
bb
Yes*,
cc
Yes* Yes*,
cc
GMPS Yes Yesx Yes* Yes*
PPM1G Yes
CENPE Yes
PRC1{ Yes Yes Yesk Yes* Yes*,
cc
Yes* Yes*,
cc
NOL5A Yes Yes* Yes*
TPX2 Yes Yesx,k Yes* Yes*
NUSAP1 Yes Yesk Yes* Yes*,
cc
Yes* Yes*,
cc
ZWILCH Yes
NCAPH Yes
HMMR Yes Yesx,k,** Yes*,
cc
Yes*,
cc
PAICS Yes Yesk
RCC1 Yes
CTPS Yes Yes
TYMS Yes Yes* Yes*
CKS1 Yes Yes* Yes* Yes* Yes*
FOXM1 Yes Yesx,k Yes*,
cc
Yes*,
cc
HNRPF Yes Yes** Yes* Yes* Yes*
HPRT1 Yes
SMC4 Yes Yesk
CCNE2 Yes Yesk
GMNN Yes Yes* Yes*
UBE2S Yes Yesx,**
CDC2 Yes Yes Yesk Yes*,
cc
Yes*,
cc
Yes* Yes*,
cc
GINS2 Yes Yesx
PLK4 Yes
DNMT1 Yes
(Continued on the following page)
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CCNA2 , and CCNE2), cyclin-dependent kinases (CDC2), and
proteins involved in nucleotide synthesis (GMPS, PAICS, CTPS,
TYMS , and HPRT1), spindle formation, and checkpoint control
(PLK1, TTK, NEK2, CDCA8, CENPA, CENPF, CENPE , and KNSL6 ;
Table 1). According to recent reports, ATC overexpressed UBE2C
(UBCH10), which encodes an E2 ubiquitin-conjugating enzyme
that is required for cell cycle progression (27), and genes of the
minichromosome maintenance–deficient (MCM) family, involved in
licensing DNA for replication (25). Genes encoding other compo-
nents of the DNA replication initiation complex, such as CDC6,
ORC1 , and PCNA , also tended toward up-regulation in ATC
(Supplementary Table S4). ATC frequently features genetic alter-
ations in the phosphoinositide-3-kinase (PI3K)/AKT pathway (5, 6);
accordingly, the screening revealed the altered expression of some
genes of this pathway in ATC samples (Supplementary Table S5).
Some cis-regulatory DNA elements, e.g., binding sites for E2F and
NF-Y (CCAAT box binding) transcription factors and cell cycle-
dependent element (CDE)/cell cycle gene homology region (CHR)
DNA orphan binding sites, were highly represented in the promoters
of the 54 genes up-regulated in ATC (refs. 10, 28–30; Table 1). The E2F
family of transcription factors includes positive (E2F1-3) and
negative (E2F4-6) regulators of cell cycle progression (28, 29).
Activator E2Fs (in particular E2F1) are linked to the activation of
genes involved in G1-S progression, whereas repressor E2Fs (in
particular E2F4) bind gene promoters featuring the NF-Y-CDE/CHR
DNA module that often peak at the G2 or G2-M phase (10, 28–30).
Many G2-M phase genes (like PLK1, TTK, PRC1, CENPE, CENPF,
FOXM1, CCNB2, CDC2, CDCA8, CCNA2, TOP2A, UBE2C , and
CDC25C) were up-regulated in ATC. Based on such a promoter
architecture, it can be argued that some of the gene expression
changes associated to ATC may be influenced by the loss of p53 or
pRB family gene function, which is able to influence the function of
E2F and NF-Y proteins (10, 30–33). Accordingly, as many as 31 of the
54 genes up-regulated in ATC samples were previously reported to
be under p53 negative control (Table 1; refs. 13, 32, 33). Although the
p53 gene status of the examined ATC samples is unknown, the
microarray screening (Supplementary Table S2) showed that four
out of five ATC samples overexpressed HMGA1 (weight = 4.3), a
negative regulator of the p53 function (7).
We selected an independent set of ATC samples for validation
experiments. A total of 2 out of 10 of these samples harbored R248E
and R280T p53 mutations, respectively (data not shown). Moreover,
five of them up-regulated HMGA1 mRNA at a RT-PCR analysis
(Supplementary Fig. S1). These samples were examined by triplicate
quantitative RT-PCR for the expression of 10 of the genes reported
in Table 1. The results of these experiments were in agreement with
the microarray screening data. Although the expression level of
single genes varied among individual ATC samples, these genes
were up-regulated in practically all ATC samples examined versus
normal thyroids and PTC (Fig. 1A). The difference between ATC and
normal tissue was P < 0.001 with the Tukey-Kramer multiple
comparisons procedure and P < 0.0001 with the one-way ANOVA
test. We also measured the expression levels of the 10 genes in a
panel of ATC cell lines expressing a mutated p53 allele (34) in
comparison to normal thyroid cells. All of them invariably up-
regulated in cancer cells (Table 2).
Table 1. Proliferation- and chromosomal instability-related genes up-regulated in ATC (Cont’d)
Gene Gene description (gene ontology biological process) Unigene
number
Weight N
versus ATC
FEN1 Flap structure-specific endonuclease 1
(DNA replication)
Hs.409065 5.38
C20orf24 Chromosome 20 open reading frame 24
(RAB5-interacting protein)
Hs.584985 5.34
MCM5 Minichromosome maintenance-deficient 5
(DNA replication)
Hs.517582 5.32
UBE2C Ubiquitin-conjugating enzyme E2C (mitosis) Hs.93002 5.09
MCM7 Minichromosome maintenance-deficient 7
(DNA replication)
Hs.438720 5.00
ATAD2 ATPase family, AAA domain containing 2 (ATP binding) Hs.370834 4.69
POLE Polymerase (DNA directed), epsilon (DNA replication) Hs.524871 4.30
CKS2 CDC28 protein kinase 2 (cell cycle) Hs.83758 4.25
MCM6 Minichromosome maintenance-deficient 6 (DNA replication) Hs.444118 4.25
CDC25C Cell division cycle 25C (cell cycle) Hs.656 4.05
RFC1 Replication factor C (activator 1) 1 (DNA replication) Hs.507475 4.05
*Ref. 10.
cRef. 11.
bRef. 12.
xRef. 13.
kRef. 33.
{Genes whose up-regulation was studied also by Q-RT-PCR.
**Ref. 32.
ccRef. 28.
bbRef. 38.
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PLK1 and TTK transcriptional promoters are negatively
controlled by p53 in ATC cells. We focused on PLK1 and TTK ,
which encode two protein kinases involved in cell cycle progression
(13, 14). As shown in Table 2, the ATC cell lines analyzed
overexpressed PLK1 and TTK compared with the average
expression level of normal thyrocytes (P < 0.0001). NPA cells,
which are derived from a poorly differentiated thyroid carcinoma,
also up-regulated PLK1 and TTK mRNAs. The up-regulation of
PLK1 and TTK occurred also at protein level (Fig. 1B).
We cloned the PLK1 gene transcriptional promoter (148 to +63;
ref. 35) and a putative TTK promoter (524 to +72; ref. 28) in the
pGL3 vector upstream from the Firefly luciferase reporter (Fig. 2A).
We transiently transfected the pGL3-PLK1-LUC and pGL3-TTK-
LUC constructs (or the empty vector) in triplicate in a continuous
line of normal thyrocytes (PC) and in ATC cells and measured
luciferase activity. Transcription from the TTK (P < 0.0013) and the
PLK1 (P < 0.0019) promoters was strongly up-regulated in ATC
with respect to normal cells (Fig. 2B).
TTK and PLK1 feature the typical combination of E2F, NF-Y, and
CHR elements (Table 1) and were reported to be negatively
controlled by p53 (13, 32). To explore the mechanism of PLK1 and
TTK up-regulation in ATC cells, we measured the effects of wild-
type p53 and the cyclin-dependent kinase inhibitor p21 (CIP1/
WAF1). As shown in Fig. 2C , adoptive overexpression of both p53
and p21 decreased TTK (f2- and 3-fold, respectively) and PLK1
(f2–3- and 3–5-fold, respectively) promoter activity in FRO and
CAL62 cells (P < 0.0001). Transient expression of the negative E2F,
E2F4, also reduced the activity of both promoters in ATC cells
(P < 0.0001; Fig. 2C).
PLK1 knockdown induces mitotic death of ATC cells. PLK1
depletion or inactivation decreased the viability of several tumor
cell types (14, 26, 36, 37). We used the RNA interference method to
deplete endogenous PLK1 from ATC cells; normal PC thyrocytes
served as a control. Twenty-four hours after transfection with
PLK1-specific siRNA, PLK1 protein was silenced in CAL62 (z75%)
and ARO (f60%) cells, whereas a scrambled control had no effect
(Fig. 3A and B). Forty-eight hours post-transfection, CAL62 cells
treated with scrambled RNAi numbered 381  103, whereas those
treated with PLK1 RNAi numbered 73  103 (P < 0.0001; Fig. 3A);
ARO cells treated with scrambled RNAi numbered 285  103,
and those treated with PLK1 RNAi numbered 106  103 (P = 0.0014;
Fig. 3B). Virtually no effect was observed in normal cells, although
RNAi depleted PLK1 in PC cells, albeit with a lower efficiency than
in cancer cells (Fig. 3C).
To better characterize the effects of PLK1 knockdown, we
transfected CAL62 cells with PLK1 siRNA or the scrambled control
and analyzed them by immunoblot at different time points. Thirty-
six hours post-transfection, two biochemical markers of apoptosis,
i.e., cleaved products of caspase-3 and of PARP, were visible in PLK1-
silenced cells but not in cells transfected with the scrambled control
(Fig. 4A). Accordingly, PLK1 depletion, but not control RNAi,
strongly increased the rate of inter-nucleosomal DNA fragmentation
in a TUNEL assay (Fig. 4B). Forty-eight hours after transfection, the
percentage of apoptotic cells with a subgenomic DNA (sub-G1)
content at the fluorescence-activated cell sorter (FACS) was higher
in PLK1-depleted cells than in control cells (14% versus 4%; data not
shown). In addition, the fraction of cells with a 4N DNA complement
was higher in PLK1-depleted cells (59% versus 14%) versus control
cells, which indicates incomplete cytokinesis (data not shown).
We stained PLK1-silenced and control-treated CAL62 cells with
anti–a-tubulin antibody and examined the mitotic spindle by
confocal microscopy. Consistent with the FACS results, the number
of mitotic (prometaphase-like state) cells was increased in PLK1-
depleted cells as early as 12 h post-transfection. Forty-eight hours
after transfection, 53 F 5% of PLK1-depleted cells versus 3 F 2% of
control-treated cells were in the M phase (Fig. 4C). As shown in
Fig. 4D , PLK1-depleted cells had monopolar (20% versus 0% in
control cells) and disorganized (48% versus 9.8% in control cells)
spindles. Moreover, in PLK1-depleted cells, there was an increase of
bi-nucleated cells (5.4% versus 1.4% in control cells) and cells with
an aberrant nuclear morphology (dumbbell-like chromatin; 12%
versus 4.3% in control cells; data not shown). A dumbbell-like
structure suggests the inability to separate sister chromatids at the
onset of anaphase. This feature is a hallmark of so-called mitotic cell
death or mitotic catastrophe, a type of apoptosis cells that are
committed to when they are unable to complete cytokinesis.
Table 1. Proliferation- and chromosomal instability-related genes up-regulated in ATC (Cont’d)
Gene Included in p53 inhibited DNA elements (binding sites)
Proliferation
cluster*
44-gene
proliferation cluster
c
CIN70
b
E2F NF-Y CDE CHR
FEN1 Yes Yes Yes Yesx,k
C20orf24 Yes Yes* Yes* Yes*
MCM5 Yes Yes Yes*,
cc
Yes*
UBE2C Yes Yes Yesx,k Yes*,
cc
Yes*,
cc
MCM7 Yes Yesx,k,** Yes* Yes*
ATAD2 Yes
POLE Yes Yesk Yes* Yes* Yes*
CKS2 Yes Yes Yes Yesx Yes*,
cc
Yes* Yes*,
cc
MCM6 Yes Yes Yesk,** Yes*,
cc
Yes* Yes*
CDC25C Yes Yes Yes* Yes*
RFC1 Yes Yes* Yes*
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Discussion
This study shows that ATC is characterized by the over-
expression of genes associated with cell proliferation and
chromosomal instability. This feature, not being detected in well-
differentiated PTC, is typical of ATC and is consistent with the
highly mitogenic and aneuploid ATC phenotype (1, 2, 9). The
promoters of most of the proliferation-related genes up-regulated
in ATC contain a typical combination of NF-Y and E2F binding sites
and CDE/CHR cis-elements, a feature that suggests an indirect
control exerted by p53 and pRB tumor suppressors. Consistently,
we could show that TTK and PLK1 promoters are negatively
controlled by p53-p21(CIP/WAF1) axis in ATC cells.
Activator E2Fs-regulated promoters are repressed by pRB family
members; such a repression is alleviated on by pRB phosphory-
lation by cyclin-associated kinases (CDK; refs. 29, 38). By
stimulating increased levels of the CDK inhibitor p21(CIP/WAF1),
p53 reduces pRB phosphorylation levels and, in turn, E2F
transcriptional activity (29). Moreover, CDK2 activity, and there-
fore, p53-mediated p21(CIP/WAF1) induction, also controls NF-Y
through direct phosphorylation (28). Finally, by directly associating
with NF-Y, p53 suppresses NF-Y binding promoters, like the
CCNB2, CDC25C , and CDC2 gene promoters (31).
The CDE/CHR DNA elements are targets of repressor E2Fs (E2F4
and 5; ref. 30). E2F4 is under the negative control of the pRB-like
Figure 1. A, expression levels of ATC-specific genes in human thyroid samples. Quantitative RT-PCR analysis of 10 ATC-specific genes in normal thyroid (N ), PTC,
and ATC samples. TTK and PLK1 expression was measured in 20 N, 16 PTC, and 13 ATC samples. The other eight genes were measured in five N, nine PTC,
and six ATC samples. For each gene, the expression level in a given tumor sample (T ) was obtained by comparing its fluorescence threshold with the average
fluorescence thresholds of normal samples (N ). Values are the average results of three independent determinations. B, PLK1 and TTK protein levels in human thyroid
cell lines. Fifty micrograms of protein lysate harvested from primary cultures of normal human thyroid follicular (N ) and ATC cells were examined by immunoblot using
anti-PLK1 and anti-TTK antibodies. Equal protein loading was verified with an anti–a-tubulin antibody. Data are representative of three independent experiments.
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p107 (RBL1) and p130 (RB2) proteins, and thus, also E2F4 and pRB-
like proteins might be implicated in the regulation of proliferation-
associated genes in ATC. We could indeed show that TTK and PLK1
promoters are negatively controlled by E2F4 in ATC cells.
Finally, gene promoters containing NF-Y/CDE-CHR modules
often contain ELK1-binding sites (10, 28). ELK1 transcription
factors are downstream targets of the mitogen-activated protein
kinase pathway, and ATC often features mutation in genes (RAS or
Table 2. Expression levels of ATC-specific genes in human ATC cell lines
Expression level (fold change ATC cells versus normal thyrocytes)*
Cell line P53 status TOP2A CENPA PRC1 CCNB2 CDCA8 NEK2 TTK PLK1 CDC20 CENPF
ARO R273H
c,b 1.6 2.4 6.1 3.9 4.3 6.8 8 6.5 2 4
SW1736 Nullx 8.8 13.5 7.7 10.4 12.9 18 25 81 ND ND
NPA G266V
c,b 4.8 14.4 8.1 9 6.3 11.7 16.5 46.6 8 8
BHT101 I251T
b
2.1 3.5 1.8 2.2 2.5 3.6 16.7 10.8 ND ND
KAT-4 R273H
c,b 6.7 5.9 5.5 9.7 9.2 14 13 27.1 10 8
C643 R248Q
b
2.7 3.9 2.5 4 6.5 5.9 25.5 8.3 ND ND
CAL62 A161D
b
ND ND ND ND ND ND 25.7 25.7 8 8
FRO Null
c
3.8 3.9 3.1 3.5 4.5 9.1 32.5 14.3 ND ND
NOTE: Values are the average results of three independent determinations.
Abbreviation: ND, not done.
*Quantitative RT-PCR analysis done as indicated in the legend to Fig. 1A . For each gene, the expression level in a given ATC cell line was obtained by
comparing its fluorescence threshold with the average fluorescence thresholds of two normal thyroid cell populations (P53N and S11N).
cRef. 22.
bRef. 34.
xRef. 24.
Figure 2. PLK1 and TTK gene promoter
activity in ATC cells. A, the two promoters
are schematically represented. B, the
indicated cell lines were transiently
transfected with pGL3-TTK-LUC (left ) or
pGL3-PLK1-LUC (right ) plasmids. The
average levels of luciferase activity in three
independent experiments are reported.
Bars, 95% confidence intervals. C, FRO
and CAL62 cells were co-transfected with
p53, p21(CIP/WAF1), or E2F4 expression
vectors (or the empty vector), together with
pGL3-TTK-LUC (left) or pGL3-PLK1-LUC
(right ). Relative luciferase activity is
reported. The average results of three
independent assays are reported, and 95%
confidence intervals are shown; promoter
activity values in vector-transfected cells
were arbitrarily set at 100.
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BRAF) in this cascade (1–4). Therefore, it is likely that pathways
other than the p53 and pRB ones concurrently regulate the
expression of genes of the proliferation cluster.
ATC surgery is often only palliative, and there is no effective
systemic treatment (2). PLK1 kinase inhibitors are currently being
evaluated in clinical trials for various cancer types (14, 26, 36, 37).
Here, we show that PLK1 is required for ATC cell proliferation and
survival. This requirement was restricted to ATC cells and was not
detected in normal thyroid follicular cells. Although the exact
mechanism of this selectivity is unknown, it has been shown that p53
depletion increases the sensitivity of various cell types to PLK1
knockdown (36, 37). Whatever the mechanism, our findings indicate
Figure 3. Effects of PLK1 knockdown on ATC cell
growth. CAL62 (A), ARO (B), and normal PC (C )
cells were transfected with either PLK1-siRNA or the
scrambled oligonucleotide control. Cells were
harvested and counted at the indicated time points.
Values represent the average of triplicate
determinations. Bars, 95% confidence intervals
(right ). Equal amounts of protein lysates were
subjected to immunoblot with anti-PLK1 or a-tubulin
antibodies (left ).
Cancer Research
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that PLK1 addiction might be an Achilles’ heel of ATC cells and might
be exploited to develop novel treatment strategies for this cancer.
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Figure 4. Effects of PLK1 knockdown on
apoptosis and cell cycle progression in ATC
cells. A, CAL62 cells transfected with either
PLK1 siRNA or its scrambled control were lysed
at the indicated time points and subjected to
immunoblot with anti-cleaved caspase-3
antibodies, which detect only the p17 and p12
cleaved caspase-3 fragments (*) and anti-PARP
antibodies, which detect both the intact 116 kDa
and its cleaved 89-kDa (*) fragment. Anti-PLK1
immunoblot was used to verify RNAi; a-tubulin
levels are shown for normalization. Data are
representative of at least three different
experiments. B, TUNEL analysis of PLK1-siRNA
and scrambled control-treated CAL62 cells
(48 h posttransfection). The percentage of
positive cells represents the average value of
triplicate experiments F SD, in which at least
300 cells were counted. C, CAL62 cells, grown
on glass coverslips, were transfected with
PLK1-siRNA or with its scrambled control
sequence. At the indicated time points, cells
were fixed, stained with anti–a-tubulin, and
analyzed by confocal microscopy. The
percentage of mitotic cells represents the
average F SD of three experiments in which at
least 400 cells were counted. D, mitotic cells with
normal spindles, monopolar spindles, or grossly
disorganized spindles were counted. Values
refer to the average F SD of triplicate
experiments in which at least 200 mitotic cells
were counted; insets, representative images.
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Abstract
Anaplastic thyroid carcinoma (ATC) is a rare thyroid cancer
type with an extremely poor prognosis. Despite appropriate
treatment, which includes surgery, radiotherapy, and chemo-
therapy, this cancer is invariably fatal. CXCR4 is the receptor
for the stromal cell-derived factor-1 (SDF-1)/CXCL12 chemo-
kine and it is expressed in a variety of solid tumors, including
papillary thyroid carcinoma. Here, we show that ATC cell lines
overexpress CXCR4, both at the level of mRNA and protein.
Furthermore, we found that CXCR4 was overexpressed in ATC
clinical samples, with respect to normal thyroid tissues by
real-time PCR and immunohistochemistry. Treatment of ATC
cells with SDF-1 induced proliferation and increase in
phosphorylation of extracellular signal-regulated kinases
and protein kinase B/AKT. These effects were blocked by the
specific CXCR4 antagonist AMD3100 and by CXCR4 RNA
interference. Moreover, AMD3100 effectively reduced tumor
growth in nude mice inoculated with different ATC cells. Thus,
we suggest that CXCR4 targeting is a novel potential strategy
in the treatment of human ATC. [Cancer Res 2007;67(24):1–9]
Introduction
Thyroid cancer accounts for the majority of endocrine neo-
plasms worldwide (1). Malignant tumors derived from the thyroid
gland include well-differentiated thyroid carcinomas (WDTC;
papillary and follicular) and undifferentiated or anaplastic thyroid
carcinomas (ATC). Another group of cancers falls between these
two types, the so-called poorly differentiated thyroid carcinomas
(PDC). WDTC represents >90% of all thyroid cancers, whereas
ATC accounts for approximately 2% to 5% of them (2–4). WDTC
management requires surgery and adjuvant radioactive iodine
(5, 6). Whereas most of the patients with WDTC have an excellent
prognosis, those that present with PDC or ATC have a poor
prognosis. PDC displays intermediate biological and clinical
features between WDTC and ATC. Indeed, these tumors display
high propensity to recur and metastasize. Furthermore, they tend
to a progressive dedifferentiation, which leads to the decrease in
the levels of the sodium iodide symporter. As a consequence of this,
these tumors are unable to concentrate iodine and become
resistant to radiometabolic therapy (4, 7). ATC is the most
malignant thyroid tumor and one of the more fatal human
malignancy with a median survival from the time of diagnosis of
only 4 to 12 months (8, 9). ATC is more frequent in iodine-deficient
areas and can be associated with other thyroid disorders. These
tumors arise at a mean age of 55 to 65 years, are more common in
women, and present usually as a rapidly growing mass, localized in
the anterior neck area, which rapidly metastasizes at lungs, bone,
and brain. Treatment of ATC with surgery, radiotherapy, and
chemotherapy, alone or in combination, shows little or no effect on
patient’s survival (10). For these reasons, novel treatment strategies
are urgently needed. Unlike the WDTC, the molecular mechanisms
underlying the development of human ATC are largely unknown.
Genetic rearrangements of the RET and TRKA tyrosine kinase
receptors, point mutations of the BRAF serine-threonine kinase or,
less frequently, RAS mutations, are typically found in papillary
thyroid carcinoma (PTC). Rearrangements of PPARg or RAS point
mutations are instead found in human FTC (11, 12). Among these
genetic alterations, RAS or BRAF point mutations are detected at
low frequency in ATC, suggesting that some ATC may arise from a
preexisting WDTC, whereas others arise de novo (12, 13).
Inactivating point mutations of the p53 tumor suppressor and
activating point mutations of the h-catenin or the PIK3CA are also
found in ATC (13, 14).
In the attempt to better characterize human ATC at the
molecular level, we aimed to study the involvement of chemokine
and chemokine receptors in these tumors. Chemokines are small
secretory proteins that were initially reported to control the
recruitment and the activation of immune cells in inflammation
(16). These molecules exert their action through binding to a group
of seven-transmembrane G protein–coupled receptors. All chemo-
kine receptors initiate signal transduction by activating a member
of the Gi family of G proteins which, on receptor activation,
dissociates into a and hg subunits. The Ga subunit inhibits
adenylyl cyclase, whereas the Ghg dimer activates the phospho-
lipase Ch and the phosphatidylinositol 3-kinase pathways, with the
activation of downstream signaling. It has becoming clear recently
that chemokines are also involved in cancer cell migration,
survival, and growth (17). Not only chemokines regulate some
important features of cancer cells but are also involved in the
regulation of tumor angiogenesis and leukocyte recruitment (17).
In particular, the chemokine receptor CXCR4 and its ligand stromal
cell-derived factor-1 (SDF-1)/CXCL12 have been implicated in the
metastatic spread of breast cancer cells (18). CXCR4 is one of the
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most important chemokine receptors for cancer cells. Indeed, it is
expressed in a great number of human solid and hematologic
cancers, including breast, prostate, brain, colon, and lung cancer
(19, 20). We and others previously reported the overexpression and
functional activity of CXCR4 in thyroid cancer (21, 22). In this
report, we show that human ATC cells express high levels of CXCR4
and that the CXCR4-SDF-1/CXCL12 axis sustains the growth of
ATC cells. Finally, we provide evidences that targeting CXCR4
might be exploited as a novel anticancer therapy for human ATC.
Materials and Methods
Cell lines. Human primary cultures of normal thyroid and ATC cells
were obtained from F. CurcioQ3 (P5, P5-2N, P5-3N, P5-4N, and HTU8) and H.
ZitzelsbergerQ4 (S11T, S77T, and S14T) and cultured as described previously
(23). Primary cultures of ATC were also a kind gift of H. Zitzelsberger. Of
these, only the S11T displays a BRAF(V600E) mutation in heterozygosis.4FN1
Human thyroid papillary cancer cell lines TPC1, FB2, and NIM have been
described previously (24–26). TPC1 and FB2 cells harbor a RET/PTC1
rearrangement. NPA87 cells derive from a PDC and harbor a BRAF(V600E)
mutation in homozygosis (23). The anaplastic cells ARO, KAT4, BHT101,
and FB1 cells harbor a BRAF(V600E) mutation in heterozygosis; 8505C and
FRO harbor a BRAF(V600E) mutation in homozygosis (23); and CAL62 cells
express wild-type BRAF but mutant NRAS allele. Continuous cell lines were
maintained in DMEM supplemented with 10% fetal bovine serum, 1%
penicillin-streptomycin, and 1% glutamine.
RNA extraction and reverse transcription PCR. Total RNA was
isolated by the RNeasy kit (Qiagen) and subjected to on-column DNase
digestion with the RNase-free DNase set (Qiagen) according to the
manufacturer’s instructions. The quality of RNA was verified by electro-
phoresis through 1% agarose gel and visualized with ethidium bromide.
RNA (1 Ag) from each sample was reverse transcribed with the QuantiTect
Reverse Transcription (Qiagen) using an optimized blend of oligo(dT) and
random primers according to the manufacturer’s instructions. To design
a quantitative reverse transcription-PCR (RT-PCR) assay, we used the
Human ProbeLibray system (Exiqon). Briefly, Exiqon provides 90 human
prevalidated Taqman probes (8–9 nucleotides long) that recognizef99% of
human transcripts in the RefSeq database at the National Center for
Biotechnology Information. The ProbeFinder assay design software
(available online)5FN2 was used to design primer pairs and probes. All
fluorogenic probes were dual labeled with FAM at 5¶-end and with a black
quencher at the 3¶-end. Primer pairs and PCR conditions are available on
request. Quantitative RT-PCR was performed in a Chromo 4 Detector (MJ
Research) in 96-well plates using a final volume of 20 AL. For each PCR, 8 AL
of 2.5 RealMasterMix Probe ROX (Eppendorf AG), 200 nmol/L of each
primer, 100 nmol/L probe, and cDNA generated from 50 ng of total RNA
were used. PCRs were performed in triplicate and fold changes were
calculated with the following formula: 2(sample 1 DC t  sample 2 DC t), where
DCt is the difference between the amplification fluorescent thresholds of
the mRNA of interest and the mRNA of RNA polymerase 2 used as an
internal reference.
Immunohistochemistry. Retrospectively collected archival thyroid
tissue samples from patients affected by ATCs were retrieved from the
files of the Pathology Department of the University of Pisa on informed
consent. Sections (4 Am thick) of paraffin-embedded samples were stained
with H&E for histologic examination to ensure that the samples fulfilled the
diagnostic criteria required for the identification of ATC. Normal thyroid
tissue samples were also retrieved from the files of the Pathology
Department of the University of Pisa.
For immunohistochemistry, paraffin sections (3–5 Am) were dewaxed in
xylene, dehydrated through graded alcohols, and blocked with 5%
nonimmune mouse serum in PBS with 0.05% sodium azide for 5 min.
Mouse monoclonal antibody against CXCR4 (clone 12G5; R&D Systems)
was added at 1:1,000 dilution for 15 min. After incubation with biotinylated
anti-mouse secondary antibody for 15 min followed by streptavidin-biotin
complex for 15 min (Catalyzed Signal Amplification System, DAKO),
sections were developed for 5 min with 0.05% 3,3¶-diaminobenzidine
tetrahydrochloride and 0.01% hydrogen peroxide in 0.05 mol/L Tris-HCl
buffer (pH 7.6), counterstained with hematoxylin, dehydrated, and
mounted.
Protein studies. Immunoblotting experiments were performed accord-
ing to standard procedures. Briefly, cells were harvested in lysis buffer
[50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1% Triton
X-100, 1 mmol/L EGTA, 1.5 mmol/L MgCl2, 10 mmol/L NaF, 10 mmol/L
sodium pyrophosphate, 1 mmol/L Na3VO4, 10 Ag/mL aprotinin, 10 Ag/mL
leupeptin] and clarified by centrifugation at 10,000  g . For protein
extraction from human tissues, snap-frozen samples were immediately
homogenized in lysis buffer by using the Mixer Mill apparatus (Qiagen).
Protein concentration was estimated with a modified Bradford assay (Bio-
Rad). Antigens were revealed by an enhanced chemiluminescence detection
kit (Amersham). Anti-CXCR4 antibodies were from Abcam Ltd. For the
evaluation of mitogen-activated protein kinase (MAPK) and AKT activity on
SDF-1a triggering, BHT101 and S11T cells were serum deprived for 12 h and
then stimulated with human recombinant SDF-1a (R&D Systems) for the
indicated time. Anti-phosphorylated p44/42 MAPK, anti-p44/42 MAPK,
anti-phosphorylated AKT, and anti-AKT antibodies were from New England
Biolabs. Anti-tubulin monoclonal antibody was from Sigma Chemical.
Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish
peroxidase were from Bio-Rad.
Flow cytometric analysis. Subconfluent cells were detached from
culture dishes with a solution of 0.5 mmol/L EDTA and then washed thrice
in PBS buffer. After saturation with 1 Ag of human IgG/105 cells, cells were
incubated for 20 min on ice with phycoerythrin (PE)-labeled antibodies
specific for human CXCR4 (R&D Systems) or isotype control antibody. After
incubation, unreacted antibody was removed by washing cells twice in PBS
buffer. Cells resuspended in PBS were analyzed on a FACSCalibur
cytofluorimeter using the CellQuest software (Becton Dickinson). Analyses
were performed in triplicate. In each analysis, a total of 104 events were
calculated.
Cell proliferation. S-phase entry was evaluated by bromodeoxyuridine
(BrdUrd) Q6incorporation and indirect immunofluorescence. Cells were grown
on coverslips, kept in 2.5% serum for 24 h, and then treated with
recombinant SDF-1a (100 ng/mL) for 48 h. BrdUrd was added at a
concentration of 10 Amol/L for the last 1 h. Subsequently, cells were fixed in
3% paraformaldehyde and permeabilized with 0.2% Triton X-100. BrdUrd-
positive cells were revealed with Texas red–conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Inc.). Cell nuclei were
identified by Hoechst staining. Fluorescence was visualized with a Zeiss 140
epifluorescent microscope.
For growth curves, cells were plated at a density of 0.5  105 in low-
serum conditions (2.5%) and counted at the indicated time points.
RNA interference. Small inhibitor duplex RNAs targeting human CXCR4
have been described previously (27) Q7and were chemically synthesized by
Proligo. Sense strand for human CXCR4 small interfering RNA (siRNA)
targeting was the following: 5¶-GAGGGGAUCAGCAGUAUAUAC-3¶.
Small duplex RNAs containing the same nucleotides, but in scrambled
fashion (siRNA SCR), were used as a negative control. For siRNA transfection,
ATC cells were grown under standard conditions. The day before
transfection, cells were plated in six-well dishes at 50% to 60% confluency.
Transfection was performed using 5 to 15 Ag of duplex RNA and 6 AL of
Oligofectamine reagent (Invitrogen). Cells were harvested at 48 and 72 h after
transfection and analyzed for protein expression and biological activity.
Xenografts in nude mice. Mice were housed in barrier facilities and
12-h light-dark cycles and received food and water ad libitum at the
Dipartimento di Biologia e Patologia Cellulare e Molecolare (University of
Naples ‘‘Federico II,’’ Naples, Italy). This study was conducted in accordance
with Italian regulations for experimentation on animals. All manipulations
were performed while mice were under isoflurane gas anesthesia. No mouse
4 G. Salvatore, unpublished observation.
5 http://www.probelybrary.comQ5
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showed signs of wasting or other signs of toxicity. BHT101, ARO, or KAT4
cells (5  106 per mouse) were inoculated s.c. into the right dorsal portion
of 4-week-old male BALB/c nu/nu mice (The Jackson Laboratory). When
tumors measured 40 mm3, mice were randomized to receive AMD3100
(n = 10; 1.25 mg/kg/twice daily) or vehicle alone (n = 10; PBS) by i.p.
injection for 5 consecutive days per week for 3 to 4 weeks. Tumor diameters
were measured at regular intervals with calipers. Tumor volumes (V ) were
calculated with the following formula: V = A  B2 / 2 (A = axial diameter;
B = rotational diameter). Tumors were excised and fixed overnight in
neutral buffered formalin and processed by routine methods.
Statistical analysis. To compare CXCR4 mRNA levels in normal thyroid
tissues versus ATC samples, we used the Mann-Whitney nonparametric test
and the GraphPad Instat software, v.3.0b. To compare ATC xenograft
growth in AMD3100-treated versus untreated animals, we used the
unpaired Student’s t test (normal distributions and equal variances) and
the GraphPad Instat software, v.3.0b. All P values were two sided, and
differences were considered statistically significant at P < 0.05.
Results
CXCR4 is overexpressed in surgical samples of human ATC.
We compared CXCR4 mRNA levels in a set of ATC samples (n = 15)
versus different samples of normal thyroid tissue (n = 5). As shown
in Fig. 1A F1, CXCR4 mRNA was found to be up-regulated in most of
the tumor samples (11 of 15). When we performed statistical
analysis, the differences in the expression levels of CXCR4 between
tumors and normal thyroid tissues were statistically significant
(P = 0.0084; Fig. 1A).
To verify whether CXCR4 mRNA overexpression resulted in an
increase in the protein levels, we used protein extracts from a
different set of ATC samples and three normal thyroid tissues in an
immunoblot experiment with CXCR4-specific antibodies. As shown
in Fig. 1B , CXCR4 protein levels were higher in ATC samples than
in normal thyroid. As a positive control for CXCR4 expression, the
ATC cell line ARO was used.
Finally, CXCR4 antibodies were used in immunohistochemical
experiments. We evaluated CXCR4 expression in normal thyroid
tissues and a set of ATC samples (n = 33). Whereas no CXCR4
expression was detected in normal thyroid tissues, 13 (39%) of the
ATC samples scored positive for CXCR4. A representative CXCR4
immunostaining is shown in Fig. 1C . These data indicate that a
significant fraction of human ATCs, similarly to other epithelial
Figure 1. A, expression levels of CXCR4 in human ATC samples versus six normal thyroid tissues by real-time RT-PCR. CXCR4 expression levels of tumors (Y axis )
are calculated relative to the mean CXCR4 level of normal human thyroid tissues (NT). All experiments have been performed in triplicate, and the average value of the
results was plotted on the diagram. P value was calculated with the two-tailed, nonparametric Mann-Whitney test. B, protein lysates (100 Ag) extracted from the
indicated samples underwent Western blotting with anti-CXCR4-specific antibodies. Immunocomplexes were revealed by enhanced chemiluminescence. Equal protein
loading was ascertained by anti-tubulin immunoblot. C, immunohistochemical staining for CXCR4 of formalin-fixed, paraffin-embedded ATCs. Tissue samples from
normal thyroid or ATC were incubated with a mouse monoclonal anti-CXCR4 antibody. ATCs show a strong immunoreactivity for CXCR4, whereas normal thyroid
tissue is negative. Representative pictures of normal and pathologic positive samples are shown. Isotype control was also performed (data not shown). D, the
expression levels of CXCR4 protein were analyzed in thyroid tumor samples from transgenic mice models. Tumor tissues were snap frozen and immediately
homogenized by using the Mixer Mill apparatus in lysis buffer. Equal amounts of proteins were immunoblotted and stained with anti-CXCR4 polyclonal antibodies
(Abcam). ATC-like samples displayed a more intense immunoreactivity for CXCR4. As a control for equal loading, the anti-a-tubulin monoclonal antibody was used.
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cancers, feature high expression levels of the CXCR4 receptor.
Furthermore, they suggest that the increase in CXCR4 levels occurs
at the transcriptional level.
CXCR4 is highly expressed in animal models of ATC. Several
transgenic mice model of thyroid cancer have been developed by
using various oncogenes under the transcriptional control of the
thyroid-specific thyroglobulin bovine promoter. Depending on the
specific transgene, these mice develop carcinomas that resemble,
for cytologic and histologic features, human PTC, FTC, or ATC.
In particular, mice expressing either RET/PTC3 (TGPTC3) or
TRK/T1 (TGTRK) oncogene develop PTC-like tumors (28, 29).
NRAS transgene expression results in follicular tumors that
progress to poorly differentiated carcinomas (TGNRAS; ref. 27).
Finally, animals expressing the SV40 large T antigen (TGSV) present
aggressive thyroid cancer with features similar to human ATC (30).
To evaluate the expression of CXCR4 in these animal models, we
extracted proteins from different tumor samples of the different
transgenic lines and performed Western blot analysis with CXCR4
antibodies. Histologic diagnosis of the thyroid lesion was verified
before processing of the samples. As shown in Fig. 1D , CXCR4
levels were higher in ATC models than in normal mouse thyroid
tissue. PTC samples displayed intermediate levels of CXCR4. These
data, together with previously published data (21, 22), suggest that
CXCR4 up-regulation is a frequent event in thyroid tumorigenesis
and that it correlates with the malignancy of the disease.
CXCR4 is a functional receptor in human ATC cells. To study
the role of CXCR4 in human ATC, we first needed to identify a
suitable cell model. To this aim, various normal thyroid and ATC-
derived primary cultures and continuous cell lines were tested for
CXCR4 expression by Western blot analysis. As shown in Fig. 2A
and B F2, whereas normal thyroid cultures displayed low or unde-
tectable CXCR4 expression levels, several ATC cell lines featured
high levels of the CXCR4 receptor. In particular, of 10 ATC cell
lines, 7 displayed high expression levels of CXCR4. In the case of
ATC cells, the increased levels of CXCR4 proteins were associated
to an increase in CXCR4 mRNA levels as assessed by quantitative
PCR analysis (Fig. 2C). We then asked whether this receptor was
expressed on the cell surface. To this aim, we performed flow
cytometry experiments using a PE-conjugated mouse monoclonal
anti-CXCR4 antibody. The percentage of CXCR4-positive cells was
Figure 2. A, CXCR4 up-regulation in cell lines derived from human thyroid carcinomas was evaluated by immunoblot with a polyclonal anti-CXCR4 antibody.
The expression levels of CXCR4 protein were analyzed in the P5 human primary thyroid cells, and in the indicated cell lines, derived from human PTCs (NIM, TPC1,
FB2, and NPA) or from human ATCs (8505C, ARO, CAL62, BHT101, FRO, and FB1). B, ATC-derived (S11T, S77T, S14T, and HTU8) and normal thyroid
primary culture (P5) were screened for CXCR4 expression by Western blot analysis with the polyclonal anti-CXCR4 antibody. As a control for equal loading, the
anti-a-tubulin monoclonal antibody was used. C, expression levels of CXCR4 in human ATC cells versus the P5 normal thyroid culture were evaluated by real-time
RT-PCR analysis. CXCR4 expression levels of ATC cell lines (Y axis ) are calculated relative to the expression level in the normal human cell culture P5. All
experiments were performed in triplicate, and the average value of the results was plotted on the diagram. SDs were smaller than 25% in all the cases (data not shown).
D, flow cytometric analysis (fluorescence-activated cell sorting) of surface-expressed CXCR4 in ATC cells. Subconfluent cells were detached from culture dishes
and incubated with PE-labeled antibodies specific for human CXCR4.
Cancer Research
Cancer Res 2007; 67: (24). December 15, 2007 4 www.aacrjournals.org
07-0899
determined. As shown in Fig. 2D , CXCR4 was expressed in almost
all the ATC cell lines tested, with the exception of the FB1 cells. The
ARO cells, which in a previous report were shown to feature high
CXCR4 levels (21), were included as a positive control. In contrast,
normal thyroid cells did not express CXCR4 (data not shown).
SDF-1, the CXCR4 ligand, was not expressed by ATC cells as
assessed by quantitative PCR or ELISA assay (data not shown).
We selected two cell lines, S11T and BHT101, for further
experiments. First, we tested the ability of recombinant SDF-1a to
stimulate signal transduction in ATC cells. It has been previously
reported that stimulation of CXCR4 induces the activation of
several kinase cascades mainly through the activation of the Ghg
subunit of the Gi protein (31, 32). We therefore tested the
phosphorylation of two downstream effectors, extracellular sig-
nal-regulated kinase (ERK) 1/2 and AKT, using phosphorylated-
specific antibodies. To this aim, cells were serum starved for 12
h and then stimulated with SDF-1a for different time points. As
shown in Fig. 3A and BF3 , SDF-1a induced rapid and sustained
activation of ERK1/2 in both cell lines. AKT activation was also
achieved in BHT101 cells on SDF-1a treatment, whereas it was less
evident in S11T cells. Together, these data indicate that CXCR4 is
functional in ATC cells. Activation of ERK1/2 and AKT was
observed in virtually all the ATC cell lines expressing CXCR4,
whereas normal thyroid cells, which do not express CXCR4, did not
display these effects (data not shown).
Biological activity of CXCR4 in ATC cells. To further test the
functional responsiveness of CXCR4 in ATC, we stimulated these
cells with SDF-1a and evaluated its ability to induce cell
proliferation. To this aim, BHT101 and S11T cells were maintained
in low-serum (2.5%) growth conditions for 24 h and then either left
untreated or stimulated with SDF-1a for 12 h. As a measure of DNA
synthesis, we counted BrdUrd-positive cells on a 1-h BrdUrd pulse.
As shown in Fig. 4F4 , SDF-1a consistently enhanced DNA synthesis in
both BHT101 and S11T cells. We then used a specific CXCR4
inhibitor, AMD3100, to block this effect. AMD3100 is a competitive
antagonist of SDF-1a, but it also displays partial agonist activity
(33). Normal thyroid cells were insensitive to SDF-1a stimulation
and to the effect of AMD3100 (data not shown). As shown in
Fig. 4A , AMD3100 inhibited SDF-1a–mediated BrdUrd incorpora-
tion in ATC cells. The positive effect of SDF-1 on cell proliferation,
measured as S-phase entry, was also observed in other ATC cell
lines (Fig. 5CF5 ). To evaluate whether SDF-1a could stimulate ATC
cell growth, we also performed growth curves in low-serum (2.5%)
conditions. As shown in Fig. 4B , the stimulation of BHT101 with
SDF-1a increased their proliferation rate, and AMD3100 reverted
this effect. SDF-1a was also able to increase the proliferation rate
of three different ATC cell lines, KAT4, CAL62, and ARO, which
express CXCR4, but was unable to do so on FB1 cells, which we
previously reported to be devoid of CXCR4 (Fig. 4B). AMD3100
alone did not have any effect on ATC cells (data not shown).
To exclude off-target effects of AMD3100 and to directly
determine the role of CXCR4 on ATC cell proliferation, we used
small duplex RNA oligos to knock down CXCR4. CXCR4 RNA
interference was verified by Western blot analysis in BHT101 cells
(Fig. 5A). We then transfected CXCR4 siRNAs into BHT101, KAT4,
CAL62, and 8505C cells. CXCR4 silencing substantially impaired
SDF-1a–induced S-phase entry in all the ATC cells but had no
effect on BrdUrd incorporation in the absence of the chemokine, as
shown in Fig. 5. When we used the control scrambled siRNA, this
inhibitory effect was not observed. Furthermore, scrambled oligos
had no effect on CXCR4 protein levels (Fig. 5A).
AMD3100 inhibits ATC tumor formation in nude mice. It has
been previously shown that the CXCR4/SDF-1 axis plays an
important role in the growth and in the metastatic ability of
several epithelial cancers (20). Because we had shown that CXCR4
inhibition blocked SDF-1a–mediated ATC cell growth in culture,
and because it has been shown that this chemokine is secreted by
stromal tumoral cells (34), we reasoned that SDF-1a-CXCR4 axis
blockade by AMD3100 might inhibit ATC tumor growth. To this
aim, we selected BHT101, ARO, and KAT4 cells for their ability to
respond to SDF-1a and their ability to form tumors in vivo with
high efficiency. Nude mice were injected s.c. with 5  106 cells.
When tumors measuredf40 mm3, mice (n = 20 for each cell line)
were randomized to receive AMD3100 (1.25 mg/kg/twice daily
i.p.) or vehicle 5 days per week for 3 to 4 weeks. Tumor diameters
were measured at regular intervals with caliper. After 21 days, the
mean volume of BHT101 tumors in mice treated with AMD3100
was 48 mm3, whereas that of mice treated with vehicle was
620 mm3. Representative experiments are shown in Fig. 6A and B F6.
Tumors induced by ARO and KAT4 reached the volume of 40 mm3
in only 1 week. In addition, in this case, AMD3100 was able to
inhibit tumor growth, although to a lesser extent. In fact, ARO-
induced tumor mean volume at the end of treatment with
AMD3100 was 220 mm3, whereas that of mice treated with vehicle
was 625 mm3. Similar results were also obtained when KAT4 cells
were used. In this case, the difference between the mean volume
of AMD3100-treated versus vehicle-treated tumors was not
statistically significant after 3 weeks. However, when treatment
Figure 3. A and B, protein extracts from the
indicated cell lines were subjected to
immunoblotting with anti-phosphorylated
p44/42 MAPK (apMAPK) and with
anti-phosphorylated AKT (apAKT)
antibodies. The blots were reprobed with
anti-p44/42 and anti-AKT antibodies for
normalization.
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was extended for 1 additional week, AMD3100-treated tumor mean
volume was 180 mm3, whereas that of mice treated with vehicle
was 690 mm3, and the P value was 0.039 (Fig. 6A). These data,
taken together, show that treatment with AMD3100 strongly inhi-
bits ATC tumor growth.
Discussion
Despite ATC is a rare disease, it is one of the most aggressive
human cancers (9). Although various therapeutic strategies have
been exploited to slow down the growth of this tumor, none of
these treatments improved survival (10). The molecular pathways
implicated in this disease are poorly understood, and this hampers
the application of novel rational therapeutic strategies. Genetic
alterations found in ATC are inactivating mutations of the p53
tumor suppressor and activating mutations of h-catenin, RAS,
BRAF, and PIK3CA (11). Recently, molecular genetic alterations of
FHIT have been also detected in ATC (35). Among the genes
involved in ATC, BRAF serine-threonine kinase has been exploited
as a potential therapeutic target (23).
Most epithelial cancers feature high levels of expression of the
chemokine receptor CXCR4 (20). This receptor has been widely
Figure 4. A, BrdUrd incorporation was measured to evaluate S-phase entry on treatment of BHT101 and S11T cells with SDF-1a in the presence or absence of
the CXCR4 inhibitor AMD3100. Columns, average results of three independent experiments; bars, SD. P < 0.05. B, the indicated cell lines were plated at the same
density (5  104) in 2.5% serum, harvested, and counted at the indicated time points. Columns, average results of at least three independent determinations; bars, SD.
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studied because its expression contributes to several phenotypes of
cancer cells, such as the ability to grow, survive, and spread
throughout the body. On the contrary, most epithelial cancers do
not express SDF-1, the unique CXCR4 ligand, whereas SDF-1 is
produced in high amounts in specific body districts. It has been
suggested that the role of this chemokine in cancer is mainly to
attract cancer cells to these districts (18). In support of this
hypothesis, it has been shown that SDF-1 is produced in several
metastatic sites. Recently, it has also been suggested that tumoral
stroma secretes high amounts of SDF-1, supporting the concept
that this chemokine is pivotal in sustaining local protumorigenic
events, such as growth and survival of cancer cells (34). Further-
more, the expression of SDF-1 by stromal cancer cells directly
recruits endothelial progenitors that are required for tumor
angiogenesis (19). As most epithelial and hematopoietic malignan-
cies, also thyroid cancer expresses high levels of CXCR4.
We previously reported functional expression of CXCR4 in
human papillary thyroid cancer (22). Furthermore, Hwang et al.
(21) showed that an anaplastic cell line, ARO, expressed high levels
of functional CXCR4. In this report, we analyzed human ATC
samples for CXCR4 expression. We also screened a large panel of
human ATC established and primary cell cultures for CXCR4
expression. We show that, both at the mRNA and at the protein
level, this receptor is overexpressed in ATC with respect to normal
thyroid samples. In contrast, SDF-1 was not detected. The
molecular mechanisms underlying CXCR4 up-regulation in ATC
are currently unknown. Because we had previously shown that
CXCR4 expression was under the control of the RET/PTC-RAS-
BRAF-ERK pathway in PTCs (22), and because this pathway is also
activated in ATC, we asked whether CXCR4 expression correlated
with the BRAF status in ATC. The ATC cell lines that we used in
this study had been previously characterized for BRAF mutations.
Figure 5. A, CXCR4 RNA interference was used to transiently suppress CXCR4 expression in BHT101 cells. BHT101 cells were transfected with siRNAs against
CXCR4 (siRNA CXCR4) or control nonspecific small duplex RNA containing the same nucleotides, but in scrambled fashion (siRNA SCR ), and harvested
48 and 72 h later. Protein lysates were subjected to immunoblotting with anti-CXCR4 and anti-tubulin antibodies. Control siRNA did not affect CXCR4 protein levels.
B, CXCR4 RNA interference (siRNA CXCR4 ) in BHT101 cells inhibited SDF-1a–stimulated S-phase entry as evaluated by BrdUrd incorporation assay. Control
siRNA (siRNA SCR ) did not inhibit DNA synthesis. Unstimulated BHT101 cells were not affected by siRNA transfection. C, CXCR4 RNA interference (siRNA CXCR4 )
inhibited S-phase entry in SDF-1a–stimulated KAT4, CAL62, and 8505C. ATC cells were transfected with siRNAs against CXCR4 (siRNA CXCR4 ) or control
siRNA (siRNA SCR ) and harvested 48 h later. Control siRNA did not inhibit DNA synthesis. Unstimulated cells were not affected by siRNA transfection.
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Furthermore, human ATC samples were screened for the presence
of BRAF mutations.6 FN3We found that most of the samples expressed
CXCR4, and this expression was present in both the BRAF-positive
and in the BRAF-negative tumors and cell lines. These data suggest
that CXCR4 up-regulation in ATC is not necessarily linked to the
BRAF pathway and that it can be possibly achieved through
different mechanisms. The mechanisms of CXCR4 up-regulation in
cancer thus far described are various and complex. It has been
shown that nuclear factor-nB (NF-nB) positively regulates the
expression of CXCR4 (36) in breast cancer cells. Interestingly,
NF-nB is activated in human thyroid cancer cells (37, 38). Interest-
ingly, transduction of human thyroid cancer cells with the mutant
BRAF(V600E) allele induced an increase in NF-nB DNA-binding
activity (39). Thus, it is possible that CXCR4 expression in ATC is
sustained by high NF-nB activity, which can be the result either of
BRAF activation or of the activation of other still undiscovered
pathways.
We also show that the CXCR4 expressed on the ATC cell surface
is able to transduce biochemical signals into the cell. Indeed,
stimulation of ATC cells with recombinant human SDF-1a
activated ERK1/2 and, less consistently, AKT pathways in ATC
cells. Moreover, we found that SDF-1a stimulated cell growth of
different ATC cell cultures, which was inhibited by the small
CXCR4 inhibitor AMD3100. Given the high rate of mortality of this
cancer and the lack of effective therapies, we focused our efforts in
the identification of novel potential therapeutic targets in ATC. We
found that the treatment with AMD3100 significantly suppressed
the development of tumors in different xenograft models of ATC
cells in nude mice.
The more dramatic biological effects of CXCR4 inhibition
observed in the animals with respect with those observed in cell
culture could be explained by the fact that SDF-1 can act, in
tumor microenvironment, at multiple levels. Indeed, tumoral
stromal cells, such as fibroblasts and bone marrow–derived cells,
express high levels of SDF-1 (34), which can directly enhance the
growth of epithelial tumoral cells and can recruit endothelial
progenitors, thus favoring angiogenesis. However, when we
analyzed xenograft tumors for CD31-positive tumor capillaries,
we found that there were no differences in vessel density of
AMD3100-treated versus untreated tumors. Preliminary data
suggest that AMD3100 activity in xenografts correlates better
with a proapoptotic than with an antiproliferative activity.7 FN4Our
findings are in accord with previous reports about the use of
CXCR4 inhibitors in brain tumor models (40, 41). Although
treatment of ATC xenografts with AMD3100 did not induce a
complete regression of tumors, we observed a strong reduction in
growth rate, which was more dramatic in the case of BHT101
xenografts. It is conceivable that the combination of conventional
anticancer therapies with CXCR4 targeting would display a
stronger antineoplastic effect. Given the strong antitumor activity
of AMD3100, newer-generation compounds have been developed,
such as AMD3465. This compound differs from the bicyclam
AMD3100 in that it is a monocyclam endowed with greater
solubility in water, higher affinity for CXCR4, and a potent
antitumor activity (41). Although these compounds are effective in
inhibiting various cancers, long-term sustained dosing of
Figure 6. A, antitumorigenic effects of AMD3100 in ATC cell xenografts.
BHT101, ARO, and KAT4 cells (5  106 per mouse) were injected s.c. into the
right dorsal portion of BALB/c athymic mice. When tumors measured 40 mm3,
mice were randomized to two groups (10 mice per group) to receive AMD3100 or
vehicle (PBS) by i.p. injection. Treatment was given for 5 consecutive days per
week for 3 to 4 wks (day 1 is the treatment starting day). Tumor diameters
were measured with calipers and tumor volumes were calculated. Unpaired
Student’s t test (normal distributions and equal variances) was applied. All
P values were two sided, and differences were statistically significant at
P < 0.05. B, tumors were excised and photographed. Two representative
examples of BHT101 xenografts are shown.
6 F. Basolo and P. Faviana, unpublished observations.
7 V. Guarino et al., unpublished observation.
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AMD3100 displayed a certain toxicity (42). For this reason, further
studies, aimed at understanding the effects of long-term
administration of CXCR4 inhibitors, must be pursued. Despite
these considerations, our data, together with several other reports,
strongly indicate that the inhibition of this pathway should be
actively evaluated as a novel anticancer therapy.
In conclusion, in this report, we identify CXCR4 as another
potential target of ATC anticancer therapy and suggest that
AMD3100, or other specific CXCR4 inhibitors, should be developed
and tested for the therapy of human ATC.
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Abstract 
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and chemoresistant type of 
cancer. The serine/threonine kinase Polo-like kinase 1 (PLK1), a key regulator of multiple 
steps during mitotic progression, is highly expressed in ATC. Here we used BI 2536, a potent 
small molecule PLK1 inhibitor, on a panel of ATC and normal thyroid follicular cell lines. 
Our data show that ATC cells are addicted to high levels of PLK1 activity for proliferation 
and viability. Upon treatment with nanomolar doses of BI 2536, ATC cells progressed 
normally through S phase but underwent massive apoptosis thereafter, directly from mitotic 
arrest. Immunofluorescence microscopy, immunoblot and flow cytometry analysis showed 
that, upon PLK1 blockade, ATC cells arrested in prometaphase with a 4N-DNA content. 
Treated ATC cells accumulated phosphohistone H3 and displayed characteristic mitotic 
(Polo) spindle aberrations. Normal thyroid cells were 3-13 fold less susceptible to BI 2536-
induced cell cycle effects compared to ATC cells. These findings identify PLK1 as a 
promising target for the molecular therapy of ATC. 
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Introduction 
Anaplastic (undifferentiated) thyroid carcinoma (ATC) is the most aggressive thyroid tumor 
and ranks among the most lethal human malignancies, with a median survival from diagnosis 
of ∼ 4-12 months (1-3). Despite accounting for only 2-5% of all thyroid tumors, ATC is 
responsible for more than half of the deaths attributed to thyroid cancer (1-3). ATC usually 
presents during the 6th to 7th decade of life as a rapidly enlarging neck mass that extends 
locally, compresses the adjacent structures and tends to disseminate to regional nodes and 
distant sites (1-3). Multimodal therapy, including surgery, chemotherapy and radiotherapy, 
does not change the natural course of the disease; thus, treatment of ATC has often only 
palliative purposes (1-3). Such a dismal outcome demands for the development of novel 
treatment strategies. 
 
Several genetic alterations involved in the pathogenesis of ATC are known. Some of them, 
namely point mutations in RAS and BRAF (4-8) and point mutations or gene amplification of 
PIK3CA (9, 10), are found not only in ATC but also in well-differentiated (papillary-PTC or 
follicular-FTC) carcinomas, suggesting that ATC may develop secondary to neoplastic 
progression of well-differentiated thyroid cancers. Conversely, p53 mutations are rarely seen 
in well-differentiated lesions (<10%) whereas they occur in 67-88% of ATC (4, 5). Other 
mechanisms, besides gene mutation, may functionally impair p53 in ATC (11, 12).  
 
We have recently identified a gene expression signature associated with the high proliferative 
and aneuploid ATC phenotype (13). Such expression profile features up-regulation of Polo-
like kinase 1 (PLK1) (13). PLK1 belongs to the Polo family of serine/threonine kinases, that 
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also includes PLK2, 3 and 4 (14). PLK1 plays a pivotal role in several G2 and M-phase 
related events, i.e., centrosome maturation, γ-tubulin association with centrosome and 
microtubule nucleation, bipolar spindle formation, CDC2 (CDK1)-cyclin B activation, 
anaphase-promoting complex/cyclosome (APC/C) activation by direct APC phosphorylation 
and by inactivation of the APC/C inhibitor Emi1, chromosome segregation and cytokinesis 
(14-17). Consistent with its prominent role in G2/M phase, PLK1 expression and activity is 
low throughout G0, G1 and S phase, and then rise in G2 and peaks during M phase (15).  
 
PLK1 is overexpressed in several cancer types and its up-regulation often correlates with poor 
prognosis (14-16). Adoptive overexpression of PLK1 causes NIH 3T3 cell transformation, 
while its depletion/inactivation by a variety of methods (antisense oligonucleotides, small 
interfering RNA and dominant negative constructs) leads to mitotic arrest and cell death (18-
21). Therefore, PLK1 has been envisaged as a potential target in cancer therapy, and PLK1 
kinase inhibitors are currently being evaluated in preclinical and clinical studies for various 
cancer types (17, 22-28).  
 
BI 2536 is a dihydropteridinone compound that inhibits PLK1 activity in a ATP-competitive 
manner (17, 22). BI 2536 inhibited PLK1 with high potency (half-maximal inhibitory 
concentration –IC50-of 0.83 nM); it showed a ≥10,000-fold selectivity relative to a panel of 63 
other protein kinases and equipotently blocked human, rat and mouse PLK1 (22). Here, we 
show that BI 2536 selectively induces mitotic arrest and apoptotic death of ATC cells, 
suggesting that targeting PLK1 could be pursued as a novel strategy in the treatment of ATC. 
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Materials and Methods  
Compound. BI 2536, 4-((R)-8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydro-
pteridin-2-ylamino)-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide, was provided by 
Boehringer Ingelheim Austria GmbH (Wien, Austria). BI 2536 was dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 10 mM and stored at – 80°C. Vehicle alone was used 
as a control. 
 
Cell cultures. The human ATC cell lines CAL62 (29), ARO (5), SW1736 (30), and the poorly 
differentiated thyroid carcinoma cell line NPA (5) were grown in Dulbecco's modified Eagle's 
medium (DMEM) (Invitrogen, Groningen, The Netherlands) containing 10% fetal bovine 
serum. The Fischer rat-derived differentiated thyroid follicular cell line PC Cl 3 (hereafter 
“PC”) was grown in Coon’s modified Ham F12 medium supplemented with 5% calf serum 
and a mixture of six hormones (6H), including thyrotropin (10mU/ml), hydrocortisone 
(10nM), insulin (10µg/ml), apo-transferrin (5µg/ml), somatostatin (10ng/ml), and glycyl-
histidyl-lysine (10ng/ml) (Sigma-Aldrich, St. Louis, MO, USA). For cell proliferation assays, 
5x104 cells were plated in 35-mm dishes. The day after plating, BI2536 or vehicle was added. 
Cells were counted in triplicate every day. Cell counts after 72 hours treatment were used for 
dose-response curves and for half maximal effective concentrations (EC50) calculation (Graph 
Pad InStat software program, version 3.06.3, San Diego, CA). 
 
Protein studies. Immunoblotting experiments were performed according to standard 
procedures. Briefly, cells were harvested and lysed in a buffer containing 50 mM HEPES (pH 
7.5), 1% Triton X-100, 50 mM NaCl, 5 mM EGTA, 50 mM NaF, 20 mM sodium 
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pyrophosphate, 1 mM sodium vanadate, 2 mM PMSF, and 1 µg/ml aprotinin. After 
clarification, lysates containing comparable amounts of proteins, estimated by a modified 
Bradford assay (Bio-Rad, Munich, Germany), were subjected to immunoblot. Immune 
complexes were detected with the enhanced chemiluminescence kit (Amersham Pharmacia 
Biotech, Piscataway, NJ). 
 
Antibodies. Anti-PLK1 monoclonal antibody was from Zymed Laboratories (San Francisco, 
CA); monoclonal anti α-tubulin was from Sigma-Aldrich; anti-cyclin B1 and anti-geminin 
(FL-209) polyclonals were from Santa Cruz Biotechnology (Santa Cruz, CA); anti-cleaved 
(Asp175) caspase-3 p17 and p19 fragments polyclonal (5A1) and monoclonal anti-phospho-
histone H3 (Ser10) (6G3) were from Cell Signaling Technology, Inc. (Beverly, MA); anti-
PARP [Poly (ADP-ribose) Polymerase] monoclonal antibody, which detects full-length PARP 
and the large fragment (89 kDa) produced by caspase cleavage, was from BD Biosciences 
(San Jose, CA). Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish 
peroxidase were from Bio-Rad.  
 
Immunofluorescence. Cells, fixed with 3% paraformaldehyde and permeabilized with 0.2% 
Triton X-100, were incubated with anti-α-tubulin or anti-phospho-histone H3 antibodies for 
45 min at 37°C. Washed coverslips were then incubated with fluoresceine or rhodamine 
conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 30 min at 
37°C. After 5 min DAPI counterstaining and coverslips mounting, cells were observed with a 
Zeiss Axioskop 2 microscope (Zeiss, Gottingen, Germany).  
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Cell cycle analysis. CAL62 cells were synchronized at the G1/S boundary by double 
thymidine block. Briefly, exponentially growing cells were treated with thymidine (4 mM) 
(Sigma) for 16 hours, washed thrice and incubated in normal growth medium for 6 hours and 
then again with thymidine for 14 hours. Released G1/S synchronized cells or unsynchronized 
cells were incubated with BI 2536 or vehicle. At the indicated time intervals, cells were 
harvested and fixed in 70% ethanol for 4 hours. After washing with PBS, cells were treated 
with RNAse A (100 U/ml) and stained with propidium iodide (25 µg/ml) (Sigma) for 30 min. 
Samples were analyzed with a CyAn ADP flow cytometer interfaced with the Summit V4.2 
software (DakoCytomation, Carpinteria, CO).  
 
Statistical analysis. The two-tailed unpaired Student’s t test was used for statistical analysis.  
All p value were two sided and differences were significant when p < 0.05. Statistical 
analyses were carried out using the Graph Pad InStat software program (version 3.06.3, San 
Diego, CA). 
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Results 
BI 2536 reduces viability of ATC and PDC cells.  
We used ATC cell lines CAL62, SW1736, ARO and the poorly-differentiated carcinoma 
(PDC) cell line NPA. These cells overexpress PLK1 (13) and have varied patterns of 
chromosome aberrations (30) and oncogene mutations: ARO, SW1736 and NPA, but not 
CAL62, harbour the BRAF V600E  mutation; all of them have p53 gene alterations (ARO, 
CAL62 and NPA are p53 mutated while SW1736 are negative for p53 expression) (5, 13, 30). 
Cell were treated with BI 2536 over a 1000-fold concentration range (starting at 0.1 nM) and 
counted every day. Vehicle alone was used as a control. Fig. 1 shows the average result of 
three independent experiments. BI 2536 treatment caused a significant (p < .0001) reduction 
of viability in the cancer cell lines. After 72 hours treatment with 5 (CAL62) or 10 (SW1736, 
ARO and NPA) nM BI 2536 virtually no viable cell remained in culture dishes. Half maximal 
effective concentrations (EC50) was of 1.4 nM, 3.2 nM, 5.8 nM, 5.9 nM for CAL62, SW1736, 
ARO and NPA cells respectively. To analyse BI 2536 effects on non-transformed cycling 
thyroid cells, we used normal thyroid follicular PC cells. BI 2536 showed an EC50 value for 
PC cells (17.8 nM) that was 3-13-fold higher compared to ATC and PDC cells (p < .0001) 
(Fig. 1). 
 
BI 2536 induces prometaphase arrest and apoptotic death in ATC cells.  
To investigate the mechanisms of cell viability reduction upon BI 2536 treatment, 
exponentially growing CAL62 and SW1736 cells were treated with BI 2536 at the lowest 
effective concentration as estimated by the cell viability assays, and cell cycle profile was 
analyzed by flow cytometry, immunofluorescence microscopy and immunoblot. Vehicle was 
PLK1 targeting in ATC 
9 
used as a negative control. As shown in Fig. 2A, starting at 12 hours treatment, 5 and 10 nM 
BI 2536 increased the 4N-DNA fraction in CAL62 and SW1736 cells, respectively. This was 
followed at 36 and 48 hours by the appearance of a sub-G1 peak (at 48 hours, 20 % vs 0.67%  
in vehicle-treated cells for CAL62 and 6.15 vs 1.7 in vehicle-treated cells for SW1736), 
indicative of apoptosis. Cell fractions with a >4N DNA peak were hardly detectable, 
indicating that the treatment did not cause reduplication of unseparated sister chromatids after 
failure of cytokinesis (see also below) (Fig 2A). None of the aforementioned effects could be 
seen in PC cells upon incubation with 10 nM BI 2536 (Fig. 2A). In normal cells, only 
treatment with ≥50 nM concentrations of the compound gave results similar to those observed 
in ATC cells (data not shown). 
 
The accumulation of cells with a 4N DNA content was indicative of a cell cycle block in 
either G2 or M phase. To distinguish between the two possibilities, BI 2536 or DMSO-treated 
cells were either stained with anti-phospho-histone H3 for immunofluorescence or analyzed 
by immunoblot for cyclin B1. Also, PLK1 protein levels were examined as surrogate G2/M 
phase marker. The percentage of mitotic (phospho-histone H3 positive) cells was increased in 
BI 2536-treated ATC, but not PC cells, as soon as 12 hours after treatment, peaking at 24 
hours and decreasing thereafter (Fig. 2B). Both cyclin B1 and PLK1 protein levels underwent 
analogous changes upon BI 2536 treatment (Fig. 2C). These findings indicated that the 
compound caused M phase arrest of ATC cells. Concentrations ≥50 nM were required to elicit 
similar responses in normal PC cells (data not shown). 
 
The reduction of phospho-histone H3 positive cells and cyclin B1 levels at the 36 hours time 
point could be due to the onset of apoptosis directly from mitosis; alternatively, upon the 4N 
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block cells may attempt to start a novel cycle and reduplicate their genome. As mentioned 
above, this second hypothesis could be ruled-out given the absence of >4N DNA peaks at 
flow cytometry. On the other hand, two biochemical markers of apoptosis, i.e. cleaved 
products of caspase-3 and PARP (poly ADP-ribose polymerase), were visible by immunoblot 
in both ATC cell lines treated with BI 2536 (Fig. 2C). In CAL62 cells, which displayed a 
major reduction of cyclin B1 levels after 36 hours treatment, cleaved caspase-3 and PARP 
fragments were detectable as soon as 24 hours after incubation with BI 2536, and peaked at 
36 and 48 hours, respectively. SW1736 cells, which showed modest reduction of cyclin B1 
after 36 hours treatment, had a milder and delayed increase of the apoptotic markers 
compared to CAL62 cells. Taken together, these findings suggest that upon PLK1 inhibition, 
ATC cells rapidly undergo apoptosis directly from mitosis. 
 
To further characterize the cell cycle effects of PLK1 inhibition, we synchronized CAL62 
cells at the G1/S transition by double thymidine block; cells were released in the presence of 5 
nM BI 2536 or vehicle and analyzed by flow cytometry and immunoblot at different time 
points. As shown in Fig. 3A, BI 2536-treated cells progressed normally through S phase and 
then arrested in G2/M (at 11 hours). Sub-G1 DNA fractions became detectable after 29-48 
hours from release (Fig. 3A). Instead, cell released in control medium normally progressed 
through S and G2/M and then re-entered a new G1 phase (Fig. 3A). Western blot analysis 
showed consistent results: in vehicle-treated cells, cyclin B1 was downregulated after 24 
hours from release as cells had exited mitosis. Instead, in cells treated with BI 2536, cyclin B1 
downregulation was delayed until 35 hours because of the G2/M arrest (Fig. 3B). In treated 
cells, cleaved caspase-3 fragments were clearly detectable after 24 hours treatment, again 
suggesting apoptosis may occur directly from mitosis. Moreover, despite a reduction of cyclin 
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B1 levels at the latest time points, BI 2536-treated cells failed to downregulate geminin (Fig. 
3B), an event that is required to start a new DNA duplication cycle (31). This indicates that 
treated cells remained unlicensed for replication, ruling-out the possibility of reduplication of 
undivided cells. 
 
BI 2536 induces characteristic mitotic-spindle aberrations in ATC cells. Depletion or 
inactivation of PLK1 has been reported to induce characteristic mitotic-spindle aberrations in 
several cancer cells (14-17, 19, 21, 22, 24). To further prove that BI 2536 effects in ATC cells 
were mediated by PLK1 inhibition, we asked whether treatment phenocopied PLK1 
knockdown. Exponentially growing CAL62 and SW1736 cells were treated with BI 2536 (5 
and 10 nM, respectively), collected at different time intervals and stained for 
immunofluorescence with anti-α-tubulin to visualize mitotic spindle and DAPI to visualize 
DNA. Consistent with the results obtained by anti-phospho-histone H3 staining, both ATC 
cell lines showed an accumulation of mitotic cells in a prometaphase state starting at 12 hours 
and peaking at 24 hours; in treated cells, anaphase and cytokinesis figures were virtually 
absent (Fig. 4A). No increase in the mitotic fraction could be seen in control PC cells upon 
treatment with 10 nM BI 2536, and all the mitotic phases were normally represented (Fig. 
4A).  
 
A characteristic phenotype in inhibitor-treated ATC cells, but not PC cells, was the presence 
of aberrant monopolar (Polo) spindles, a hallmark of PLK1 depletion/inactivation (Fig. 4B). 
Such Polo spindles are monoastral microtubule arrays nucleated from a single organizing 
centre and containing unseparated centrosomes circled by a ring of condensed chromosomes 
(15). Monopolar spindles seem to occur secondary to a defect in timely organization of 
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microtubule asters at prophase, followed by the instantaneous polymerization of mitotic 
microtubules in a monopolar aster only after nuclear envelope breakdown (17). They occurred 
in BI 2536-treated ATC cells along with other aberrant spindle phenotypes, like multipolar 
spindles and spindles without a clear spatial organization (disorganized) that accumulated 
with time (Fig. 4B). After 36 hours treatment, albeit only very few mitotic cells could be seen 
on coverslips, virtually 100% of them had an abnormal spindle. Moreover, after 36 and 48 
hours treatment, in parallel with the reduction of phospho-histone H3-positive cells, cyclin B1 
levels and increased levels of caspase-3 and PARP fragments, most of the remaining ATC 
cells either showed a nuclear apoptotic morphology or harbored decondensed/partially 
condensed nuclei with gross morphological aberrations (Fig. 4A). These are hallmarks of the 
so called mitotic catastrophe, a form of cell death taking place from within mitosis. In normal 
cells, a similar effect could only be obtained with compound doses ≥ 50 nM (data not shown). 
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Discussion 
ATC displays overexpression of genes controlling multiple steps involved in mitotic 
progression, a signature that included the up-regulation of PLK1 (13). Targeting key 
components of the mitotic machinery has been envisaged as a possible strategy in cancer 
treatment. Among them, PLK1 has emerged as a promising candidate (15, 16). PLK1 
depletion/inhibition reduces survival of several cancer cells and inhibits tumor growth in vivo 
in xenograft models (19-27). It is feasible that, based on the specific role of PLK1 in mitosis,  
its inhibition may avoid some of the side effects associated with current anti-mitotic agents 
(like taxanes and Vinca alkaloids derivatives) that, by targeting microtubules, affect many 
critical cellular processes (e.g. axonal transport) unrelated to mitosis (15, 16).  
 
Here, we took advantage of the high potency and selectivity of BI 2536, a compound able to 
inhibit PLK1 activity at low nanomolar concentrations, to exploit PLK1 requirement of ATC 
cells. ATC cells proved to be extremely sensitive to PLK1 inactivation. Concentrations as low 
as 5-10 nM of BI 2536 were sufficient to cause prometaphase arrest with characteristic 
spindle aberrations. This likely caused mitotic entrapment, activation of the spindle assembly 
checkpoint and mitotic cell death (16). These effects are hallmarks of PLK1 inhibition, 
suggesting that the compound is exerting its effects in ATC cells by blocking PLK1 and not 
other targets (15-17). It is known that BI 2536 also affects the activities of PLK2 and PLK3 
albeit at higher concentrations (IC50 of 3.5 and 9.0 nM, respectively) than PLK1 (17, 22). 
However, PLK2 and 3 are though to function in G1 and S phases of the cell cycle, phases that 
were not significantly affected by BI 2536 treatment of ATC cells. Interestingly, polyploidy, a 
major concern when targeting kinases involved in mitosis/cytokinesis as it may promote 
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tumorigenesis (16, 32-34) was not detected, and the possibility of reduplication was ruled-out. 
Instead, this potentially harmful phenomenon was reported with Aurora B inhibitors that 
silenced the mitotic spindle checkpoint, causing precocious mitotic exit and polyploidy (16). 
 
Importantly, in agreement with our previous observations on siRNA-induced PLK1 depletion 
(13), normal thyroid follicular cells proved to be less susceptible  to BI 2536-induced PLK1 
inactivation (with a 3-13 fold difference in potency) compared to ATC cells, suggesting the 
possibility of achieving a therapeutic window in vivo. The reason for such different PLK1 
requirement remains unknown. Several reports have indicated that p53 protein is stabilized in 
PLK1-depleted cancer cells (20, 21), p53-depletion enhances the sensitivity of various cell 
types to PLK1 knock-down (21) and PLK1 expression is negatively controlled by p53 also in 
ATC cells (13, 15). Thus, one possibility is that p53 function may be required to survive 
PLK1 depletion and the frequent impairment of p53 would make ATC cells particularly 
susceptible to PLK1 inhibition. Importantly, all of the ATC cell lines used in this study either 
harbour p53 gene mutations (ARO, CAL62 and NPA) or are negative for wild type p53 
expression (SW1736) (5, 13, 30). Another possibility is that high proliferation rate and 
chromosomal instability could turn mitosis and cytokinesis into critical steps in ATC cell 
cycle progression. Fine-tuning of the events occurring at such steps would then become vital, 
making ATC cells (similarly to other highly malignant cancer cells) extremely dependent on 
the high concentrations of functional PLK1 for faithful bipolar spindle assembly and mitosis. 
Consistent with this hypothesis, at low nM doses of BI 2536, ATC, but not normal, cells exert 
typical defects in centrosome maturation with the formation of monoastral spindles. Instead, 
the threshold of PLK1 activity to sustain a normal mitotic cycle was apparently lower in 
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normal PC cells, where the same mitotic phenotype was observed only at high doses of BI 
2536.  
 
Whatever the mechanism, our findings suggest that PLK1 might be exploited as a molecular 
target in ATC therapy and BI 2536, that has already progressed into phase I clinical trials in 
patients with advanced solid tumors (28), or other specific PLK1 inhibitors could be 
examined in clinical studies for the treatment of such deadly human cancer. 
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Figure legends 
 
Figure 1: Cell viability effects of BI 2536 in thyroid cells 
The indicated cell lines were treated in triplicate with different doses of BI 2536 or vehicle 
(NT) and counted at the indicated time points. The average results of three independent 
experiments are reported; error bars represent 95% confidence intervals.  
 
Figure 2: Cell cycle effects of BI 2536 in ATC cells 
A) The indicated cell lines were treated with 5 nM (CAL62) and 10 nM (SW1736 and PC) BI 
2536 or vehicle (NT) and DNA content was analyzed by flow cytometry at different time 
points. B) CAL62 and SW1736 ATC cells or control PC cells, grown on glass coverslips, 
were treated with BI 2536. At the indicated time points, cells were fixed, stained with a anti-
phospho-histone H3 (Ser10) and analyzed by fluorescence microscopy. The percentage of 
positive cells represents the average of three experiments in which at least 500 cells were 
counted. Representative micrographs are shown in the insets. C) CAL62 and SW1736 cells, 
treated with BI 2536 or vehicle (NT), were lysed at the indicated time points and subjected to 
immunoblot with anti-cyclin B1 and anti-PLK1, to monitor cell cycle progression, and anti-
cleaved caspase-3 antibodies (which detect only the p17 and p19 cleaved caspase-3 
fragments) or anti-PARP antibodies (which detect both the intact 116 kDa and its cleaved 89 
kDa fragment), to monitor apoptosis. Tubulin levels are shown for normalization. Data are 
representative of at least three different experiments.  
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Figure 3: BI 2536 effects on cell cycle synchronized ATC cells 
CAL62 cells were synchronized at the G1/S transition by double thymidine block, released in 
the presence of 5 nM BI 2536 or DMSO and analyzed, at the indicated time points, by flow 
cytometry (panel A) or immunoblotted with cyclin B1, geminin and cleaved caspase-3 
antibodies (panel B). Tubulin levels are shown for normalization. Data are representative of at 
least three different experiments. 
 
Figure 4: Mitotic spindle defects in BI 2536-treated ATC cells 
Exponentially growing PC, CAL62 and SW1736 cells were treated with BI 2536 or vehicle 
(NT) and stained by immunofluorescence with anti-α-tubulin (red) and DAPI (cyan) at 
different time points. Representative micrographs are reported in panel A and percentages of 
mitotic cells with monopolar (Polo), multipolar or grossly disorganized mitotic spindles are 
reported in panel B. Values refer to the average of triplicate experiments in which at least 300 
mitotic cells were counted. Of note is the nuclear apoptotic morphology showed by ATC cells 
after 36-48 hours treatment (panel A). 
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ABSTRACT 
Purpose: Here we have studied the consequences of MEK inhibition with the potent and 
selective PD0325901 compound in thyroid carcinoma cells. Experimental design: We 
used thyroid carcinoma cell lines carrying the BRAF V600E mutation to examine cell 
proliferation and phosphorylation levels of ERK cascade components. Results: 
PD0325901 exerted potent cytostatic effects on carcinoma cell lines, but not normal 
thyroid follicular cells, confirming recent published data with other MEK inhibitors. These 
effects were accompanied by increased p27Kip1 and p21Cip1 and decreased 
phosphorylated Rb levels. While inhibiting MEK-mediated phosphorylation of ERKs, 
PD0325901 rapidly caused increased MEK phosphorylation in the activation loop. 
Moreover, at compound doses close to its IC50 for MEK, ERK inhibition was not durable 
and resumed after few hours treatment. Reduced levels of ERK-mediated inhibitory 
phosphorylation of CRAF and ERK-specific phosphatases (DUSP5 and MKP3) may 
account for the transient nature of ERK inhibition. Conclusions: MEK inhibition is a 
promising approach to reduce proliferation of BRAF mutation-positive thyroid carcinoma 
cells. Strategies to counteract the regulatory circuits that are elicited by the treatment need 
to be envisaged to further increase its efficacy.  
.
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INTRODUCTION 
The RAS-RAF-ERK (extracellular signal regulated kinase) cascade is a highly conserved 
signaling module in eukaryotes, that is often targeted by oncogenic mutations. The RAS 
small GTPase is activated upon growth factor stimulation, and, in turn, activates RAF 
family (CRAF, BRAF, ARAF) serine/threonine kinases. RAFs activate MEK1/2 dual-
specificity kinases through phosphorylation on Ser217/Ser221 in their activation loop. 
MEK1/2, in turn, activate the ERK (p44 and p42 ERKs) subgroup of MAPKs (mitogen 
activated protein kinases) by dual-phosphorylation on Thr202/Tyr204 within the Thr-Glu-
Tyr motif in the activation loop (1, 2). MEK and ERK activation is transient and is 
followed by the initiation of negative feedback mechanisms that terminate the signal (1, 
2). Dual-specificity phosphatases (DUSPs, also referred to as MAPK phosphatases -
MKP), which are able to dephosphorylate ERKs, control intensity and duration of ERKs 
stimulation (3).  
 
Thyroid carcinomas are often associated to oncogenic conversion of proteins acting in the 
ERK cascade (4, 5). In particular, activation of BRAF occurs in about 44% of papillary 
(PTC) and 25% of undifferentiated (anaplastic) (ATC) thyroid carcinomas (4-8). BRAF 
mutations are associated with such adverse PTC clinical features as extracapsular 
invasion, lymph node and distant metastases, and clinical recurrence (5-8). ATC is one of 
the most aggressive and chemoresistant type of cancer; multimodal therapy approaches 
failed so far to improve the survival of ATC patients (9, 10).  
 
The T1799A BRAF mutation, which causes a V600E amino acid change, accounts for the 
vast majority of BRAF mutations in PTC and ATC. By targeting the activation loop of the 
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kinase, the V600E mutation strongly potentiates BRAF catalytic activity (11). Moreover, 
mutated BRAF is able to activate MEK also indirectly by allosterically activating CRAF 
through heterodimerization (11).  
 
Solit and colleagues have shown that cancer cells bearing an activating BRAF mutation 
are extremely sensitive to MEK kinase inhibitors (12). Available MEK targeting agents 
are allosteric inhibitors, rather than competitive with ATP, a feature that may contribute to 
their high specificity (2, 13-15). PD98059 and U0126 were initially developed as MEK 
inhibitors for in vitro studies (2). CI-1040 was the first MEK inhibitor (IC50 = 17 nM) 
evaluated in clinical trials (2, 15). A structurally related molecule, AZD6244 (ARRY-
142886), is a potent MEK inhibitor (IC50 = 12 nM) and entered clinical trials for various 
tumors (2, 15, 16). Finally, PD0325901 was recently developed as another potent MEK 
inhibitor (IC50 = 1 nM); phase II trials with this agent are underway (17).  
 
MEK inhibition with U0126 inhibited proliferation of ARO and NPA thyroid carcinoma 
cells (18) and partially restored thyroid differentiated phenotype (19). Recently, Ball et al 
(20) and Liu et al (21) have studied the effects of AZD6244 and CI-1040 on thyroid 
carcinoma cells. MEK inhibition had potent cytostatic effects in thyroid carcinoma cells 
harbouring the BRAF (20, 21) or the HRAS (21) mutation but not in wild type BRAF 
cells. The two compounds inhibited the growth of xenograft tumors in nude mice (20, 21) 
and CI-1040 restored the expression of some thyroid cell differentiation markers (21). 
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Here we have studied the effects of PD0325901 on cell proliferation and the mechanism 
of PD0325901-mediated downregulation of ERK signaling in BRAF mutant thyroid 
carcinoma cells.  
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MATERIALS AND METHODS  
 
Compounds 
PD0325901 was synthesized by Pfizer Global Research and Development, Ann Arbor, 
MI, USA. PD0325901 was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 
10 mM and stored at –80°C. U0126, was purchased from Cell Signaling (Beverly, MA, 
USA), dissolved in DMSO at a concentration of 10 mM and stored at –20°C. 
Orthovanadate was purchased from Sigma-Aldrich (St. Louis, MO, USA) and used at a 
concentration of 100 µM. 
 
Cell cultures  
The human thyroid carcinoma cell lines ARO, FRO, NPA, BHT101, FB1, BCPAP, and 
SW1736 were grown in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, 
Groningen, The Netherlands) containing 10% fetal bovine serum. The Fischer rat-derived 
differentiated thyroid follicular cell lines PC Cl 3 (hereafter “PC”) and FRTL5 were 
grown in Coon’s modified Ham F12 medium supplemented with 5% calf serum and a 
mixture of six hormones (6H) (Sigma-Aldrich), as previosuly reported (22).  
 
Cell proliferation and Flow Cytometry assays 
For cell proliferation assay, 5x104 cells were plated in 35-mm dishes in low serum (2.5% 
for carcinoma cell lines and 1.25% for normal cell lines). The day after plating, 
PD0325901 or vehicle was added. The media was changed every 2 days and cells were 
counted in triplicate every day.  
MEK inhibition in thyroid carcinoma 
  
 
 7 
For flow cytometry analysis, 5x105 cells were treated with vehicle or PD0325901 (10 nM) 
in low serum and collected every 12 hours. Cells were fixed in ice-cold 70% ethanol in 
phosphate-buffered saline. Propidium iodide (25 µg/ml) was added in the dark, and 
samples were analyzed with a FACSscan flow cytometer (Becton Dickinson, San Jose, 
CA) interfaced with a Hewlett Packard computer (Palo Alto, CA).   
 
Protein studies 
Immunoblotting experiments were performed according to standard procedures. Briefly, 
cells were harvested in lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 
1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM sodium 
pyrophosphate, 1 mM Na3VO4, 10 µg of aprotinin/ml, 10 µg of leupeptin/ml) and clarified 
by centrifugation at 10,000 g. Protein concentration was estimated with a modified 
Bradford assay (Bio-Rad, Munich, Germany). Antigens were revealed by an enhanced 
chemiluminescence detection kit (ECL, Amersham Pharmacia Biotech, Little Chalfort, 
UK). Signal intensity was evaluated with the Phosphor-imager (Typhoon 8600, 
Amersham Pharmacia Biotech) interfaced with the ImageQuant software.  
 
Antibodies 
Anti-phospho p44/42 (#9101), specific for MAPK (ERK1/2) phosphorylated at 
Thr202/Tyr204, anti-p44/42 (#9102), anti-phospho p90RSK (90 kDa ribosomal S6 kinase) 
(#9344), specific for p90RSK phosphorylated at Thr359/Ser363, anti-p90RSK (#9347), 
anti-phospho MEK1/2 (#9121), specific for MEK1/2 phosphorylated at Ser217/Ser221, 
anti-MEK1/2 (#9122), anti phospho-CRAF (#9431) specific for CRAF phosphorylated at 
Ser289/296/301, anti phospho Rb (#9301) specific for Rb phosphorylated at Ser795 and 
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anti p27Kip1 antibodies were from Cell Signaling (Beverly, MA). Anti p21Cip1 (F5) and 
secondary antibodies coupled to horseradish peroxidase were from Santa Cruz 
Biotechnology (Santa Cruz, CA).  
 
RNA extraction and RT-PCR 
Total RNA was isolated with the RNeasy Kit (Qiagen, Crawley, West Sussex, UK). One 
µg of RNA from each sample was reverse-transcribed with the QuantiTect® Reverse 
Transcription (Qiagen) according to manufacturer’s instructions. Expression levels of 
ERK phosphatases DUSP-5 and MKP-3 were measured by quantitative RT-PCR, using 
the Human ProbeLibrayTM system (Exiqon, Denmark). PCR reactions were performed in 
triplicate and fold changes were calculated with the formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where 
ΔCt is the difference between the amplification fluorescent thresholds of the mRNA of 
interest and the mRNA of RNA polymerase 2 used as an internal reference. Primers 
sequences are available upon request.  
 
Statistical analysis 
Two-tailed unpaired Student’s t test (normal distributions and equal variances) were used 
for statistical analysis. Differences were significant when P < 0.05. Statistical analysis was 
performed using the GraphPad Prism software program (version 4, San Diego, CA, USA). 
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RESULTS 
PD0325901 inhibits the proliferation of BRAF mutant thyroid carcinoma cells  
We initially tested the effects of PD0325901 on the proliferation rate of ARO, BHT101, 
FRO and SW1736 ATC cell lines carrying homozygous or heterozygous BRAF V600E 
alleles (Fig. 1). Normal PC and FRTL5 thyrocytes were used as control. Cells were treated 
with different concentrations of PD0325901 or vehicle (NT) and counted every day for 
four days. The average results of three independent determinations are reported in Fig. 1. 
Treatment with PD0325901 caused a dose-dependent growth inhibition of all carcinoma 
cell lines with a half maximal efficacy concentration (EC50) ranging from 0.4 to 5 nM; 
doses of 10 nM or higher had to be used to suppress ATC cell proliferation by 90%. 
Importantly, 50% growth inhibition was observed in normal thyrocytes only at 
concentrations ≥ 50 nM (Fig. 1).  
 
ARO and SW1736 cells underwent a marked G1 arrest upon PD0325901 (10 nM) 
treatment, starting at 24 hours and lasting up to 96 hours (Fig. 2A). No signficant sub G1 
fraction was detectable, indicating that the treatment did not kill thyroid carcinoma cells 
(Fig. 2A). PD0325901 (10 nM) did not modify cell cycle profile of normal control cells 
(Fig 2A). ARO cells were treated with 1 and 10 nM PD0325901 and expression levels of 
p27Kip1, p21Cip1, and phospho Rb (Ser795) were determined by immunoblot at different 
time points. A remarkable increase in the expression levels of p27Kip1 and p21Cip1 was 
observed starting at 6 hours and lasting up to 24 (p27Kip1) or 48 (p21Cip1) hours upon 
treatment (Fig. 2B). Consistently, the phosphorylation of Rb was inhibited compared to 
untreated cells (Fig. 2B). Treatment with U0126, used as control, gave similar results (Fig. 
2B).  
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Effects of PD0325901 on ERK phosphorylation in thyroid carcinoma cells 
We examined the phosphorylation levels of downstream effectors of MEK, p44 and p42 
ERKs, and RSK, a kinase that is phosphorylated by ERK. This was perfomed in the same 
ATC cell lines (ARO, BHT101, FRO, SW1736) used for the proliferation assays as well 
as in additional cell lines. These included: FB1 (an ATC cell line which carries a 
heterozygous BRAF V600E mutation), NPA (a poorly-differentiated PTC cell line which 
carries only the BRAF V600E allele) and BCPAP (a PTC cell line, which carries a 
heterozygous BRAF V600E mutation). After 12 hours in low serum (2.5%), cells were 
treated for 2 hours with different concentrations of PD0325901 or vehicle (NT) and 
examined by immunoblot. Treatment with PD0325901 strongly reduced the 
phosphorylation of ERK at the activatory sites Thr202/Tyr204 and of RSK (IC50 of about 
1 nM for NPA, FRO, BHT101, FB1,  BCPAP and between 1 and 10 nM for ARO and 
SW1736) (Fig. 3). The compound also efficiently inhibited MAPK pathway 
phosphorylations in PC cells (Fig. 3), demonstrating that its reduced growth inhibitory 
activity in normal thyrocytes was not due to defective effects on the target kinase but 
rather to the fact that normal cells are not addicted to MEK signaling.  
 
Transient nature of ERK inhibition in thyroid carcinoma cells 
We measured time-course of ERK phosphorylation upon PD0325901 treatment in ARO 
cells. Phosphor-imager quantitation of three independent experiments (1 and 10 nM 
PD0325901) at various time points is reported in Fig. 4A,  a representative immunoblot 
(10 nM PD0325901), performed at early times, is reported in Fig. 4B. ERK inhibition was 
very rapid and detected as soon as after 15 min of treatment (Fig. 4B). It was almost 
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complete, at both 1 and 10 nM PD0325901, after 1 hour of treatment (Fig. 4A, B). Then, 
ERK phosphorylation started to resume after 3 hours (Fig. 4B) and returned to levels 
almost equivalent to untreated cells after 6 hours (Fig. 4A, B). RSK phosphorylation 
paralleled ERK activity (Fig. 4A, B). These transitory effects were also detected in the 
other BRAF mutant thyroid carcinoma cells, although they were more evident in ARO 
cells (not shown). The transient nature of ERK inhibition was not unique to PD0325901, 
because it was seen also with U0126 (Fig. 4A). Compound decay did not account for the 
transient nature of the effects, because PD0325901 replenishment one-hour before protein 
harvest did not prevent ERK phosphorylation recovery (not shown). Moreover, recovered 
ERK phosphorylation remained MEK-sensitive because it could be abrogated by 
increasing the doses of PD0325901 or U0126 (Fig. 4C).  
 
Regulatory circuits elicited by MEK inhibition in thyroid carcinoma cells 
ERK phosphorylation at Thr202/Tyr204 may resume either secondary to reduced response 
of MEK kinases to PD0325901 (which would increase the “on” rate), or to reduced levels 
of ERK-specific phosphatases (which would decrease the “off” rate). We explored both 
possibilities. Fig. 5A shows that, as soon as after 1 hour of PD0325901 treatment, MEK 
phosphorylation levels at the activatory sites Ser217/Ser221 increased and remained 
elevated thereafter for at least 12 hours. Noteworthy, phosphorylation at these sites 
enhances by 7,000-fold the MEK kinase activity and it is expected to reduce MEK 
inhibitor binding (23, 24).  
 
RAF proteins are the only kinases known to phosphorylate Ser217/Ser221 of MEK (1, 2). 
Importantly, active ERKs phosphorylate CRAF on various Ser/Pro sequences (Ser29, 
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Ser289, Ser296, Ser301, and Ser642), this resulting in the inhibition of CRAF catalytic 
activity, membrane localization and association to BRAF (25, 26). CRAF, in turn, is 
involved in oncogenic BRAF-triggered phosphorylation of MEK (11). Thus, PD0325901 
treatment could result in the potentiation of CRAF secondary to the blockade of ERK-
mediated inhibitory phosphorylations. We used the available phospho-antibodies specific 
for CRAF phosphorylated at Ser289/296/301 to test this possibility. Fig. 5B shows that 
indeed the phosphorylation state of CRAF at these inhibitory sites was decreased starting 
at 1-6 hours after PD0325901 treatment; again these effects were also seen with the 
control MEK inhibitor. It is important to note that also BRAF is directly phosphorylated 
and inhibited by ERK (27), and therefore also BRAF de-phosphorylation upon 
PD0325901 may contribute to MEK hyper-phosphorylation. Accordingly, our preliminary 
data indicate that both CRAF and BRAF kinase activities are potentiated upon 
PD0325901 treatment (not shown). 
 
DUSP/MKP are transcriptional targets of the ERK pathway, this representing a negative 
feedback circuit that is able to terminate ERK signal (3). Changes in expression levels of 
DUSP/MKPs may modify the “off” rate of ERK phosphorylation and contribute to the 
transient nature of ERK de-phosphorylation upon treatment with pathway inhibitors. 
Accordingly, Ouyang et al showed that BRAF inhibition caused reduced levels of MKP3 
and DUSP5 ERK phosphatases in thyroid carcinoma cells (28). We treated ARO cells 
with orthovanadate, a potent DUSP/MKP inhibitor. This treatment increased the 
phosphorylation levels of ERK, suggesting that, at the steady state, ERK phosphorylation 
is under phosphatases control in ARO cells (Fig. 5C). Then, we measured expression 
levels of DUSP5 and MKP3 in ARO cells treated with PD0325901, by quantitative RT-
MEK inhibition in thyroid carcinoma 
  
 
 13 
PCR. PD0325901 treatment, evoked a rapid and sustained decrease of mRNA abundance 
of both phosphatases starting 30 minutes upon treatment and lasting up to 12 hours (Fig. 
5D). 
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DISCUSSION  
Advanced PTC typically exhibits radioiodine resistance and there is currently modest 
therapeutic option for these patients (29, 30). ATC is a very rare but almost invariably 
fatal tumor (9, 10). Thus, novel therapeutic strategies are urgently needed for these 
particular patients.  
 
The BRAF/MEK/ERK pathway seems a promising molecular therapeutic target for PTC 
and ATC (18-21, 28, 31). Here we studied at the molecular level the effects of MEK 
targeting in BRAF mutant thyroid carcinoma cells. Our findings confirm the efficacy of 
this approach to arrest thyroid carcinoma cell proliferation (18-21). However, they also 
anticipate possible shortcomings of this strategy.  
 
Signal transduction pathways are controlled by a network of regulatory circuits (32). 
Although the major effect of these circuits is probably to prevent excessive signaling, their 
abrogation by molecularly targeted agents, may cause a compensatory stimulation of the 
pathway and therefore limit treatment efficacy. As an example, treatment with inhibitors 
of mTOR, a kinase acting downstream AKT and PI3K, by removing negative feedbacks 
that act upstream or at the level of AKT, exerted only transient biological effects (33, 34). 
Importantly, this could be circumvented by combining PI3K and mTOR inhibitors (35).  
 
Multiple levels of control exist in the ERK cascade (1, 2). Our data show that treatment 
with MEK targeting agents is able to tune many of these controls (Fig. 5E) and kinetics 
analysis suggests that these events contribute to rapidly attenuate ERK inhibition upon 
PD0325901 and U0126 treatment. Our findings show that, at the transcriptional level, the 
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downregulated expression of MKP3 and DUSP5, likely reduces the turn-over of ERK 
phosphorylation thereby blunting ERK inhibition upon MEK blockade. We also show that 
at the post-translational level, treatment with MEK targeting agents attenuated ERK-
dependent inhibitory phosphorylations of RAF kinases; it is feasible that this accounts for 
the rapid attenuation of MEK inhibition in cells treated with PD0325901.  
 
We cannot exclude that additional regulatory mechanisms result in MEK overactivation, 
thus hampering the efficacy of MEK inhibitory agents. For instance, in some (36, 37) but 
not all (38) reports, ERK-mediated phosphorylation of MEK1 on Thr292 was found to 
attenuate MEK activity, anticipating that ERK inhibition could potentiate it. Furthermore, 
changes in the expression levels of MEK phosphatases such as PP2A (39) may occur and 
affect cell response to MEK inhibtion. Whatever the mechanism, our findings suggest that 
the resumed ERK pathway remains MEK-dependent and, accordingly, we could keep it 
knocked-down by using higher doses of PD0325901. 
 
In conclusion, although MEK inhibitory agents exert significant growth inhibitory 
properties for thyroid carcinoma cells, they also elicit compensatory mechanisms that 
attenuate the duration of their effects. Increasing the dose of one inhibitor, as our data 
suggest, or combining inhibitors that act at different levels of the ERK cascade, like 
compounds targeting MEK and RAF (RAF kinase inhibitors or  Hsp90 inhibitors, ref. 18) 
may counteract these regulatory circuits and prove to be an effective targeting strategy. It 
is feasible, however, that compensatory mechanism adjunctive to those described here 
may occur under MEK inhibition and affect other components of the cascade, even 
upstream from MEK and RAF kinases (like RAS or membrane receptors). This may result 
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in the activation of pathways other than the ERK one, and therefore require a rationally-
designed multi-pathway targeting approach.  
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FIGURE LEGENDS 
 
Figure 1. Growth inhibition by PD0325901 of BRAF mutant thyroid carcinoma cells.  
The indicated cell lines (5x104) were plated in triplicate in 35-mm dishes (in 2.5% serum). 
The BRAF status of the different cell lines is reported. One day later, different 
concentrations of PD0325901 or vehicle (NT) were added. Cells were counted at different 
time points. Day 0 was the treatment-starting day. Each point represents the mean value 
and error bars represent 95% confidence intervals. Statistical significance was determined 
by the two-tailed unpaired Student’s t test.  
 
Figure 2. Mechanisms of PD0325901 growth inhibition in thyroid cancer cell lines.  
A) Cells were incubated with 10 nM PD0325901 at the indicated time points and cell 
cycle distribution was determined by flow cytometry. B) ARO cells were treated with 
PD0325901, U0126 or vehicle (NT) at different time points and expression levels of cell 
cycle regulatory proteins were determined by immunoblot. Anti tubulin was used for 
normalization.  
 
Figure 3. Inhibition of ERK cascade in thyroid carcinoma cells by PD0325901. 
The indicated cell lines (their BRAF status is indicated) were kept in 2.5% serum and 
treated with increasing concentrations of PD0325901 or vehicle (NT) for 2 hours. Cell 
lysates were immunoblotted with the indicated antibodies. Total amounts of proteins are 
shown for normalization. Data are representative of at least three different experiments. 
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Figure 4. Transient ERK inhibition by PD0325901 in ARO cells.  
A) ARO cells were incubated with different doses of PD0325901 or U0126 for the 
indicated time points. Protein extracts were immunoblotted with phosphoERK antibodies 
and the results were measured by phosphor-imaging; the average pERK/total ERK results 
of three independent experiments are reported in the bar graphs. B) Cells were treated with 
PD0325901 or vehicle (NT) and ERK and RSK phosphorylations were measured by 
immunoblot at early time points.  C) Cells were treated with PD0325901 for 2 or 6 hours 
and kinetics of ERK phosphorylation was measured by immunoblot. 
 
Figure 5. Altered regulatory phosphorylations and DUSPs levels upon treatment with 
MEK targeting agents.  
A, B) ARO cells were treated with PD0325901 or U0126 at the indicated time points. 
Total cell lysates were analyzed by western blotting with phosphospecific antibodies 
detecting activatory MEK phosphorylations on Ser217/Ser221 (A) or inhibitory CRAF 
phosphorylations on Ser289/Ser296/301 (B). C) Cells were treated with orthovanadate at 
the indicated time points and cell extracts were immunoblotted with the indicated 
antibodies. D) Cells were incubated with PD0325901 (10 nM), RNA was extracted and 
MKP-3 and DUSP5 mRNA leves were measured by quantitative RT-PCR and reported as 
% change with respect to vehicle treated cells. E) A scheme of the activatory (↓) and 
inhibitory (⊥) regulatory circuits that are affected by MEK targeting in thyroid carcinoma 
cells. 





